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(iii) SUMMARY
The aim of the work presented in this thesis was to assess the 
physiological significance and role of reversible phosphorylation- 
déphosphorylation in the short-term regulation of the activity of 
hepatic HMG-CoA reductase in vivo. Such a mechanism has been well 
characterized for this enzyme m  vitro (see Chapter 1) but, until 
the present work no demonstration has been made of the influence of 
this system on the regulation of the enzyme ^  vivo in response to 
normal physiological stimuli (see Chapter 1 and Chapter 3). It 
seemed unlikely that such a complex mechanism of covalent 
modification would go unused vivo. The previous work on whole 
animals was, therefore, reassessed. Particular care was taken in the 
sampling and homogenization of the tissue to preserve the 
phosphorylation status of the enzyme that exists in the tissue at the 
moment of sampling.
Chapter 3 describes a technique, the cold-clamping technique, 
designed especially for this study. Not only did this technique meet 
the criterion for the rapid processing of liver tissue (see above) 
but it also allowed the physical removal of a HMG-CoA lyase activity 
(which interferes with the assay of HMG-CoA reductase) in whole 
mitochondria by differential centrifugation of the homogenates. The 
suitability of this technique for the study of short-term changes in 
HMG-CoA reductase activity was validated by directly comparing its 
efficiency in preserving the phosphorylation state of pyruvate 
kinase, previously established to undergo rapid interconversion 
between active and inactive forms, with the widely used 
freeze-clamping technique and the conventional method of mincing 
tissue prior to homogenization.
Chapter 4 describes the use of the cold-clamping technique to 
quantitate changes in the fraction of the enzyme in the active, 
dephosphorylated form in a number of physiological conditions 
characterized by acute hormonal and/or nutritional changes. It was 
demonstrated that this parameter of HMG-CoA reductase showed a marked 
diurnal rhythm; its value was rapidly reduced under conditions of 
food deprivation for periods ranging from 4 to 24h. It also varied 
widely in rats during the transition between the gravid and lactating 
states. These changes appeared to occur independently of large 
changes in the total enzyme activity, (an indication of the amount of 
enzyme protein) suggesting that each parameter was controlled either 
by different hormones by a differential response to the same hormonal 
or nutritional factor. Significantly, the change in the 
phosphorylation status of the enzyme in each condition appeared to be 
the primary mechanism through which the expressed activity (the 
closest estimate of the actual activity vivo of HMG-CoA reductase 
was rapidly modulated in co-ordination with the immediate 
physiological significance of the animal (see Section 4.5).
In the final two chapters experiments are described which were 
designed to assess the importance of hormonal (Chapter 5) and/or 
nutritional (Chapter 6) factors in the short-term regulation of 
HMG-CoA reductase by reversible phosphorylation ^  vivo. A 
significant observation from Chapter 4 indicated that the changes in 
the fraction of enzyme in the active form in each physiological 
condition (except lactation) closely reflected the expected changes 
in the plasma insulin concentration in the animal. In Chapter 5, 
this suggestion was supported by, for example, the acute and chronic
Vchanges observed in this parameter in animals treated with 
anit-insulin serum and in severely insulin-dependent diabetic animals 
respectively. Further investigation into the role of hormones having 
antagonistic effects to insulin on liver metabolism (e.g. glucagon 
and epinephrine) revealed that insulin had a dominant role in the 
regulation of the phosphorylation state of HMG-CoA reductase in 
vivo. The observations are discussed in the light of the response 
of this parameter to different physiological conditions, in the light 
of the current knowledge of the regulation of cellular kinases and 
phosphatases for which HMG-CoA reductase enzyme is a substrate.
In Chapter 6, the previously published effects of 
mevalonolactone on the phosphorylation state of HMG-CoA reductase 
both iji vivo and ^  vitro were confirmed using the cold-clamping 
technique on the livers of animals intubated with mevalonolactone. 
Most significantly, however, this treatment produced a reversal of 
the dominant effect of insulin during the early hours of the dark 
period. The mechanism by which this could be achieved is discussed. 
This chapter also describes the apparently little effects of various 
dried milk fractions (with the exception of buttermilk) administered 
to animals by stomach intubation on the phosphorylation state of 
HMG-CoA reductase.
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CHAPTER 1
INTRODUCTION
The enzyme 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) 
reductase; (E.C. 1.1.1.34) catalyzes a major regulatory step in 
cellular cholesterol synthesis (see e.g. Rodwell et al., 1976; Fig. 
1.1) as well as the synthesis of other compounds essential for cell 
proliferation and maintenance. Under most physiological conditions 
the activity of HMG-CoA reductase determines the flux through the 
cholesterogenic pathway (Fig. 1.1) from cytosolic acetyl-CoA (Shapiro 
& Rodwell; 1971; Brown et al., 1979). The enzyme catalyzes the 
reduction of HMG-CoA (formed from acetyl-CoA by the successive 
actions of acetoacetyl-CoA thiolase (E.C. 2.3.1.9) and HMG-CoA 
synthase (E.C. 4.1.3.5) in the cytosol) to mevalonate (Fig. 1.2).
The latter is known to serve at least two functions in cell 
proliferation and maintenance: (i) It is a precursor of cholesterol 
which is primarily required for membranogenesis (see Section 1.1) and
(ii) it is the precursor of a number of non-sterol products required 
for cell growth (for reviews see Brown & Goldstein, 1980; Siperstein, 
1984). These products include dolichol (which is required for the 
synthesis of many cell surface and secreted glycoproteins), 
ubiquinone (a component of the mitochondrial electron transport 
chain) and isopentenyladenine (which subsequently forms an important 
component of tRNA) (see Fears, 1981; Fig.1.1). Furthermore, recent 
evidence suggests that mevalonate serves as a rapid and essential 
initiator of DNA replication during the S-phase of the cell cycle
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i
HMG-CoA
i HMG-CoA reductase
Mevalonate
1
Mevalonate
Pyrophosphate
Isopentenyl ■ ■  H> Dimethylallyl ^  Isopentenyl
Pyrophosphate ^ .....  Pyrophosphate Adenine
Geranyl
Pyrophosphatei
Farnesyl
Pyrophosphate
Squalene Synthase
Squalene
i
CHOLESTEROL
Ubiquinone
Dolichol
Fig. 1.1 Biosynthetic pathway of cholesterogenesis from acetyl-CoA
Figure also demonstrates the branched pathway of mevalonate metabolism.
(Redrawn from Brown & Goldstein, 1980)
possibly through the formation of isopentenyl adenine (Fig. 1.3); for 
a review see Siperstein (1984).
1.1 Overview of Cholesterol Homeostasis
Cholesterol (see Fig. 1.1) is the most abundant sterol in
vertebrates and is essential for body function (Myant, 1981). It is
a major component of cell membranes where it plays an important role 
in their structural and functional integrity (Chen, 1984; Sabine, 
1977; 1983). Thus every cell has a universal requirement for 
cholesterol and this is reflected by the fact that every mammalian 
cell-type investigated, except for the enuclear erythrocyte, has the 
capacity to synthesize cholesterol (Sabine, 1977).
Cholesterol is also the major precursor for the biosynthesis
of steroid hormones in steroidogenic tissues (Gwynne & Strauss,
1982), bile acids (Myant, I98I) and vitamin D (Lehninger, 1982) in 
the liver. In addition, cholesterol is a major constituent of the 
plasma lipoproteins.
1.1.2 The Role of Liver in the Control of Body Cholesterol 
Homeostasis
In the rat, approximately 50^ of the total body sterol
■o
synthesis, (determined by the rate of [ HJ-H^O incorporation into 
digitonin-precipitable sterols, see Jeske & Dietschy, 198O) occurs 
in the liver. The majority of the outstanding synthesis occurs in 
the intestine, skin and carcass (primarily striated muscle and bone 
marrow) (Turley e^ a^., I98I). This situation is, however, 
apparently unique to the rat since similar analyses conducted in
Acetyl-CoA
Acetyl-CoA (a)
Acetoacetyl-CoA 
Acetyl-CoA     (b)i
HMG-CoA
1 (c)
MEVALONATE
1
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adenine)
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M G
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Fig. 1.2 Relation of HMG-CoA reductase to the pathways of formation 
of intermediates required for cell growth and proliferation
(Redrawn from Siperstein, 1984)
other animal species reveal that, in general, the liver contributes 
less than 50^ and, in some cases i.e. in rabbit and guinea-pig, only 
16-18% to the total body sterol synthesis (Spady elb , 1983).
This predominance of hepatic synthesis in the rat may be related to 
the large absolute amount of cholesterol synthesized by the rat 
(lOOmg/day per kg body wt.; Turley & Dietschy, 1982). For example, 
it is possible that in man (where total body synthesis amounts only 
to 9mg of cholesterol/day per kg body wt.; (Turley & Dietschy, 1982) 
the liver may account for a lower percentage contribution to the 
total body sterol formation (see Dietschy, 1984).
The important functions served by cell cholesterol necessitate 
that the amount and distribution of the body (and cellular) pools of 
cholesterol are strictly controlled (Spector et al., 1979). Since 
mammals do not possess enzymes that are capable of degrading the 
sterol nucleus, the rate at which the body acquires cholesterol (from 
the diet or from ^  novo synthesis) must be balanced by the rate at 
which the body can excrete the sterol molecule (through the formation 
of bile or the excretion of steroids in the urine) (see Turley & 
Dietschy, 1982; Dietschy, 1984). This concept is schematically 
represented in Fig. 1.3.
This critically important balance of cholesterol across the 
body is maintained by an elaborate series of regulatory and transport 
mechanisms in which the liver plays a central role (Fig. 1.4). 
Cholesterol is absorbed from the diet by the epithelial cells of the 
small intestine, a process facilitated by the detergent action of 
bile salts secreted into the intestine (Westergaard & Dietschy, 1976; 
Thomson & Dietschy, 1981). The cholesterol thus absorbed and that
Mem brane
Exogenous 
cholesterol
turnover
Excretion ♦
POOL OF CELLULAR 
CHOLESTEROL >  Bile
Steroid hormones
Cholesterol
synthesis
Cell growth 
(proliferation)
Fig. 1.3 The principal determinants of cholesterol homeostasis 
The body pool of cholesterol remains relatively constant in the 
adult animal. The rate of cholesterol excretion through the skin 
and gastrointestinal tract ("excretion”) and conversion to bile 
acids and steroid hormones must equal the rate of cholesterol 
acquisition. (----) signifies eventual excretion.
synthesized ^  novo from acetyl-CoA in these cells is incorporated 
into chylomicrons (Fig. 1.4). These particles are secreted into the 
lymphatic system and thence into the peripheral bloodstream. Here 
they are depleted of triglyceride by the action of lipoprotein lipase 
situated on the endothelial surface of the capillaries of peripheral 
tissue like adipose tissue and muscle (Fielding, 1978; Cryer, 1981). 
The residual chylomicron remnants which still contain nearly all the 
absorbed cholesterol (in both free and esterified forms) are cleared 
almost quantitatively by the liver via receptor-mediated endocytosis 
after binding by specific receptors (Hui e^ al., 1981; Kita e^ al., 
1982; Cooper et al., 1982). The liver also receives cholesterol 
from remnants of very-low-density-lipoprotein (VLDL) (i.e. 
intermediate-density-lipoprotein (IDL) and low-density-lipoprotein 
(LDL) (Goldstein eb al,, 1983) and from high-density lipoprotein 
(HDL) (Mahley, 1983; see Fig. 1.4). However, the cholesterol in 
these particles is primarily of endogenous origin.
The liver secretes cholesterol- and triglyceride-rich VLDL 
into the plasma. These particles are also metabolized in peripheral 
muscle and adipose tissues by lipoprotein lipase and the resultant 
cholesterol-rich particle (IDL) binds with high affinity to hepatic 
LDL-receptors. These particles are rapidly cleared from the plasma 
by this route (Eisenberg & Levy, 1975). The LDL particles, which 
have a high cholesterol/apoprotein ratio, are then cleared from 
the plasma relatively slowly by binding to the high-affinity 
LDL-receptors in both the liver and peripheral tissues (Pittman et 
al., 1979; Kita et al., 1982; Brown & Goldstein, 1983). The 
accumulation of cholesterol within the peripheral tissues is
Exogenous Pathway Endoganous Pathway
LDL LDL
ïïïïmïïïïïïTmnïïiTTrr’
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/Ui 8-1008-100
LCAT
Fig. 1.4 Separate pathways for receptor-mediated Metabolism of
lipoproteins carrying endogenous and exogenous cholesterol
The distinction between exogenous and endogenous cholesterol applies 
to the immediate source of the cholesterol in the plasma lipoproteins 
The role of each lipoprotein in cholesterol homeostasis is discussed 
in the text. The ’labels’ to the lipoproteins in the diagram signify 
the prominent apoproteins associated with the binding of that lipo­
protein with its receptors.
VLDL: Very Low Density Lipoprotein
LDL: Low Density Lipoprotein
HDL: High Density Lipoprotein
LCAT: Lecithin Cholesterol Acyltransferase
(from: Goldstein et al. 1983)
prevented by its abstraction from these tissues by HDL (Tall & Small, 
1979; Nicoll al., 1979; Daniels et al., I98I; Mahley, 1983) and 
the cholesterol is then either transferred to IDL via a mechanism 
involving LCAT (see Fig. 1.4; Owen & McIntyre, 1982) or directly to 
the liver (Brown et al., 198I; Hui et al., I98I).
In view of the constant delivery of cholesterol to the liver 
by these various mechanisms, it is necessary that the intracellular 
concentration of free cholesterol of this organ be carefully 
controlled. The liver has three ways of maintaining an optimal 
cholesterol concentration; namely by the co-ordinate regulation of 
(i) uptake, (ii) excretion/storage and (iii) synthesis.
(i) Uptake: In some species (e.g man, hamster) the rate of 
uptake of LDL is decreased under conditions of increased dietary 
cholesterol delivery to the liver. This is achieved by reducing the 
number of its specific receptors on the surface of the liver (see 
Goldstein & Brown, 1984). In man (Applebaum-Bowden ^  al., 1984) or 
rabbits (Kovanen et al., 198I) this phenomenon results because, 
contrary to the LDL receptors, chylomicron remnant receptors are not 
regulated (Brown & Goldstein, 1983; Mahley & Innerarity, 1983). In 
the rat, however, neither of these receptors appear to be regulated 
(Wade e^ al., 1984).
(ii) Excretion/Storage : In all mammalian species the
formation of bile acids is the major mechanism for the excretion of 
cholesterol of both endogenous and exogenous origin from the liver 
(Myant, 198I). Consistent with this function, dietary cholesterol 
increases the rate of bile acid synthesis which is achieved through 
the activation of the first enzyme in the pathway, c’holesterol
7a-hydroxylase, (Choi 7a-0Hase; E.C. 1.14.13*17; Myant & Mitropoulos, 
1977). The main function of bile acids synthesis is to ensure an 
optimal supply of bile salts for the digestion and absorption of 
lipid from the small intestine. Consequently, the flux through this 
pathway is controlled by 'feedback' inhibition by both bile acids 
synthesized for secretion (Shefer et al., 1969) and bile acids 
delivered back to the liver after reabsorption from the intestine as 
part of the enterohepatic cycle (EHC; Grundy, 1978). Dietary 
cholesterol increases the rate of bile acid synthesis through the 
activation of Choi 7a-0Hase (Myant & Mitropoulos, 1977; Mitropoulos 
et al., 1978); the increase in bile acid synthesis is also 
accompanied by an increased secretion of free cholesterol in the 
bile.
In conditions of increased delivery of cholesterol to the 
liver, free-cholesterol homeostasis is further maintained through 
increased formation of cholesterol esters which can be stored without 
detrimental effects to the cell. Under these conditions the 
activity of acyl CoA:cholesterol acyltransferase (ACAT; E.C.
2 .3 .1.26) is stimulated (Spector e^ al., 1979; Mitropoulos et al., 
1978; Erickson et al., 1980).
In view of the common roles of ACAT and Choi 7a-0Hase together 
with HMG-CoA reductase (see below) in cholesterol homeostasis, it 
would be expected that the enzymes are co-ordinately regulated. It 
is noteworthy that each of these enzymes is regulated by reversible 
phosphorylation (see Scallen & Sanghvi, 1983)* However, whereas 
increased phosphorylation of HMG-CoA reductase results in its 
inhibition (see Section 1.4) phosphorylation of ACAT and Choi
77ct-0Hase results in their activation. Furthermore, all three enzymes 
are associated with the endoplasmic reticulum (Scallen & Sanghvi, 
1983). This common localization may facilitate the co-ordinate 
regulation of the enzymes by factors which affect the membrane 
environment of the enzymes e.g. cholesterol itself.
(iii) Synthesis: Modulation of the rate of cholesterol
synthesis is potentially a very complex process because (a) the 
number of steps involved is large (see Fig. 1.1), (b) the 
cholesterogenic pathway competes for substrate with fatty acid 
synthesis (Gibbons et al. . 19821 _ _ and (c) cholesterol is only one 
of the several products formed from a common intermediate, farnesyl 
pyrophosphate (see Section 1.1; Fig. 1.1). However, one enzyme in 
particular, HMG-CoA reductase, is thought to be most closely linked 
to the regulation of cholesterol synthesis. Thus under a wide range 
of physiological conditions varying from fasting to cholestyramine 
feeding, the large (approximately 50-fold) changes in the rate of 
cholesterogenesis are closely paralleled by changes in HMG-CoA 
reductase activity (Shapiro & Rodwell, 1971; Brown et aT., 1979). 
However, several groups of workers have suggested that other 
regulatory sites in the cholesterol pathway may also become important 
under certain conditions, including cholesterol feeding (White & 
Rudney, 1970; Clinkenbeard e^ ^ . , 1975a), glucocorticoid 
administration (Ramachandran et al., 1978 and fasting (Rodwell et 
al., 1976). These alternative sites include HMG-CoA synthase (E.C.
4.1.3 .5 ; White & Rudney, 1970; Clinkenbeard et al., 1975b; 
Ramachandran et al., 1978; Balasubramaniam et al., 1977) and
squalene synthase (E.C. 2.5.1.21; Rodwell et al., 1976; Slakey et 
al., 1972; Faust ^  al., 1979).
The work reported in the present thesis was concerned 
exclusively with the regulation of HMG-CoA reductase activity in 
vivo. In the following section, a detailed discussion of the 
mechanisms involved in the regulation of HMG-CoA reductase activity 
is presented with an emphasis on the involvement of reversible 
phosphorylation-déphosphorylation.
1.2 Hepatic HMG-CoA Reductase
1.2.1 The reaction
HMG-CoA reductase catalyzes the reduction of HMG-CoA (from 
acetyl-CoA, see Section 1. 2) to mevalonate in a 2-stage mechanism 
which is essentially irreversible and requires NADPH as co-factor 
(Fig. 1.5).
When assayed vitro in microsomal preparations of rat liver,
HMG-CoA reductase has a pH optimum of 7.3-7.7 (Shapiro & Rodwell,
1969). The K values for HMG-CoA and NADPH have been reported to be 
m
within the ranges of 0.5-2.6pM and 30.0-73.0pM respectively (see 
Rogers £t al., 1983).
1.2.2 Topology
The development of a cell line (UT-1) which massively 
over-produces (100- to 1000-fold) HMG-CoA reductase protein when 
adapted to grow in the presence of a competitive inhibitor of the 
enzyme, compactin (Chin e^ aT., 1982a; Luskey et aT., 1983)> has 
enabled the topographical study of HMG-CoA reductase. These studies
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have revealed that HMG-CoA reductase is a 97kDa transmembrane 
glycoprotein (Chin et a]^., 1982, 1984; Liscura et al., 1983a; Brown 
& Simoni, 1984) consisting of 887 amino acids (Chin et , 1984) 
and comprised of two domains (Liscum e^ al., 1985; Fig. 1.6). The 
NH^-terminal domain (35kDa; 339 amino acids) is extremely hydrophobic 
and believed to cross the endoplasmic reticular membranes seven times 
(Liscum et al., 1985). It is glycosylated by a N-linked 'high 
mannose' type oligosaccharide (Liscum et al^., 1983a). This domain 
is inserted into the membrane co-translationally, although apparently 
without a hydrophobic signal sequence (Brown & Simoni, 1984; see 
Goldstein & Brown, 1984). The second hydrophilic domain (62kDa) 
projects out into the cytoplasm and contains the catalytic site 
(Liscum et al., 1983b, 1985; Phillips & Ness, 1984; see Fig. 1.5).
The reason for this complex structure of HMG-CoA reductase is not 
known but it is possible that the membrane domain serves as a 
receptor for LDL-derived cholesterol (see Section 1.1.2 & 1.3.1(i)j 
Liscum e^ al., 1985). The hydrophilic catalytic domain can be 
separated from the hydrophobic membrane domain by treatment with a 
Ca^^-dependent, leupeptin-and calpastatin-sensitive protease 
calpain-II (Parker et al., 1984; Liscum e;b al., 1983b; see Fig.
1.6). This treatment yields a membrane-bound (62kDa; termed '62k') 
and soluble (53kDa; termed '53k') catalytically active fragments 
(Parker et al., 1984). The '62k' fragment is possibly a precursor 
of the '53k' soluble fragment although the '53k' species may also be 
released directly from the native 97kDa enzyme (termed '97k') (Parker
et al., 1985).
Lumen of E.R.
E.R. membrane
Cytoplasm
c
♦  ▼
62K 53K COOH
Fig. 1.6 Schematic model representing the topology of HMG-CoA reductase 
in the endoplasmic reticulum (E.R.) membrane
Seven hydrophobic regions, indicated by the'waved lines, span the E.R. 
membrane. The cytosolic domain (C-terminus) contains two sites of 
proteolytic cleavage yielding the loosely bound 62K and soluble 53K 
species of HMG-CoA reductase respectively. The N-linked carbohydrate 
chain is indicated between the sixth and seventh membrane spanning region,
(Redrawn from Liscum et al. 1985)
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1•3 Multivalent Control of HMG-CoA Reductase
As would be expected from the fact that the expressed activity 
of HMG-CoA reductase is the principal determinant of the rate of 
cholesterol biosynthesis, the activity of the enzyme changes in 
response to alterations in cellular and body cholesterol homeostasis 
(Section 1.1). The effective activity of HMG-CoA reductase in vivo 
is determined by two parameters; (a) the quantity or concentration of 
enzyme protein (i.e. the number of enzyme molecules as a gene 
product) in the tissue. This depends on the relative rates of enzyme 
synthesis and degradation, (b) The specific activity of the 
individual enzyme molecules. This is known to be modulated by 
covalent modification and the state of the membrane in which 
reductase resides. Although the mechanisms through which these two 
parameters control the activity of HMG-CoA reductase are distinct, a 
number of effectors of HMG-CoA reductase e.g. cholesterol, oxysterols 
or insulin/glucagon (Ingebritsen, 1983) operate via both mechanisms 
(see below) and as will be described later covalent modification of 
the enzyme may affect its rate of degradation.
1.3.1 Regulation of HMG-CoA Reductase by Modulation of Hepatic 
Enzyme Concentration: Factors that Influence Enzyme
Synthesis and Degradation
1.3.1 (i) Lipoprotein cholesterol
As implied in the previous section, the increased delivery 
of cholesterol to the liver either by chylomicron remnants (exogenous 
cholesterol) or LDL (endogenous cholesterol) produces a feedback 
inhibition of cholesterol biosynthesis and a parallel decrease in the
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acitivity of HMG-CoA reductase (Nervi al., 1975; Nervi &
Dietschy, 1975; Rodwell ^  al., 1976). Although changes in the 
intracellular levels of cholesterol acutely modulate the catalytic 
activity of existing enzyme (see Chapter 6), studies on cells in 
culture have shown that the synthesis and degradation of HMG-CoA 
reductase protein are also affected by the inclusion of 
LDL-cholesterol in the culture medium (Brown e^ al., 1974; Faust £t 
al., 1982; Hardgrave et , 1979). Thus, for example, the addition 
of LDL to the medium of UT-1 cells suppresses the synthesis of 
immunoprecipitable HMG-CoA reductase protein by more than 98$ (Faust 
^  al., 1982) and antagonizes the over-production of enzyme 
characteristic of these cells. In addition, a 3-fold enhancement of 
the rate of degradation of HMG-CoA reductase was observed in these 
cells which was accompanied by the regression of the extensive 
proliferation of the endoplasmic reticulum in these cells (Orel et 
al., 1984; Anderson et a]^., 1983). By contrast, fibroblasts 
genetically deficient in LDL-receptors exhibit elevated HMG-CoA 
reductase activity (Brown et al., I98I). Similarly, the removal of 
cholesterol from the plasma membranes of cells with HDL results in 
the increased synthesis and decreased degradation of HMG-CoA 
reductase (Gibson & Parker, 1985).
The mechanism by which cholesterol mediates these effects is 
unclear. The exposure of UT-1 cells to LDL in culture diminishes the 
level of HMG-CoA reductase mRNA (Chin e^ al., 1982b; Luskey et al., 
1982, 1983). A decrease in the level of HMG-CoA reductase mRNA (also 
accompanied by a decrease in immunoprecipitable protein) is observed 
in vivo in the liver of cholestyramine mevinolin-treated rats fed a
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cholesterol-supplemented diet (Liscum e^ al., 1983b). These 
observations suggest that cholesterol affects the control of 
transcription of the HMG-CoA reductase gene and it may be relevant
that Erickson eb al. (1975) have previously shown that the
concentration of non-esterified cholesterol associated with chromatin
in the rat liver increases prior to the normal diurnal decrease in
the activity of HMG-CoA reductase (see Section 4.2; Gould, 1977).
1.3.1 (ii) Oxysterols
Oxygenated cholesterol derivatives (oxysterols), in 
particular 25-hydroxycholesterol (Kandutsch & Chen, 1975) and 
7-ketocholesterol (Brown & Goldstein, 1974), have been shown to be 
powerful inhibitors of HMG-CoA reductase activity (for review see 
Gibbons, 1983a). Culture of cells in the presence of 
25-hydroxycholesterol results in the inhibition of the synthesis of 
HMG-CoA reductase (Faust ^  al., 1982; Tanaka ^  al., 1983; Sinensky 
et al., 1981 ; Luskey et ^ . , 1983); this is associated with 
regulation both at the level of transcription (decrease in HMG-CoA 
reductase mRNA, Luskey et ^ . , 1983) and translation (no change in 
mRNA; Tanaka et ^ . , I983). In addition, 25-hydroxycholesterol also 
enhances enzyme degradation (Faust ^  al., 1982; Tanaka et al.,
1983) and may involve other 'médiating-proteins' since this effect is 
diminished in the presence of protein synthesis inhibitors (Chang ^  
al., 1981 ; Chen et al., 1982). The possible physiological 
significance of these effects observed vitro is indicated by the 
fact that 25-hydroxycholesterol can reproduce any of the effects of 
LDL-cholesterol on cellular activity i.e. suppression of cholesterol
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biosynthetic enzymes ACAT and the LDL-receptor (see Section 1.1.2; 
Gibbons et al., 1983b). Therefore, the similarity of the effects of 
these related moieties suggests that oxysterols, possibly formed by 
the action of the P450-cytochrome oxidase on the microsomal membrane 
(Gupta et al., 1985), may be the mechanism through which changes in 
the availability of cholesterol are transmitted to the systems 
controlling the rates of synthesis and/or degradation of HMG-CoA 
reductase. Inhibition of the formation of polar sterols in cultured 
rat intestinal epithelial cells was shown to result in the 
de-repression of the activity of HMG-CoA reductase (Gupta et al., 
1985; see also Sexton et al., 1983).
1.3.1 (iii) Bile Acids and the Enterohepatic Circulation (EHC)
The interruption of the enterohepatic circulation by use 
of the bile acid séquestrant, cholestyramine (see Section 1.1.2), 
results in the 5- to 8-fold increase in the activity of HMG-CoA 
reductase (Goldfarb & Pitot, 1972; Tanaka ^  al.j 1982). This is 
the consequence both of the activation of existing enzyme (Tanaka et 
al., 1982) and of the increased amount of enzyme protein (Goldfarb & 
Pitot, 1972; Hardgrave et al., 1979). Cholestyramine-treatment of 
animals increases the amount of mRNA for HMG-CoA reductase (Clarke 
et al., 1983) and the rate of synthesis of the enzyme protein 
(Edwards et ^ . , I983). Since cholesterol and oxysterol derivatives 
control the amount of enzyme protein by operating at the level of 
transcription and translation, it seems likely that cholestyramine 
produces its effects by the depletion of the hepatic pool of free 
cholesterol. In addition, bile acids may have a direct effect
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through inhibition of enzyme synthesis (Barth & Hillmar, 1980; see 
Myant, I98I).
1.3.1 (iv) Mevalonate and its derivatives
The addition of mevalonate (or its lactone, which is rapidly 
hydrolyzed to mevalonate in the cell; Mitchell & Avigan, 198I) to 
cell cultures has the same effect as the addition of LDL with respect 
to the decrease in the concentration of HMG-CoA reductase (due to 
increased enzyme protein synthesis and increased degradation)
(Edwards et al., 1983; Haro e^ al., 1985). A marked reduction in 
the levels of HMG-CoA reductase mRNA was observed in UT-1 cells 
exposed to mevalonate (Luskey et al., 1983) and in the liver of 
cholestyramine-treated animals to which mevalonate had been 
administered by stomach-tube (Clarke e^ al., 1983).
The mechanism of the mevalonate effect may be in part 
identical to that of LDL-cholesterol since mevalonate can potentially 
give rise to cholesterol and its derivatives in the liver. However, 
in cells in which HMG-CoA reductase is not subject to feedback 
regulation by exogenously added cholesterol (e.g. Drosophila embryo 
cells) the effect of mevalonate persists (Brown e;t al., I983). This 
suggests that mevalonate (or a non-sterol derivative thereof) 
is capable of acting on HMG-CoA reductase synthesis independently of 
its role as substrate for cholesterol synthesis. This effector is 
likely to act at the translational level since its effects occur in 
the absence of any decrease in the quantity of mRNA coding for 
HMG-CoA reductase protein (Peffley & Sinensky, 1985). It is 
noteworthy that in Swiss 3T3 cells labelled mevalonate is
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incorporated covalently into a set of proteins (Schmidt e^ al., 
1984). This has been suggested to represent protein terpenylation 
(Peffley & Sinensky, 1985) which would possibly explain the observed 
involvement of the monoterpenes, cineole and menthol in the feedback 
repression of HMG-CoA reductase activity (Clegg et al., 1982).
1.3*2 Regulation of HMG-CoA Reductase by Modulation of Expressed 
Activity
(i) Microenvironment of HMG-CoA reductase in the endoplasmic 
reticulum
HMG-CoA reductase is an integral protein component of the 
endoplasmic reticulum (see Section 1.2.2). Consequently, its 
activity is capable of being modulated by changes in the properties 
of the membrane in which it resides. Mitropoulos (1983 a,b) has 
recently reviewed evidence which suggests that HMG-CoA reductase 
could be modulated by interactions with the immediate lipid 
environment. Thus a decrease in activity of HMG-CoA reductase, 
measured in microsomes isolated from the liver of animals fed a diet 
supplemented with cholesterol, was accompanied by distinct changes in 
the Arrhenius plot for the activity of the enzyme in the microsomes 
isolated from the liver of these animals. The changes were 
attributed to an increase in the pool-size of non-esterified 
cholesterol in the membrane. Another microsomal enzyme, ACAT (see 
Section 1.1.2), shows a direct relationship between activity and the 
membrane content of free cholesterol (Mitropoulos et al., 1981;
1983a,b; Hashiraoto e^ al., 1983).
16
Similar changes to the Arrhenius plot of HMG-CoA reductase 
activity are also observed in microsomes obtained from the liver of 
rats which have been starved (Mitropoulos 1983b), infused 
(intravenously) with mevalonic acid (Mitropoulos e^ al^., 1978) or 
fed an unsaturated fat-supplemented diet (Mitropoulos et al., 1980).
Moreover, work from a number of laboratories (e.g. Sabine & 
James, 1976; Sipat & Sabine, 1981; Finkel & Volpe, 1979; Ramirez ^  
al., 1984; Richert et al., 1984) supports the concept that the 
modulation of HMG-CoA reductase activity by cholesterol (detected by 
changes in the Arrhenius plot) is achieved by virtue of its ability 
to alter the fluidity of the endoplasmic reticulum membrane. Thus 
Davis & Poznansky (1985) demonstrated that when the fluidity of the 
microsomal membrane fraction was altered without changing the 
cholesterol content by enrichment with a saturated 
phosphatidylcholine preparation, the activity of HMG-CoA reductase 
was still depressed. However, this mechanism does not appear to 
effect the changes observed in other cholesterol metabolizing enzymes 
(e.g. ACAT; see above) or the effects of starvation on HMG-CoA 
reductase (see above; Sipat & Sabine, 1981). This suggests that both 
mechanisms exist to regulate microsomal enzymes (see Hashimoto ^  
al., 1983; Van Huesden & Wirtz, 1984).
(ii) Effector proteins and metabolites
A number of liver cytosolic proteins are known to 
influence the activity of HMG-CoA reductase. Amongst these are a 
number of sterol and lipid carrier proteins that seem to function 
directly in the multi-enzyme process of lanosterol conversion to
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cholesterol in the microsomal membranes (see Trzaskos & Gaylor,
1983). An iron-containing protein has also been found to inhibit 
HMG-CoA reductase activity (Menon et , 1982). HMG-CoA reductase 
is also allosterically activated by thiol agents including 
glutathione (GSH) and dithiothreitol (DTT) (Roitelman & Schechter,
1984); these effects may have physiological significance since marked 
diurnal variations are observed in the liver ratios of reduced (GSH) 
and oxidized (GSSG) forms of glutathione (Roitelman & Schechter, 
1984). This mechanism could be involved in the regulation of a 
proposed conversion of an inactive, dimer of the '97k' HMG-CoA 
reductase to an active, monomer form under reducing conditions (Ness 
et ^ . , 1984; Edwards et a^., 1985).
(iii) Covalent modification of HMG-CoA reductase 
The reversible phosphorylation of serine and threonine amino 
acid residues of proteins is one of the major mechanisms by which 
metabolic processes are controlled by neural and hormonal stimuli. 
More than forty enzymes are now known to be regulated in this manner 
(Krebs, 1983) including important regulatory enzymes of carbohydrate 
and lipid metabolism in the liver (see Geelen ^  al., 1980). In 
addition phosphorylation of tyrosine residues appears to be involved 
in the function of certain cell surface hormone receptors (Hunter & 
Cooper, 1985). Sections 1.4 and 1.5 present the evidence to date 
which suggests that HMG-CoA reductase is also regulated by reversible 
phosphorylation.
1*3.3 Modulation of Hepatic HMG-CoA Reductase Activity in the
Physiological Setting: The Diurnal Rhythm
The best documented example of changes in the concentration of 
HMG-CoA reductase in the microsomal fraction of rat liver under 
different physiological conditions is the diurnal variation observed 
when rats are kept under a 12h light:12h dark cycle and fed ad 
libitum. At the peak of this rhythm, which occurs at the middle of 
the dark period (and coincides with active feeding) the activity of 
HMG-CoA reductase is 5- to 10-fold higher than that at the nadir of 
the rhythm during the light period (see Rodwell e^ al., 1976;
Gibbons ^  al., 1982) as the consequence of equivalent changes in 
the concentration of enzyme protein (Clarke e;t al., 1984). The 
physiological role of this rhythm is discussed in detail in Chapter 
4.
From experiments involving the determination of the 
incorporation of [^H]-leucine into enzyme protein (Higgins et al., 
1974)j the effects of cycloheximide administration (see Rodwell ^  
al., 1976) and the turnover rate of the enzyme (Dugan et ^ . , 1972; 
Edwards & Gould, 1974-) it was concluded that changes in the rate of 
enzyme synthesis were responsible for diurnal changes in HMG-CoA 
reductase activity. The rate of enzyme degradation appeared to be 
uniform throughout the day (see Rodwell et al., 1976). Further 
studies revealed that the diurnal increase in HMG-CoA reductase 
depends on an initial period of ^  novo RNA synthesis (Edwards & 
Gould, 1974) and that changes in the amount of HMG-CoA reductase 
enzyme protein are accompanied by parallel changes in the functional 
mRNA content of the liver throughout the diurnal cycle (Clarke et 
al., 1984).
19
Since HMG-CoA reductase has a very short half-life in the cell 
(approximately 2.2h; see Rodwell e^ al., 1976) it is possible that 
the sharp decline in HMG-CoA reductase activity observed from the 
peak of the rhythm is fully accounted for by the cessation of enzyme 
synthesis (see Dugan, 1981). This does not, however, exclude the 
possibility that the rate of enzyme degradation may be raised during 
the diurnal cycle. Such modulation of the rate of degradation is 
evident under conditions of greatly increased rates of enzyme 
synthesis e.g. cholestyramine plus mevinolin treatment vitro 
(Tanaka et al., 1982). Using cholestyramine alone, a dissociation 
between mRNA content and peak activity is evident (Tanaka et al.,
1982). Therefore mevinolin may induce a specific inhibition of the 
degradation of HMG-CoA reductase, possibly as a result of a decreased 
cellular concentration of an endogenously produced metabolite of 
mevalonate (Edwards ^  al., 1983b). This observation, coupled with 
the demonstration that mevalonate will accelerate enzyme degradation 
(Edwards e^ al., 1983a&b; Section 1.3.1(iv)) suggests that this 
variation in the cellular concentration of a metabolite(s) of 
mevalonate may have an important regulatory control over the diurnal 
rhythm of HMG-CoA reductase 2^  vivo.
A number of hormones may be involved in the control of the 
diurnal rhythm of HMG-CoA reductase protein and activity (for reviews 
see Rodwell et al., 1976; Dugan & Porter, 1977). Thus, because of 
the pronounced diurnal rhythm observed in the plasma concentration of 
insulin and glucocorticoids, these hormones would appear to be 
plausible candidates for the generation of signals in the liver that 
result in the rhythm in enzyme concentration discussed above. The
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secretion of insulin would be expected to be more closely related to 
food intake and therefore to approximate to the rhythm in HMG-CoA 
reductase activity observed (which peaks in the dark, feeding 
period). Insulin deficiency induced either by treatment with 
streptozotocin (Nepokroeff et al., 1974) or alloxan (Huber et ^ . ,
1973) results in the abolition of the rhythm of a much reduced 
HMG-CoA reductase activity. The rhythm is restored by the daily 
administration of insulin (Nepokroeff et al., 1974; see Rodwell et 
al., 1976).
Moreover, insulin stimulates the increase in HMG-CoA reductase 
activity and induces proportional increases in cholesterogenesis both 
in animals in which the normal rhythm is approaching a minimum or in 
animals from which food had been withdrawn 6h earlier (Lakshmanan e^ 
al., 1973). That these effects are due to increased protein 
synthesis is suggested by studies in isolated hepatocytes which 
demonstrated that insulin stimulates the synthesis of both HMG-CoA 
reductase mRNA and enzyme protein (cf. work on fibroblasts, Avigan, 
1977; Bhathena et al., 1974).
Glucagon also shows a diurnal variation in plasma 
concentrations (Murakami et al., 1981) but it is still not clear 
whether glucagon, through its intracellular messenger, cyclic AMP, is 
a physiological regulator of HMG-CoA reductase protein synthesis. 
Little effect of this hormone is observed on the activity of HMG-CoA 
reductase in the liver of animals during the light period (Lakshmanan 
et al., 1973) or in perfused liver preparations (Raskin et al.,
1974). However, administrations of glucagon to conscious rats 
suppresses the normal diurnal rise in hepatic HMG-CoA reductase
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substantially (around 50$, Nepokroeff et al., 1974; Dugan et , 
1974; Huber et al., 1973; Lakshmanan at Al., 1973). Also, increased 
intracellular concentrations of cyclic AMP suppress the diurnal rise 
in HMG-CoA reductase activity in rat liver in vivo,
The diurnal peak in plasma concentrations of corticosterone,
the major glucocorticoid in the rat, coincides with the commencement
of the diurnal increase in HMG-CoA reductase activity towards the end
of the light period (Knox et al., 1979; cf. Rodwell et al., 1975;
see Section 4.2). Therefore it is possible that, by analogy with the
effects of glucocorticoids on the synthesis of several hepatic
enzymes e.g. tyrosine aminotransferase (TAT; Olson et al., 1980),
they also stimulate the synthesis of HMG-CoA reductase.
Experiments designed to determine a possible role of
glucocorticoids on the diurnal rhythm of HMG-CoA reductase activity
have produced conflicting reports. For example, adrenalectomy has
been reported to abolish (Hickman et ^ . , 1972; Edwards, 1973),
or
diminish (Mitropoulos & Balasubramanian, 1976)^have no effect on 
(Neprokroeff et al., 1974; Nervi & Dietschy, 1974) this rhythm. 
Equally contradictory results have been reported for the effects of 
added glucocorticoids either in whole rats or isolated hepatocytes. 
The injection of hydrocortisone into normal rats suppressed the 
diurnal-, insulin- and triiodothyronine (T^)-induced increases in 
HMG-CoA reductase activity in normal (Nepokroeff et al., 1974), 
diabetic (Dugan et al., 1974) or hypophysectomized rats 
(Dugan et al., 1974; Ness et ^ . , 1985) respectively. By contrast.
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other groups of workers using either natural glucocorticoids (e.g. 
cortisol; Mitropoulos & Balasubramaniara, 1976) in whole animals, or 
synthetic glucocorticoids (e.g. dexamethasone; Lin & Snodgrass, 1982) 
in whole animals, HeLa cells (Cavanee ^ . , 1978) or hepatocytes 
(Lin & Snodgrass, 1977; 1982; Barth & Hillmar, 1980) have presented 
evidence to suggest that the hormones could positively effect a 
diurnal increase in HMG-CoA reductase activity m  vivo. It is 
clear, however, that glucocorticoids cannot be exclusively 
responsible for the diurnal rythym in HMG-CoA reductase since both of 
the effects on whole animals ^  vivo are dependent on the 
administration of the hormone being made during a particular phase of 
the light-dark cycle.
Other hormones e.g. triiodothyronine (T^), whilst not thought 
to have a role in the initiation of the diurnal»rhythm in HMG-CoA 
reductase synthesis, may play a permissive or potentiating role for 
more direct-acting hormones. restores the diurnal rhythm of 
HMG-CoA reductase activity to hypophysectomized rats although this 
treatment produces a supranormal stimulation of this activity (Ness 
et , 1973; Fig. 1.7) and has recently been shown to be the 
consequence of increased HMG-CoA reductase mRNA and protein (Ness et 
al., 1985). Similarly, the administration of to euthyroid rats 
abolishes the same rhythm at the level of the diurnal peak after a 
time-lag of 2 days (Ness et al., 1973; Fig. 1.7). Also, prior 
administration of is required to restore the ability of insulin to 
elevate HMG-CoA reductase activity in hypophysectomized (Huber et 
al., 1974) or in diabetic-hypophyseotomized rats (Dugan et al..
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Fig. 1.7 Rat liver'HMG-CoA reductase activity in various hormonal 
states
Solid line represents the diurnal rhythm of total HMG-CoA reductase 
activity (nmoles/h per mg of microsomal protein) in normal rats or 
diabetic rats treated with insulin. L-Triiodothyronine (T^; lug/g 
body wt.) was administered 54th before the animals were killed.
(Taken from Dugan e_t 1974)
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1974). However, it is not clear whether these are direct effects of 
the hormone since the effects of can be mimicked by other 
experimental treatments such as high carbohydrate diets, or the 
injection of growth hormone (see Rodwell et , 1976).
Whereas most of the hormonal effects discussed above occur 
through the stimulation or repression of enzyme synthesis it is to be 
appreciated that some of these effects may occur indirectly through 
hormonal effects on cholesterol dynamics in the intact animal (e.g. 
see Lakshmanan et al., 1975; Ness ^  al., 1985). As mentioned 
above, this is possible because the cholesterol status can affect the 
concentration of HMG-CoA reductase and hence activity by feeding back 
on the rate of synthesis of HMG-CoA reductase (see Section 1.3.1(1)).
1.4 Reversible Phosphorylation of HMG-CoA Reductase In Vitro
1.4.1 Historical Survey
In 1973, Beg et al. reported that HMG-CoA reductase activity 
in freshly isolated, washed rat liver microsomes was inhibited by 
preincubation with Mg^^zATP and a protein fraction separated from the 
liver cytosol. The inhibition was time-dependent and was partially 
reversed by treatment of the microsomes with a second protein 
fraction of the cytosol. These investigators therefore proposed that 
HMG-CoA reductase might undergo interconversion between two forms of 
differing specific activities and suggested protein phosphorylation 
as a potential mechanism (Beg ^  aT., 1973).
Independently, Higgins and Rudney (1973) suggested that the 
response of HMG-CoA reductase activity to dietary manipulation (i.e. 
cholesterol feeding) involved variations in the degree of activation
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of the enzyme in addition to changes in its concentration. Goodwin & 
Margolis (1973) observed that the incubation of the 
post-mitochondrial supernatant of rat liver homogenate at 37°C (prior 
to assay) increased the rate of ^^C-acetate but not ^^C-mevalonate 
incorporation into cholesterol by 8- to 20-fold. Since these initial 
observations, work in numerous laboratories has yielded evidence that 
supports the concept of the existence of active and inactive forms of 
HMG-CoA reductase in rat liver (Bove and Hegardt 1978; Chow et al. 
1975; Ingebritsen e^ al. 1978; Nordstrom e^ al. 1977; Berndt e^ al. 
1976; Hunter & Rodwell 1980; Saucier & Kandutsch 1979).
In the initial stages of the characterization of the MgrATP- 
dependent inactivation system. Brown et al. (1975), working on human 
fibroblasts and rat liver, demonstrated that the factor involved was 
heat labile, non-dialyzable and precipitable with ammonium sulphate. 
Kinetic analysis showed that the inactivation produced an 8- to 
20-fold decrease in the V of HMG-CoA reductase without any change
IQ3.X
in the K for HMG-CoA (Brown et al., 1975; Nordstrom et al., 1977). 
m —  —
The activation process of HMG-CoA reductase was shown to be 
blocked by NaF, a potent inhibitor of protein phosphatase (Nordstrom 
^  al., 1977; Berndt et al., 1976; Erickson et , 1980;
Ingebritsen et al., 1978; Beg et ^ . , 1978). Ingebritsen et al.
(1978, 1981) confirmed the involvement of a protein phosphatase by 
achieving the reactivation of Mg^^iATP-inactivated HMG-CoA reductase 
by incubation with a partially purified cytosolic phosphorylase a 
phosphatase. These observations were consistent with the proposal 
that the activity of HMG-CoA reductase could be regulated by 
reversible phosphorylation.
25
This phenomenon has since been confirmed for the enzyme from a 
wide variety of tissues including liver (e.g. Ingebritsen et al., 
1978; Berndt ^  , 1976) brain (Shah, I98I), leucocytes (Harwood,
et ^ . , 1984) and intestine (Oku et , 1984; Panini & Rudney,
1980) in a variety of animal species including pigs, dogs, rodents, 
chickens, frogs, fish (Hunter ^  al., 1980), insects (Brown et al., 
1983) and humans (Harwood ^  al., 1984; Beg et , 1984a).
The involvement of reversible phosphorylation in the 
regulation of HMG-CoA reductase was not universally accepted because 
of difficulties encountered in certain experiments. Thus, whereas 
the freeze-thaw solubilized HMG-CoA reductase, then thought to be the 
native form of the enzyme, could be inactivated by Mg"'*’:ATP and a 
cytosolic preparation of reductase kinase (Nordstrom et a3 .^, 1977) 
thus had proved surprisingly difficult as compared to the 
microsomally-bound enzyme (Brown et al., 1975; Nordstrom et al., 
1977). Also Ness et (1981, 1982, 1983) pointed out that the 
decrease in the rate of mevalonate formation observed for microsomes 
preincubated in the presence of Mg"**":ATP could be due to the removal 
of mevalonate by the ATP-dependent activity of mevalonate kinase, the 
enzyme immediately distal to HMG-CoA reductase in the cholesterogenic 
pathway (Fig. 1.1). Harwood & Rodwell (1982) and Beg e^ al.
(1982) subsequently showed that mevalonate kinase and reductase 
kinase activities were readily distinguishable; this has recently 
been confirmed by Ferrer & Hegardt (1984); (for a review see Kennelly 
& Rodwell, 1985).
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Definitive proof of reversible phosphorylation was obtained
from yivo And vitro experiments in which the incorporation of 
32C P]-phosphate into HMG-CoA reductase was shown to be directly
proportional to inactivation of the enzyme. This was shown to be
true for microsomally bound (Bove et , 1978; Beg et , 1978;
Gil et al., 1980; Keith et , 1979, 1983) and for
immunoprecipitated, electrophoretically pure '53K' enzyme (Beg et
al., I98O; Ferrer & Hegardt, 1984). Phosphorylation was shown to
occur on serine residues. Furthermore, numerous laboratories have
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demonstrated that the activation of [ P]-labelled HMG-CoA reductase
32is accompanied by the concomitant release of [ P]-phosphate from the
enzyme (Beg et ^ . , 1978; Gil et ^ . , 1980; 1981a; 1981b; Brown &
Rodwell, 1983; Sitges ^  al., 1984; Ferrer & Hegardt, 1984).
The precise location of the phosphorylation site(s) on HMG-CoA
reductase has not been resolved although they are presumed to be
situated in the cytosolic domain of the '53K' HMG-CoA reductase which
has access to the modulating enzymes (Fig. 1.6). Tryptic digestion 
32of [ P]-labelled '53K' fragment yields two phosphorylated peptides 
indicating that the enzyme contains at least two structurally 
distinct phosphorylation sites. However, in two recent reports, 
evidence was presented that only one site is directly involved in the 
depression of catalytic activity of HMG-CoA reductase. First, Brown 
& Rodwell (1983) found that when partially inactivated microsomal 
HMG-CoA reductase was treated with either of two partially purified, 
high molecular weight cytosolic HMG-CoA reductase phosphatases (see
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Section 1.4.3 .2) full reactivation of the enzyme followed the release
of only about 5036 of the bound [^^P]-phosphate. Second, treatment of
homogeneous '53K'-enzyme with a purified microsomal HMG-CoA reductase 
32
kinase yielded [~ P]-labelled enzyme phosphorylated at only one site, 
as determined by analysis of the tryptic phosphopeptides (Ferrer & 
Hegardt, 1984). This single-site phosphorylation was apparently 
sufficient to produce total inactivation of the enzyme (Ferrer & 
Hegardt, 1984). The function of the putative second phosphorylation 
site is unclear. However it is possible that it may have a role in 
controlling the rate of (de)phosphorylation of the site that affects 
catalytic competence of the enzyme such as occurs in pyruvate 
dehydrogenase (Cohen, 1982). Alternatively, it may produce some 
conformational change in HMG-CoA reductase enzyme which alters its 
ability to act as a substrate for endogenous proteases, and thus 
affect its rate of degradation.
1.4.2 Bicyclic Mechanism of Reversible Phosphorylation
Further studies conducted on the activity of rat liver 
reductase kinase have revealed that this enzyme is also regulated by 
reversible phosphorylation-déphosphorylation (Ingebritsen et al.,
1978; Gibson & Ingebritsen, 1978; Beg et ^ . , 1979): the
phosphorylated enzyme is active whereas the dephosphorylated enzyme 
is inactive. It was directly demonstrated that the incorporation of 
[32p]_phosphate from [y-^^P]-ATP:Mg^* into homogeneous reductase 
kinase using reductase kinase kinase was associated with a 
concomitant activation of the enzyme (Beg et al., 1979). This 
process is reversed by protein phosphatase (Ingebritsen et al.,
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1981). On the basis of these observations it was suggested that the 
regulation of HMG-CoA reductase activity by reversible 
phosphorylation is mediated through a bicyclic system consisting of 
two separate protein kinases (see below) and at least one phosphatase 
(but the dephosphorylation of two separate phosphoproteins) (Fig. 
1.8). A similar system is thought to operate in human liver (Beg et 
al., 1984).
1.4.3 Properties of Protein Kinases and Phosphatases that act on
HMG-CoA Reductase
1.4.3.1 Reductase Kinase and Reductase Kinase Kinase
Several lines of evidence indicate that reductase kinase and
reductase kinase kinase are distinct enzymes. First the two
activities can be resolved by chromatography on DEAE-cellulose
(Ingebritsen et al., 1981). Second, reductase kinase kinase does
not catalyse the inactivation of HMG-CoA reductase (Ingebritsen e;t
al., 1981). Third, reductase kinase kinase activity is inhibited in
high-ionic-strength buffers that are routinely used to assay both
HMG-CoA reductase and reductase kinase (Ingebritsen et si., 1978).
However, both reductase kinase and reductase kinase kinase appear to
belong to a class of cyclic nucleotide-independent protein kinases
(Beg & Brewer, 198I). Neither activity is influenced by cyclic AMP,
-5 -3
cyclic CMP or cyclic IMP in a concentration range of 10 -10 M or
the specific heat stable inhibitor of cyclic AMP-dependent protein
kinase (Ingebritsen ^  al., 1981).
The initial studies demonstrating the inactivation of 
microsomal HMG-CoA reductase (Beg et al., 1973; Nordstrom et al.,
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Fig. 1.8 Bicyclic phosphorylation system for the regulation of HMG-CoA 
reductase activity
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(Taken from Ingebritsen et al. 1981)
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1977) indicated that the reductase kinase was present both in the 
microsomal fraction and in the cytosol of liver. After detailed 
examination of the cellular distribution of this kinase and of 
reductase kinase kinase (Ingebritsen ^  al., 1981) more than 80% of 
each activity was found to be in the cytosolic fraction. The 
remaining activity which sedimented with the microsomal fraction was 
readily extracted under conditions which did not solubilize HMG-CoA 
reductase (Ingebritsen ^  , 1981). It is considered that these
enzymes are primarily cytosolic and that the activities observed in 
the microsomal fraction result from adventitious binding of these 
enzymes with the microsomal membrane.
Both reductase kinase and reductase kinase kinase utilize ATP 
as phosphoryl donor. Reductase kinase has some activity with GTP but 
is virtually inactive with GTP, ITP and UTP (Brown et , 1975; 
Harwood ^  al., 1984); the nucleotide specificity of reductase 
kinase kinase is presently unknown. Interestingly, Brown et al. 
(1975) and Nordstrom et al. (1977) demonstrated that ADP was 
required for full reductase kinase activity. This property was later 
confirmed using purified (cytosolic) reductase kinase-mediated 
inactivation of either microsomal '53K' HMG-CoA reductase (Harwood 
al., 1984) or detergent-solublized '97%' enzyme (Kennelly et al^, 
1983). Using '53K' HMG-CoA reductase as substrate, the K of 
reductase kinase for ADP has been determined to be 0.1-1.4mM (Harwood 
et ^ . , 1984; Caelles et al., 1985) and thus suggesting that this 
could be a physiologically important effect. (Total intracellular 
concentration of ADP is approximately 0.8 mM; Harwood et al., 1984). 
This property appears to be unique for protein kinases and exclusive
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to cytosolic reductase kinase (Gibson & Parker, 1985). This suggests 
that cytosolic and microsomal reductase kinase may have different 
properties but the significance of this is unclear.
Beg e^ (1979), in a preliminary publication containing a 
procedure for purifying reductase kinase to apparent homogeneity from 
microsomal extracts, reported that the enzyme possessed a molecular 
weight (Mr) of 38OK as judged by gel filtration on Sepharose 6B and 
was hexameric with subunit Mr of 58K as determined by SDS-PAGE.
Ferrer & Hegardt (1984) have recently purified rat liver reductase 
kinase to homogeneity from microsomal extracts but reported that the 
enzyme possessed a native molecular weight (Mr) of 205K and monomeric 
Mr of 105K on gel filtration and SDS-PAGE respectively. The 
relationship between these two preparations is unclear. As yet the 
equivalent properties of reductase kinase kinase have not been 
assessed.
Apart from reductase kinase. Beg and co-workers have shown 
that a purified Ca^^-activated, phospholipid-dependent protein kinase 
(protein kinase-C) (Beg et al., 1985a) and a
Ca^^-calmodulin-dependent protein kinase (Beg et al., 1985b) also 
catalyze the phosphorylation and consequent inactivation of both 
microsomal '97K' and purified, soluble '53%' HMG-CoA reductase.
These effects are clearly independent of the involvement of reductase 
kinase because none of the properties exhibited by these protein 
kinases are possessed by reductase kinase. Therefore, this could 
represent a mechanism through which HMG-CoA reductase activity could 
be modulated in response to an increase in intracellular Ca“ such as 
occurs following the stimulation of hepatocytes with a^-adrenergic
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agonists (See Exton, 1985), vasopressin or angiotension II 
(Charest et al., 1983) further to the regulation of reductase kinase 
(via reductase kinase kinase). This regulation of HMG-Coâ reductase 
activity by multiple protein kinases is is illustrated in Fig, 1.9.
Reductase Phosphatase(s)
The ability of phosphorylated HMG-CoA reductase to act as 
substrate for a range of protein phosphatases that occur in mammalian 
tissues has recently been investigated (Ingebritsen & Cohen, 1983; 
Ingebritsen at al., 1983a, 1983b). The four major protein 
phosphatases have been termed phosphatases-1, -2A, -2B and -2C 
(Ingebritsen & Cohen, I983). HMG-CoA reductase-phosphate and 
reductase kinase phosphate were shown to be substrates for protein 
phosphatases-1, -2A and -2C (Ingebritsen & Cohen, 1983).
These three phosphatases can be distinguished by virtue of 
their different properties, e.g. protein phosphatase-1 is inhibited 
by protein inhibitors (inhibitors-1 and -2) whereas protein- 
phosphatases-2 are insensitive to these inhibitors. The phosphatases 
also have different substrate specificities e.g. protein 
phosphatase-1 preferentially dephosphorylates the B-subunit of 
phosphorylase kinase whereas type-2 phosphatases dephosphorylate the 
a-subunit of phosphorylase kinase (Ingebritsen & Cohen, 1983).
Protein phosphatase-2A, which acts on HMG-CoA reductase 
phosphate, is resolved by chromatography on DEAE-cellulose into three 
species, termed protein phosphatase-2AQ, -2A^ and -2A^ with Mr =
21 OK, 21 OK and 150K respectively (as determined by gel filtration; 
see Ingebritsen, 1983). Each contain the same catalytic subunit (Mr
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Fig. 1.9 Multivectorial regulation of phosphorylation of 
HMG-CoA reductase (HMG-CoA R) by kinases.
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2+CaM-kinase, Ca -calmodulin-dependent protein kinase; Red. 
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= 35K). Protein phosphatase -2C is composed of a single subunit (Mr 
= 46k) and is dependent on Mg (K^ = 1.0 mM). The mechanisms for 
regulating protein phosphatases-2A and -2C are presently unknown 
although the observed activation of the catalytic subunit of protein 
phosphatase-2A (Mr = 35K) following its dissociation from the other 
subunits subsequent to freeze-thaw treatment of the phosphatase 
preparation (Ingebritsen ^  al., 19830), suggests that mechanisms 
may exist for the regulation of this phophatase vivo.
Two important mechanisms apparently exist for the regulation 
of protein phosphatase-1 :
(i) Protein phosphatase activity is inhibited by the binding 
of inhibitor-1 only subsequent to its phosphorylation and concomitant 
activation by the phosphorylation of a specific threonine residue by 
cAMP-dependent protein kinase (Huang & Glinsman, 1975; Cohen et al., 
1977; Nimmo & Cohen, 1978). In skeletal muscle the extent of 
phosphorylation of inhibitor-1 is increased by epinephrine treatment 
(Foulkes & Cohen, 1979) and decreased by insulin, which antagonizes 
the effects of low concentrations of 3-adrenergic agonists (Foulkes 
et al., 1982) on proteins which are substrates for protein 
phosphatase-1 and which are phosphorylated by cyclic AMP-dependent 
protein kinase e.g. glycogen synthase (site 2) (Cohen, 1982). This 
represents a mechanism by which inhibitor-1 may prevent 
dephosphorylation by protein phosphatase-1 and so amplify the effects 
of cyclic AMP on their phosphorylation. In addition, since protein 
phosphatase—1 also acts on proteins phosphorylated by other protein 
kinases e.g. glycogen synthase (sites 3a+b+c) (Parker et ^ . , 1982) 
the inhibition of this enzyme by phospho-inhibitor-1 may allow cyclic
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AMP to modulate the phosphorylation of these substrates. A protein 
with properties that are very similar to those of inhibitor-1 has 
been isolated from liver (Knight & Tal, 198O; Goris et , 1978) 
and therefore it is possible that this mechanism may exist for the 
regulation of HMG-CoA reductase and reductase kinase by reversible 
phosphorylation.
(2) The second mechanism known for the regulation of protein 
phosphatase-1 involves the reversible association of the catalytic 
subunit with inhibitor-2 (Hammings et , 1982; Resink et al.,
1983). Dissociation of this inhibitor activates protein 
phosphatase-1 and depends on the phosphorylation of the latter on a 
threonine residue (Hammings et al., 1982). Consequently, when 
associated with inhibitor-2, phosphatase-1 activity is ATP-dependent. 
Although inhibitor-2 (Khandelwal & Zinman, 1978; Goris et al., 1979) 
and a suitable protein kinase, thought to be glycogen synthase 
kinase-3 (Hammings et ^ . , I98I; Yang et al., I98O), appear to be 
present in the liver, the physiological role of this interconversion 
system in liver or other tissue remains to be established.
The relative contributions of protein phosphatases-1, -2A and 
-2C to the dephosphorylation activity towards HMG-CoA reductase and 
reductase kinase vivo remains unclear. Protein phosphatase-2C 
shows the greatest activity on HMG-CoA reductase and reductase 
kinase-phosphate accounting for 60-70% and 95-100% of the 
dephosphorylating activity at high and low dilutions of liver 
homogenates respectively (Ingebritsen et ^ . , 1983b). The 
prominence of protein phosphatase-2C action may be due to the 
inhibition of protein phosphatases-1 and -2A in concentrated
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extracts; however, such a degree of inhibition may not exist in 
vivo. It is noteworthy that a significant fraction of protein 
phosphatase-1 alone among four phosphatases in the liver (20%) is 
associated with the microsomal fraction (Ingebritsen et al., 1983b) 
and consequently this phosphatase would be expected to be most likely 
to act as a microsomal membrane enzyme such as HMG-CoA reductase in 
vivo.
1.5 Intracellular Phosphorylation of HMG-CoA Reductase
Numerous previous investigations have been performed to 
determine whether the phosphorylation state of HMG-CoA reductase is 
capable of modulation within the intact cell. Ingebritsen e^ al. 
(1979) demonstrated that the phosphorylation state of the enzyme 
could be modulated by hormones in isolated rat hepatocytes.
These workers deduced these changes in the phosphorylation state from 
changes in the rates of HMG-CoA reductase activity measured in 
microsomes isolated from cell homogenates prepared in the presence of 
F" and EDTA, to block endogenous protein phosphatase and kinase 
activities respectively ('expressed' activity; 'E'; see Section 
2.8.3) to activity determined after the incubation of microsomes 
prepared in the absence of F" (but with EDTA) with sufficient added 
partially purified protein phosphatase to fully activate the enzyme 
('Total' activity, 'T' see Section 2.8.3); this ratio is designated 
as the E/T ratio (see Section 2.8.3) In control cells i.e. incubated 
in the absence of hormones the E/T ratio of HMG-CoA reductase 
activity which was initially low (approximately 20%) showed a marked 
increase (to approximately 95%) between 90 and 150 min of incubation.
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Whereas the addition of glucagon to this incubation completely- 
antagonized the rise, an effect mimicked by dibutyryl-cyclic AMP, 
insulin markedly enhanced this increase. Glucagon and insulin also 
had opposing effects (enhancement and inhibition respectively) on a 
spontaneous decline in total activity observed in control cell 
incubations.
Recently, Henneberg and Rodwell (1981, 1985) have further 
showed that glucagon can specifically lower the E/T ratio of HMG-CoA 
reductase rather than merely antagonize a spontaneous increase in 
this parameter as indicated in the study of Inegbritsen et al. 
(Henneberg & Rodwell, 1985). These effects were also mimicked by 
cyclic AMP and cyclic GMP. The effects of glucagon represent a 
paradox since both reductase kinase and reductase kinase kinase 
belong to the cyclic nucleotide-independent class of protein kinases 
(see Section 1.4.3*1). Nevertheless, Ingebritsen et al. (1979) 
showed that glucagon (and insulin) stimulated (and insulin 
diminished) the expressed activity of reductase kinase and 
subsequently proposed the involvement of protein inhibitor-1 through 
its phosphorylation by cyclic AMP-dependent protein kinase (see 
Section 1.4.3.2(i) and Chapter 5).
Subsequently two groups of workers demonstrated that changes 
in the phosphorylation state of HMG-CoA reductase could be provoked 
in the intact rat vivo by the acute administration of 
pharmacological doses of glucagon or large amounts of mevalonalactone 
or cholesterol. Beg and coworkers demonstrated that the 
incorporation of [^^P]-phosphate from [y-^^pJ-ATP into HMG-CoA 
reductase protein was increased following the acute intraperitoneal
36
injection of glucagon (Beg et al., 1980) or the oral administration 
of mevalonolactone by stomach intubation (Beg & Brewer, 1982). In 
the case of this latter treatment and similar treatments of 
cholesterol, the increased [ P]-phosphate content of HMG-CoA 
reductase was accompanied by changes in the activity of the enzyme 
(Beg & Brewer, 1982). These changes which were confirmed by 
immunotitration studies (Arebalo et , 1981, 1982). (The studies 
concerned with the effects of cholesterol and mevalonate are 
discussed in detail in Chapter 6).
Whilst these observations suggest that changes in the 
phosphorylation state occur in vivo, attempts at detecting such 
changes in the liver in vivo in response to normal physiological 
hormonal or nutritional changes e.g. the diurnal rhythm (Jenke 
al., 19 8 1) or short-term starvation (Brown et al., 1979) have been 
unsuccessful. Studies by Nordstrom et al. (1977), Brown et al. 
(1 9 7 9) and Dugan et al. (1982) led to the conclusion that under 
normal physiological conditions HMG-CoA reductase is always largely 
(about 85%) inhibited in spite of the large range of the rates of 
hepatic cholesterol synthesis in vivo (see e.g. Rodwell e^ al., 
1976). Consequently, the view that the modulation of the 
phosphorylation state of HMG—CoA reductase such as observed in 
hepatocytes or in response to acute stimuli is not relevant to the 
control of the enzyme in normal physiological conditions has 
persisted (see e.g. Berndt et al., 1976; Hardgrave e^ 5^. , 1979; 
Kleinsek et al., 1980; Jenke ^  al., 1981; Dugan et al., 1982; 
Liscum et al., 1983b; Gregg & Wilce, 1981; Ness, 1983) in spite of 
some evidence to the contrary (Edwards et al., 1980). In many of
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these studies, it has been suggested that the observed changes in the 
expressed activity of HMG-CoA reductase could be fully accounted for 
by changes in the amount of enzyme protein in the liver.
By analogy with the physiologically induced changes in the 
activity state in vivo of other enzymes regulated through a 
phosphorylation-déphosphorylation mechanism (e.g. see Cohen, 1982) it 
is highly unlikely that the bicyclic protein phosphorylation 
mechanism described for the regulation of HMG-CoA reductase activity 
goes largely unused in vivo. Therefore it is possible that the 
paradoxical situation evident in the literature could be explained if 
the expected changes in the phosphorylation state of HMG-CoA 
reductase induced by physiological stimuli such as occur during the 
diurnal cycle of feeding and short-term starvation have been 
overlooked. If this is the case then the modest change observed in 
the livers of animals challenged acutely with unphysiological 
concentrations of hormone or dietary manipulation could be only the 
residual effects of much larger responses. Therefore, the main aim 
of the work reported in this present thesis was to resolve 
definitively the controversy as to whether changes in the 
phosphorylation state of HMG-CoA reductase do occur in vivo and to 
investigate quantitatively any changes in the phosphorylation state 
that occur in response to physiological stimuli.
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CHAPTER 2 
MATERIALS AND METHODS
2.1 Animals
The rats used in this study were of the Wistar strain obtained 
from A. Tuck & Son, Battlesbridge, Essex, U.K. The animal house was 
maintained at temperatures between 20 and 25°C and on a 12h 
light: 12h dark cycle. The timing of the cycle was adjusted to 
satisfy the requirement of each experiment but a period of at least 
10 days was allowed for the animals to adapt to any new lighting 
regimen. Male rats used in experiments described in Chapters 3, 4 
and 5 were housed from birth in this lighting regimen. The animals 
were fed Oxoid breeding diet (Oxoid, Basingstoke, Hants, U.K.) ad 
libitum and were used within a weight range of l60-200g (i.e. 5-6 
wks old). The male rats used in Chapter 6 were delivered to the 
animal house at a weight of 70-90g and kept for 2 weeks on the same 
lighting regimen before use at the same weight as above (i.e. 
l60-200g). These animals were maintained on a Labsure diet 
(K . & K .—Greeff Ltd., Croydon, U .K .).
Female rats used for this study into the effects of pregnancy 
and lactation were transferred to the reversed lighting regimen 
during the first week of pregnancy except for animals used on day 12 
of pregnancy which were time—mated under the required lighting 
regimen. The rats weighed 280-300g at day 12 of pregnancy, 230-270g 
and 340-370g on day-1 and day-12 of lactation respectively. The day 
of conception, determined from the appearance of vaginal plugs, was
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counted as day-0 and animals littered on day-21. Animals used to 
study the effects of weaning had their pups removed on day-11 of 
lactation 24h before being killed.
Animals were trained individually to handling for several 
minutes each day for 4 days prior to killing in order to minimize the 
effects of stress on the day of the experiment. Anaesthesia for 
normal rats was achieved through the intraperitoneal injection of 
pentobarbital (60mg/kg body wt.) solution prepared in physiological 
(0.9% NaCI) strength saline immediately before use. Animals were 
allowed to settle for 20 min before the abdominal cavity was opened.
A reduced (67% of normal) and an increased (125-150% of normal) dose 
of pentobarbital was used to anaesthetize diabetic and late-pregnant 
animals respectively. These doses were required to achieve the same 
degree of anaesthesia achieved for animals in other physiological 
states.
2.2 Induction of Experimental Diabetes
Diabetes was induced in male animals (140-I60g) by 
intraperitoneal injection of the 6-cell cytotoxic drug, 
streptozotocin (150mg/kg body wt.). Solutions of the drug (40mg/ml) 
were prepared immediately before use in citrate-saline (pH 4.5). 
Diabetes was allowed to develop in the animals and they were used 7-8 
days later. For the first 2 days after treatment, the animals were 
given a 1% glucose solution to drink. This treatment produced an 
elevation in blood glucose concentrations between approximately 
10-40mM.
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2.3 Stomach Intubation
The rats were anaesthetized with 80% of the normal dose of 
pentobarbital and closely observed. When the animals became relaxed 
but still able to swallow a tube inserted into their mouths, they 
were intubated. This procedure facilitated the guidance of the 
plastic tube into the stomach and deleterious effects in the normal 
respiratory pattern of the animals were minimized.
Mevalonolactone (750-?80mg/kg body wt.) and four fractions of 
spray-dried milk (whole milk, buttermilk, whey proteins and skim 
milk; 1.8g/kg body wt.; see Section 2.14) were administered in 
distilled water; control animals were given distilled water only. 
Further anaesthesia was given as required in order to induce full 
anaesthesia after the intubation was completed. The abdominal 
cavities were opened and the livers of these animals sampled 20-30 
min later.
2.4 Hormonal Treatment
Insulin (30U/kg body wt.), glucagon (1.25mg/kg body wt.) and 
epinephrine (0.6-1.5yg/kg body wt.), were administered to 
anaesthetized rats intravenously via a Monoject fine-guaged needle 
(27G X  i " ;  Sherwood Medical Industries, Crawley, West Sussex, U.K.) 
inserted into the femoral vein previously exposed by a small incision 
of the skin. When administered intraperitoneally, the dose of 
insulin was higher (120U/kg). Insulin and glucagon were dissolved in 
acidified saline (0.9% NaCI, pH 3-4; Img/ml). Epinephrine was 
prepared at 1000-times the required concentration (0.8mg/ml) in lOmM 
ascorbic acid and diluted immediately prior to use in saline. Saline
41
or diluted ascorbic acid minus hormone was administered to control 
rats as appropriate.
Somatostatin (cyclic) was infused intravenously to suppress 
the endogenous secretion of insulin and glucagon from the pancreas on 
subsequent administration of either of these hormones. Using a 
syringe pump (Sage, Model 341, A.R. Horwell Ltd, Kilburn High Rd., 
London, SW6 2BP) a continuous infusion (100-200yg/kg body wt. per 
h) was maintained for 20 min through a catheter dwelling in the 
femoral vein.
2.5 Administration of Adrenergic Antagonists
Prazosin (50yg/kg body wt. in O.BmM-lactic acid) and 
propranolol (125yg/kg body wt. in saline), specific and 
non-selective 3-adrenergic receptor blockers respectively were 
administered by intravenous infusion to rats anaesthetized with ether 
1h prior to killing (as above). Immediately after the infusion a 
local anaesthetic, Lignovet (C-Vet Limited, Bury St. Edmunds, U.K.) 
was administered to the skin in the area surrounding the incision and 
the wound stitched using a Mersilk silk suture (4% guage, round 
bodied I6mm needle; Ethicon, Edinburgh, Scotland, U.K.). The 
animals, which showed no signs of discomfort, were anaesthetized as 
described above after 40 min and the liver sampled 20 min later.
2.6 Biochemicals
Inorganic chemicals used were of the highest grade 
commercially available and were generally obtained from Fisons 
Scientific Apparatus (Loughborough, Leics., LE11 ORG, U.K.), (for
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details see Easom & Zammit, 1984). In addition,
dicyclohexylcarbodiimide was obtained from Aldrich Chemical Co. Ltd., 
Gillingham, Dorset, SP8 4JL, U.K.). Insulin (crystalline, pig), 
epinephrine (free base), and propranolol-HCl (crystalline) were 
obtained from Sigma (London) Chemical Co. (Poole, Dorset, U.K.). 
Crystalline pig glucagon and streptozotocin were generously given by 
Lilly Research Laboratory (Indianapolis, I.N., U.S.A.) and the Upjohn 
Co. (Kalamazoo, N.I., U.S.A.) respectively. Cyclic somatostatin was 
obtained from Bachem U.K. (Saffron Walden, Essex, CB10 1AA, U.K.). 
Prazosin was a generous gift from Pfizer Central Research (Sandwich, 
Kent, CT13 9NJ, U.K.).
The following radioactive biochemicals were obtained from
Amersham International pic (Amersham, Bucks., HP? 9LL, U.K.):
14 3
3-hydroxy-3-methyl[3- C] glutaric acid, DL-[2- H] mevalonic acid
lactone and 3',5'-cyclic [8-^H] AMP.
2.7 Synthesis of 3-hydroxy-3-methyl[3-'*^C] glutaryl-coenzyme A
14 14
3-Hydroxy-3-methyl[3- C] glutaryl-coenzyme A (HMGÜ3- C]-
CoA) was synthesized by either of two methods: (i) The first
involved the formation of a high energy anhydride intermediate after
the nucleophilic reaction of HMG acid on dicyclohexylcarbodiimide
(DCCD) as described by Goldfarb & Pitot (1971). HMG[ 3 - -CoA was
purified by paper chromatography. Elution from the chromatogram with
ice-cold distilled water was accelerated using centrifugal force
(1500g, 5 min) as described by Edstrom (1968). This method resulted
in yields of 62-68% with final specific activity ranging from
0.30-0.70 Ci/mol.
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(ii) The second method was essentially the same as that 
described above but with the omission of the recrystallization of 
HMG-anhydride. This method (described by Williamson & Rodwell, I98I) 
involved the separation of HMG[3-^^C]-CoA by ion-exchange column 
chromatography using DEAE-cellulose (DE-52, 20cm x 2,5cm Whatman, 
Maidstone, Kent, U.K.). Elution was performed with a gradient 
(0.1-0.4m) of ammonium formate, pH 4.4. The recovery of 
radioactivity from the column (routinely at 0.20-0.22M formate) 
approached 100% as ensured by the inclusion of a 4-fold excess of 
lithium-CoA in the reaction with HMG-anhydride. The yield of 
HMG[3-"*^C]-CoA was 70-75%. The specific activity of HMG-[3-^^C]-CoA 
synthesized by this method was much higher (15-18 Ci/mol) and after 
suitable dilution with cold HMG-CoA was used at a final specific 
activity of 1.25 Ci/mol for studies in animals characterized by low 
activities of HMG-CoA reductase e.g. in diabetic animals.
The concentration of HMG [3-”'^C]-CoA was determined by the 
complete conversion to [3-^^C]-acetoacetate after incubation with 
either sonicated rat liver mitochondria or freeze-clamped liver 
homogenate (50yl). The assay medium contained 55mM-Tris/HCl (pH 8.5) 
and 5.5mM-MgCl2; the total volume was 450yl. The reaction was 
stopped after 120 min with 3% PCA (500yl). The denatured protein was 
sedimented by centrifugation (8000g, 1 min) in an Eppendorf 4312 
centrifuge, and the supernatant neutralized by the addition of solid 
KHCOg. After repeating the centrifugation step, a portion of the 
supernatant was assayed for acetoacetate by the spectrophotometric 
method described by Mellanby & Williams (1974).
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The assay medium contained SOmM-KH^PO^ pH 7.0; 0.2mM-NADH in a 
total volume of 2ml. The reaction was started by the addition of 
0.1U -hydroxybutyrate dehydrogenase and the difference in absorbance 
at 340nra determined after the reaction was complete.
2.8 Determination of Hepatic HMG-CoA Reductase Activity
2.8.1 Preparation of Liver Homogenate
Unless otherwise indicated, liver was sampled and homogenized 
by the cold-clamping technique described in Chapter 3 (see Easom & 
Zammit, 1984). The clamped liver sample was homogenized by three 
passes in a Teflon/glass homogenizer (approximately 25ml) (radial 
clearance 0.20-0.25mm) driven by a constant-torque motor (Tri-R 
Stir-R, Model K43, Camlab Ltd., Cambridge, CB4 1TH, U.K.) operated at 
1000 rev/min. The ice-cold homogenization medium contained 
50mM-sucrose, lOmM-Tris/HCl (pH 7.4), lOOmM-KF, 10mM-EDTA^ ImM-DTT 
and 0.5mM phenylmethanesulphonyl fluoride (PMSF). The homogenate was 
centrifuged at 5000g for 10 min; the procedure was then repeated. 
These were optimal conditions for the maximal removal of intact 
mitochondria concomitant with minimal loss from the supernatant of 
microsomal cytochrome-c oxido-reductase activity (Fig. 2.1).
The final supernatant was divided into two parts, and both 
were centrifuged at 100,000g for 45 min. One of the resulting 
microsomal pellets was resuspended in a buffer containing 
50mM-KH2P0^, pH 7.25, 50mM-KCl, lOOmM-KF and ImM-EDTA and the other 
in a similar buffer in which the KF had been replaced by an 
equivalent concentration of KCl. After a further centrifugation at 
100,000g for 45 min, the pellets were resuspended in the respective
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Fig. 2.1 Determination of optimal conditions for selective separation of 
mitochondria from microsomal membranes
Mitochondria marker enzymes, citrate synthase (inner membrane,#), 
glutamate dehydrogenase (matrix,H ) , and microsomal marker enzyme, cytochr 
c-oxido-reductase ijj^ ) were determined in the supernatant of cold-clamped 
liver samples (see Chapter 3) subsequent to centrifugation at the indicate 
speed (10 min, 4°C). Values are represented as a percentage of enzyme 
activities recorded in the same volume of homogenate subsequent to the 
sedimentation of cell debris by centrifugation at 2000 rpm (~500xg).
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buffers to a concentration of approximately 8-10mg of microsomal 
protein/ml and used for the assay of HMG-CoA reductase.
Freeze-clamped liver samples were processed by pulverization 
in an aluminium mortar and pestle and then homogenized (2x1 Os) with a 
Polytron disintegrator (Kinematic, Basle, Switzerland) in ice-cold 
buffer (SOmM-KH^PO^, pH 7-4), 15mM-EDTA, 15mM-EGTA, lOmM-DTT, 
0.5mM-PMSF and 0.Img/ml of each of trypsin inhibitor, antipain, 
pepstatin and leupeptin (Sigma Chemical Co., Poole, Dorset, U.K.)). 
The homogenate was centrifuged (8000g; 30s) and the supernatant used 
for the assay of HMG-CoA reductase.
2.8.2 Assay of HMG-CoA Reductase
HMG-CoA reductase activity was assayed at 37°C essentially as 
described by Shapiro ejb al., 1974, except that the assay volume was 
75]il. Microsomes (20yl) were preincubated for 2 min in a total 
volume of 50yl and the reaction was started by the addition of 25yl
of cofactor solution containing 2.5 moles glucose-6-phosphate, 0.15U
glucose-6-phosphate dehydrogenase, 225 nmoles NADP , 25 nmoles
14 1
DL-HMGC3- C]-CoA and 11,000-19,000 dpm DL-[2-^H] mevalonic acid
lactone. The reaction was stopped after 15 min by the addition of
25yl of 5M-HC1. The tubes were centrifuged for 1 min to sediment
denatured protein. After incubation at 37°C to effect complete
lactonization, samples (75yl) were applied to activated t.l.c. plates
(silica gel G; 0.5mm thickness) and chromatographed vertically in
toluene/acetone (1:1, v/v). In this system, the non-polar product
mevalonate (R^ = 0.55-0.75) is clearly resolved from the more polar
HMG-CoA (R^ = 0.1-0.3). The product (located by visual detection of
a concentrated mevalonolactone standard marker run in parallel on the
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same plates) was recovered from the gel scraped off the plates by- 
extraction with 2 vol. (7.5ml) of diethyl ether.
The combined extracts were dried down at 40°C and the residue
was dissolved in water (400 1) to which 10ml of scintillant
(Scintillator 299, Packard) was added. The amount of radioactivity 
3 14
due to ■ H and C was measured in a Packard Tri-Carb
liquid-scintillation counter and the results were corrected for the
efficiency of extraction using the added [^H] mevalonolactone as an
internal standard. This was found routinely to be 70-80%.
The formation of mevalonolactone product was linear with
respect to both time (Fig. 2.2) and microsomal protein concentration
(Fig. 2.2) over the ranges used in the experiments. Controls from
which NADP* was omitted were run concurrently. These allowed the
14subtraction from the total C-labelled products formed of the 
activity of HMG-CoA lyase (see Chapter 3).
2.8.3 Activation of HMG-CoA Reductase by Exogenous Purified Protein
Phosphatase to Obtain Total Activity
Total dephosphorylation and activation of the enzyme was 
achieved by incubating microsomes (160-200 g of protein) with 1-4U of 
exogenous protein phosphatase partially purified from rat liver (see 
Section 2.12) in the presence of 2mM-MnCl^ (concentration of free 
Mn ions was approximately ImM). Under these conditions the 
activation was rapid and complete after approximately 5 min; a 
typical progress curve of the phosphatase-induced activation of 
HMG-CoA is shovm in Fig. 2.3. Routinely, microsomes were incubated 
for 10-15 min to ensure the attainment of maximal activity (total
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Fig. 2.2 Effect of (a) time and (b) protein concentration on HMG-CoA 
reductase activity in isolated rat liver microsomes
Microsomes were prepared from homogenate of cold-clamped liver sample 
and assayed for HMG-CoA reductase activity subsequent to activation by 
partially purified protein phosphatase (Section 2.8). (a) Assay mix
(75|j.l) contained 112^g microsomal protein and (b) assay time was 15 min. 
MVAL; mevalonolactone.
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activity) of HMG-CoA reductase. Controls from which protein 
phosphatase was omitted, but in which lOOmM-KF was included were run 
concurrently. No activation of HMG-CoA reductase was evident in 
these samples (Fig. 2.3). (The incubation media for 
phosphatase-treated and non-phosphatase-treated microsomes were 
equalized with respect to KF concentration before assay of HMG-CoA 
reductase activity).
2.8.4 Expression of Activity of HMG-CoA Reductase
By analogy with terminology used for other enzymes that are 
regulated by covalent modification, the activity of HMG-CoA reductase 
obtained before full activation with phosphatase treatment is 
referred to as the 'expressed' activity, whereas that of the fully
activated enzyme is designated 'total' activity. The fraction of the
enzyme in the active form is presented as the
expressed/total-activity ratio (E/T ratio). Absolute values of 
HMG-CoA reductase for both expressed and total activities are 
presented as nmoles/min per mg of microsomal protein at 37°C.
2.9 Assay of Other Enzymes
2.9.1 Radiochemical Assay of HMG-CoA Lyase
The activity of HMG-CoA lyase in homogenates of freeze-clamped 
liver samples was determined as described by Clinkenbeard et , 
(1975a). The assay medium contained 50mM-Tris/HCl (pH 8.5), 5mM 
MgCl^, 1.5mM CaClg, 0.2mM-HMG[3-^^C]-CoA in a final volume of lOOyl. 
The incubations at 30°C were started with homogenate (lOyl) and after
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Fig. 2.3 Time course of activation of HMG-CoA reductase in rat liver 
microsomes by exogenous, partially purified liver protein 
phosphatase
Microsomes prepared from the liver of a rat killed by cervical 
dislocation were incubated with protein phosphatase (approx. 4U) in the 
presence of lOOmM-KCl ( #  ) or lOOmM-KF ( A ) . At the intervals shown, 
sauries of the incubation mixtures were assayed for activity of HMG-CoA 
reductase.
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various lengths of time (0-10 min, to ensure linearity of reaction) 
0.08ml aliquots were transferred to glass vials containing 0.2ml 
6N HCl. The volatile product [3-"'^Cl-acetoacetate was removed by 
taking this aliquot to dryness at 95°C under a constant flow of air 
and the non-volatile HMG [3-”*^C]-CoA remaining was dissolved in water 
(0.4ml) and the radioactivity counted as described above (Section 
2.8.2).
2.9.2 Pyruvate Kinase
Pyruvate kinase activity was measured as described by Zammit 
et al. (1978). The assay coupled pyruvate formation via lactate 
dehydrogenase to NADH oxidation. The change in absorbance at 3l4nm 
was followed at 25°C using a recording spectrophotometer. The assay 
medium contained l60mM-TRA, 15mM-MgCl , 80mM-KCl, 5mM-ADP,
0.2mM-NADH, 3-6U lactate dehydrogenase and various concentrations of 
phosphoenolpyruvate (PEP; Tricyclohexylammonium salt) (see section
3.3 .2). The reaction was started by the addition of PEP. Controls 
omitting ADP were run concurrently.
Phosphorylation of pyruvate kinase in fluoride-containing 
homogenates of freeze-clamped liver (lOOyl) was performed by addition 
of a mixture (lOOyl) containing lOmM-ATP, SmM-MgClg, lOOym-cyclic AMP 
and 2 units of catalytic subunit of cyclic AMP-dependent protein 
kinase. In preliminary experiments the mixture was incubated at 37°C 
and samples were taken at intervals and assayed for pyruvate kinase 
activity (with 0.6mM PEP) until a constant minimum activity was 
obtained. Routinely, phosphorylation was performed for 20-30 min.
The homogenates (termed 'phosphorylated') were then used to determine 
the activity of pyruvate kinase at various concentrations of PEP.
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2.9.3 Citrate Synthase
Citrate synthase was assayed spectrophotometrically by the 
method of Srere et al. (1963). The rate of release of CoASH from 
aoetyl-CoA was followed at 4l2nm and 25°C by use of DTNB. The assay 
medium contained 50mM-Tris/HCl (pH 7.3), 0.2mM-DTNB,
O.ImM-acetyl-CoA; 0.2mM-oxaloacetate and 0.5% (v/v) Triton X-100.
The total volume was 1.05ml. The reaction was started with 
homogenate (10 1). Controls, omitting oxaloacetate, were run 
concurrently.
2.9.4 Glutamate Dehydrogenase
The assay for glutamate dehydrogenase was based on that 
described by Schmidt (1963). The assay medium contained 70mM-Tris 
HCl (pH 7.5), lOOmM-NH acetate, 2.5mM EDTA, 0.2mM-NADH, ImM-ADP,
0.1% (v/v)-Triton X-100, and 2.5% (w/v) antimycin A to which was 
added 10 1 sample. The total volume was 2.0 ml. The reaction was 
started by the addition of 2-oxoglutarate (20 1; final concentration 
8mM) and the decrease in absorbance at 340nm due to oxidation of NADH 
was followed continuously at 25°C. Controls omitting 2-oxoglutarate 
were run concurrently.
2.9.5 Cytochrome-c (NADPH) Oxido-Reductase
The assay for cytochrome-c oxido-reductase was based on that 
described by Brown et al. (1976). The assay medium contained 
900mM-KgHP02^ (pH 7.6), 4.05mM-EDTA, 0.09%-Triton X-100, 50mM-NaN^,
0.4mg/ml-cytochrome-c to which was added 10 1 of sample. The total
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volume was 1.0ml. The reaction was started with NADPH (20yl; final 
concentration 0.2mM) and the NADPH-dependent reduction of 
cytochrome-c was followed continuously at 550nm and at 25°C using a 
recording spectrophotometer. Controls omitting NADPH were run 
concurrently.
2.10 Measurement of the Rate of Mitochondrial Oxygen Consumption 
Oxygen upake was measured using a Clark-type oxygen electrode
(Rank Bros., Bottisham, Cambridge, U.K.) as described by Zammit
(1980b). The oxygen electrode was standardized by determinations of 
the change in the output from the electrodes on addition of portions 
of spectrophotometrically standardized NADH to 2.2ml of 'basal' 
medium (see below) containing lysed mitochondria (2mg of 
mitochondrial protein) and Img of cytochrome-c. Mitochondrial 
preparations (0.2ml) were added to a basal medium (2.0ml) containing 
8mM-Tris/HCl (pH 7.4), 176mM-sucrose, 32mM-KCl, 0.8mM-EGTA, 2.5mM 
KHgPO^ and 10mg/ml-BSA. Oxygen consumption was measured after the 
addition of ADP (state-3) and its exhaustion (state-4) using malate 
and glutarate (lOyl of 1M solution of each as substrates).
2.11 Determination of Metabolites
2.11.1 Determination of Blood Glucose
Whole blood samples obtained either from the tail (incision of 
distal tip of tail) or the aorta (immediately after sampling the 
liver) were mixed with an equal volume of ice-cold 3% (v/v) HCIO^.
The concentration of glucose in the neutralized supernatant obtained 
after sedimentation of the protein was measured as described by
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Bergmeyer et al. (1974). The assay coupled the hexokinase-catalyzed 
formation of glucose-6-phosphate (G6P), via glucose-6-phosphate 
dehydrogenase (G6PDH), to the reduction of NADP^. The assay medium 
contained 200mM-Tris/HCl (pH 7.4), lOOmM-KCl, 20mM-MgSO^, 
0.25mM-NADP^, 2.0mM-ATP, 3.5U-glucose-6-phosphate dehydrogenase and 
4U-hexokinase. The total volume was 2.0ml. The reaction was started 
with hexokinase (lyl) and the reaction followed continuously using a 
recording spectrophotometer at 25°C.
2.11.2 Cyclic AMP in Freeze-Clamped Liver
Freeze-clamped liver samples were processed as described in 
section 2.8.1 but homogenization was performed in 5% PCA and for 40s 
at setting 4. The resulting samples were diluted to 40mg fresh 
wt./ml with 5% PCA and then centrifuged for 6 min at 8,000g and 0-4°C 
in a micro-centrifuge. The supernatant (pellet discarded) was 
neutralized with solid KHCOg and centrifuged for a further 3 mins. 
Aliquots (50yl) of this resultant supernatant were then assayed for 
cyclic AMP content using the method initially described by Gilman 
(1970) and modified by Tovey et a]^ . (1974). The assay is based on 
the competition between the unlabelled cyclic AMP in the sample and a 
fixed amount of [^H]-labelled nucleotide for binding to a protein 
which has a high affinity for cyclic AMP. The amount of labelled 
protein-cyclic AMP complex formed is inversely related to the amount 
of unlabelled cyclic AMP present in the assay sample. Each assay 
(final volume 0.2ml) contained 0.025yCi of cyclic [%] AMP. A
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preparation of cyclic AMP-dependent protein kinase was used, at a 
final concentration of 25yg of protein/ml, as the source of cAMP
o
binding protein. Equilibrium binding of cyclic [ H] AMP in samples 
containing up to 20pmol of cyclic AMP was achieved in 3h at 0°C.
2.12 Partial Purification of Protein Phosphatase from Rat Liver
Protein phosphatase was prepared from rat livers by the method 
of Brandt e^ a]^ . (1975) up to and including the first DEAE-cellulose 
step. The functions obtained from the column containing phosphatase 
activity were pooled and dialyzed overnight against 60% glycerol in 
imidazole buffer (50mM-immidazole/HCl (pH 7.45), 5mM-EDTA,
0.5mM-DTT). The dialysate was concentrated further to a final 
specific activity of 109-469U/ml by an ultrafiltration process 
initially through a Diaflo PM10>10,000Mr membrane (Amicon Ltd., 
Stonehouse, Glos., U.K.) and then to a smaller volume through an 
Ulvac, GI0T>10,000 Mr membrane (Chemlab Instruments Ltd., Hornchurch, 
Essex, U.K.). The final preparation was stored at -20°C in small 
batches which were dialysed for 3h against a buffer containing 
50mM-immidazole/HCl (pH 7.4), 250mM-KCl and ImM-EDTA immediately 
before being used. This preparation involves a 95%-ethanol 
precipitation step which is known to cause the dissociation of the 
catalytic subunits of protein phosphatase-1 and -2A from their native 
complexes (Ingebritsen et al^., 1983a; see Section 1.4.3.2).
Therefore, it is thought that this preparation is a mixture of the 
catalytic subunits Mr = 37kDa and 35kDa from phosphatases-1 and -2A.
Protein phosphatase activity was determined by the measurement 
of inorganic phosphate released from phosphorylase concomitant with
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its inactivation as described by Brandt et al. (1975). The unit of 
activity is the amount of enzyme which releases 1 mol of min 
at 30°C.
2.13 Preparation of Guinea-Pig Anti-Insulin Serum
Anti-insulin serum was raised in guinea pigs (300-400g) by the
serial injection of porcine insulin (Leoretard, Leo Laboratories 
Ltd., Princess Risborough, Bucks., U.K.), in a paraffin oil 
mono-oleate emulsion by the method described by Robinson & Wright 
(1961). For the initial injection, insulin (20U/ml) was emulsified 
in approximately 3 vols of complete Freunds adjuvant (Miles 
Laboratories Ltd., Slough, U.K.) containing Mycobacterium butyricum 
to induce an immune response. This emulsion was administered 
subcutaneously to 6 distinct areas of the abdomen of the guinea pigs 
because of the susceptibility of the skin to ulceration. Subsequent 
injections of insulin (20U/ml) in similar proportions of incomplete 
adjuvant (i.e. without bacteria) were made at 21-day intervals.
Blood (approximately 10ml) was obtained by cardiac puncture of 
conscious animals 14-21 days after the 3rd injection and each 
subsequent injection of insulin. Serum was separated from clotted 
blood by centrifugation (5000g, lOmin, Coolspin, Fisons Scientific 
Apparatus, Loughborough, Leics., U.K.) and stored at -20°C. Control 
serum was obtained from untreated guinea-pigs by the same method.
2.14 Preparation and Analysis of Milk Fractions
2.14.1 Preparation
Whole cow's milk was supplied by the farm at HRI. Skim milk
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(prepared by centrifugal separation of cream from whole milk), 
buttermilk (a by-product of butter-making) and a concentrated 
preparation of soluble whey proteins (40% total solids) were 
purchased from Mauchline Creamery, Ayrshire, Scotland, U.K.). Whole 
milk and bought-in products were pasteurized at Y4°C and held for 
15s. Whole milk, skim milk and buttermilk fractions were 
concentrated to approximately 40%, 45% and 45% total solids 
respectively by falling-film evaporation. The concentrated fractions 
were finally spray-dried using a gas-fired tall-form spray drier with 
nozzle atomization. Each fraction was fed into the drier at a 
temperature of 45°C and at a flow rate of 10gal/hr; the inlet 
temperature was approximately 190°C and the powder was collected at a 
temperature of 94°C. These preparations were kindly performed by Mr
I.G. West, HRI.
Crude protein was assayed by an improved Kjeldahl nitrogen 
analysis devised by Dr J.C.D. White at HRI. On digestion of the milk 
(5ml) with concentrated sulphuric acid (25ml) in the presence of 
copper sulphate (50mg) and potassium sulphate (5g), nitrogen was 
converted to ammonium sulphate. Sodium hydroxide (57ml, 48% w/w) was 
added and the liberated ammonia was distilled into boric acid and 
subsequently titrated with 0.1N hydrochloric acid using 3 drops of a 
mixture (1:1, v/v) of methyl red (0.2% in 95% ethanol, v/v) and 
methylene blue (0.1% in 95% ethanol, v/v) as indicator. Crude 
protein was estimated as nitrogen (g/IOOg x 5.38). These analyses 
were kindly performed by Miss E. Noble, at HRI.
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2.14.2 Compositional Analyses of the Milk Fractions
'Total solids' is a term applied to the dry residue obtained 
after the complete evaporation of water. The total solids content of 
each of the four milk fractions was estimated by the technique 
detailed in 'Methods for Chemical Analysis of Liquid Milk and Cream' 
(British Standard, 1741:1963). The only modification made to this 
method was that, following the initial drying step (in a 
boiling-water bath) samples were incubated in an oven at 102 + 1°C 
for 3h.
Fat content was measured by the Gerber butyrometric method 
(British Standard, 1741:1963).
Lactose was assayed polarimetrically (Grimbleby, 1950) and 
calculation of results was by the procedure of Biggs & Szijarto 
(1963). An automatic polarimeter (Thorn Automation Ltd., Nottingham, 
Model 143D) was employed for this work and was calibrated using 
standard solutions of sucrose ('Analar' grade).
2.15 Determination of Protein Concentration
Protein concentrations were assayed by the method of Lowry et 
al. (1951).
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CHAPTER 3
THE DEVELOPMENT OF COLD-CLAMPING; A TECHNIQUE 
SUITABLE FOR THE STUDY OF THE INTERCONVERSION OF HMG-CoA 
REDUCTASE BETWEEN ACTIVE AND INACTIVE STATES IN VIVO
3.1 Introduction
A paradoxical situation occurs in the literature in that 
whilst there is evidence to suggest that changes in the 
phosphorylation state of hepatic HMG-CoA reductase can be induced in 
in vitro systems e.g. isolated hepatocytes (see Ingebritsen, I983) 
or vivo by acute and non-physiological stimuli e.g. 
pharmacological doses of glucagon (see Beg & Brewer, 1982), no such 
changes can be demonstrated in the enzyme in vitro by varying the 
physiological situation of the animal despite large changes in the 
cholesterogenic capacity of the liver (see e.g. Brown e^ al., 1979); 
the enzyme was always observed to be highly phosphorylated and 
therefore mostly (> 80%) inactive (see Chapter 1; Section 1.5). 
However, as recognized by Ingebritsen et (1979) the major 
difference between these physiological studies ^  vivo and the 
studies on isolated cells ^  vitro was the ease and rapidity with 
which cells could be harvested and the enzyme assayed. The cells 
were homogenized in an appropriate medium containing inhibitors of 
protein kinase (i.e. EDTA) and phosphatase (i.e. fluoride ions; F ) 
activities in order to arrest or slow down the metabolic changes 
which may otherwise alter the phosphorylation status of an enzyme 
such as HMG-CoA reductase (see Section 1.4 &1.5). Consideration of
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the studies of the isolated cell system raised the possibility that 
the observation that HMG-CoA reductase consistently existed in a 
highly phosphorylated state ^  vivo (Brown et a]^ ., 1979) was 
artifactual and was the possible consequence of the lengthy method of 
sampling used in the vivo studies i.e. the conventional method of 
mincing, rinsing and homogenization of the tissue prior to 
preparation of microsomes by differential centrifugation.
These types of experimental problems have been encountered 
previously in the study of metabolic systems capable of very rapid 
changes iri vivo both for the determination of the activity of 
enzymes which are regulated through reversible 
phosphorylation-déphosphorylation and for the measurement of 
intracellular metabolite concentrations. These studies require that 
the metabolic processes that affect the parameters studied namely 
enzyme activity (in the case of metabolites) and in the activity of 
protein kinases and phosphatases (in the case of
phosphorylated-dephosphorylated enzymes) be instantaneously arrested. 
Artefacts arise from any delay between sampling of the liver and the
cessation of metabolic activity which is likely to alter the state of
the metabolic system from that existing vivo. To minimize these
artefacts extensive use has been made of the freeze-clamping
technique (Wollenberger et al., I960) in which whole animals (e.g.
insects) or tissues (e.g. liver, mammary gland) of anaesthetized 
larger animals are pressed between two metal blocks cooled in liquid 
N^; this results in the very rapid cooling to -197^C and cessation of 
metabolic activity within the tissue and thus preserves the 
instantaneous state of metabolic concentrations and activity status
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of the enzymes. Subsequent homogenization of the frozen tissue 
samples is performed in a medium which either destroys enzyme 
activity (e.g. in perchloric acid for the measurement of metabolites) 
or preserves the activity status of rapidly interconvertible enzymes 
(see above).
This technique has been successfully employed to demonstrate 
the modulation of the activity of a number of regulatory enzymes by 
phosphorylation-déphosphorylation in the liver and other tissues 
in vivo. For example, it has been used to demonstrate that the 
fraction of pyruvate dehydrogenase, an enzyme which regulates the 
formation of acetyl-CoA from pyruvate, that exists in the active 
(dephosphorylated) form varies in different physiological conditions 
e.g. starvation and refeeding in rat liver and adipose tissue 
(Stansbie et al., 1976a). Also, in similar metabolic conditions, 
the involvement of equivalent alterations in the phosphorylation 
state in the regulation of acetyl-CoA carboxylase in the mammary 
gland (Zammit & Corstorphine, 1982) and in the liver (Stansbie et 
al., 1976b) and of pyruvate kinase in the liver (see Engstrom, 1978) 
have also been successfully demonstrated.
The inevitable consequence, however, of the freeze-clamping of 
e.g. liver samples is the disruption, on subsequent thawing and 
homogenization of the membranes of intracellular structures such as 
mitochondria. Therefore, the success of this technique in the 
determination of the activities of HMG-CoA reductase and other 
enzymes not only requires that the enzyme is stable to the actual 
process of freezing but also that the subsequent measurement of 
enzyme activity in the resulting crude homogenate is not impaired by
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mutually interfering enzymes which, vivo, occur in different cell 
compartments.
Such interference was in fact, encountered in the 
preliminary attempts to adopt the freeze-clamping technique to study 
the changes in the phosphorylation state of HMG-CoA reductase in 
vivo. This was the consequence of the formation from HMG-CoA of 
acetoacetate by HMG-CoA lyase, an enzyme of the ketogenic pathway of 
the liver after its leakage from the lysed mitochondria of 
homogenates of freeze-clamped tissue. After its visualization using 
the 2,4-dinitrophenylhydrazine reagent for the detection of 
ketoacids, aldehydes and ketones, it was shown that acetoacetate 
migrates with the same value (0.55-0.75) as that of 
mevalonolactone in the TLC developing system used (see Methods).
This is presumably due to the similarity of the polar parts of the 
two molecules (see Fig. 3.1). Because the activity of HMG-CoA lyase 
(per g wet wt. of liver) is approximately 2 orders of magnitude 
greater than that of HMG-CoA reductase (Table 3.1) in crude
homogenates of freeze-clamped liver samples the formation of
14 14C-acetoacetate (which appears as NADP-independent C-radioactivity
at R^ 0.55-0.75) always produced a high radioactivity background.
Thus, using an estimate of the total microsomal protein content of
liver (23.41 + 1.75 mg/g wet wt.) determined by careful isolation of
microsomes from tissue homogenized in the conventional way (see
above), the incorporation of ^^C-material into R^ 0.55-0.75 was
approximately 10-fold greater when freeze-clamped homogenate rather
than an isolated microsomal membrane preparation was used in the
HMG-CoA reductase assay conditions (i.e. 14.5 v 1.5 nmoles/min per
mg of microsomal protein).
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Fig. 3.1 Similarity between the products of HMG-CoA reductase 
(mevalonolactone) arid HMG-CoA lyase(acetoacetate) 
activities as shown in acid conditions.
TABLE 3.1
Comparison of the Absolute Activities of HMG-CoA Reductase 
and HMG-CoA Lyase in Rat Liver
Portions of a single liver were either freeze-clamped and used 
for the assay of HMG-CoA lyase activity, or excised for the 
preparation of microsomes in the conventional manner and assayed for 
HMG-CoA reductase activity. The expression of HMG-CoA reductase in 
the same units as HMG-CoA lyase (pmoles/g wet wt.) was enabled by the 
quantitative determination of the microsomal protein content of liver 
(see text).
Range of Activities (pmoles/g wet wt) 
HMG-CoA lyase 6.120-9.480
HMG-CoA reductase 0.035-0.058
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In the intact cell iji vivo, the chronic interference between 
the two enzymes is prevented by the physical separation of the two 
respective pathways in the cytosol (cholestorogenesis) and the 
mitochondria (ketogenesis) (Clinkenbeard al•, 1975a see Fig.
3.2). Each pathway has been shown to be supplied by different pools 
of acetyl-CoA (Dietschy & McGarry, 1974) and to contain molecularly 
and catalytically distinct species of HMG-CoA synthase (Reed ^  al., 
1975; Clinkenbeard e^ al., 1975b) and acetoacetyl-thiolase 
(Clinkenbeard ^  al., 1973). In the conventional method of liver 
sampling (see above) the interference of HMG-CoA lyase in the assay 
of HMG-CoA reductase can be effectively eliminated by the subcellular 
fractionation of the HMG-CoA lyase-containing mitochondria from the 
reductase-containing microsomal fraction. In the case of the 
freeze-clamping technique however, unless there is some way in which 
HMG-CoA lyase can be eliminated from the crude homogenate formed, 
this technique must be considered unsuitable for the study of this 
enzyme.
These problems led to the development of a technique that was 
designed to satisfy the necessity to rapidly sample tissue and to 
arrest metabolic activity, but that allowed the subcellular 
fractionation of the liver. Mitochondria (and therefore HMG-CoA 
lyase) could thus be separated from microsomal membranes for the 
accurate determination of HMG-CoA reductase activity.
3.2 Elimination of HMG-CoA Lyase from Homogenates of
Freeze-clamped Liver
Two approaches were made in an attempt to eliminate the
CYTOSOL
acetoacetate
1
cholesterol
acetyl-CoA
acetoacetyl-CoA
1
HMG-CoA
mevalonate
REDUCTASE
MITOCHONDRION
acetyl-CoA
acetoacetyl-CoA
1
HMG-CoA
LYASE
acetoacetate
i
3-hydroxybutyrate
Fig. 3.2 Subcellular location of HMG-CoA reductase and HMGKZoA lyase 
enzymes and their involvement in the pathways of 
cholesterogenesis and ketogenesis respectively
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interfering activity of HMG-CoA lyase from homogenation of 
freeze-clamped liver.
3 .2.1 Ca^'^-sequestration
It has previously been demonstrated that HMG-CoA lyase of 
chicken liver is a Ca^'^-containing metalloprotein and that its 
activity is rapidly lost at 4°C in the absence of this ion 
(Clinkenbeard et al., 1975a). Therefore the effects of the
sequestration of Ca^* (and Mg^*) using specific chelators for these
ions (EGTA and EDTA) on the activity of HMG-CoA lyase in homogenates 
of freeze-clamped liver were investigated in an attempt to 
specifically inhibit this enzyme and facilitate the assay of HMG-CoA 
reductase.
HMG-CoA lyase activity was measured spectrophotometrically 
(see Methods) in homogenates prepared in media containing either 
50 mM-Tris/HCl pH 7.5, 250 mM-Sucrose, 2 mM-DTT (Buffer A) or 50 mM- 
K^HPO^ pH 7 .4 , 15 mM-EDTA, 15 mM-EGTA, 250 mM-NaCl, 2 mM-DTT (Buffer 
B). HMG-CoA lyase activity was markedly depressed when prepared in 
buffer containing the divalent cation chelators (Buffer B) to 33^ of
the activity observed in the control homogenate incubated in the
presence of endogenous Mg^^ and Ca^^ (Fig. 3.3). When similar 
measurements were made after an incubation period of 3h at 0-4°C, 
HMG-CoA lyase activity in the presence of EDTA and EGTA was only 15^ 
of the activity observed in the control medium; both activities had 
declined gradually over the 3h period (Fig. 3.3).
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2+ 2+Fig. 3.3 Effect of chelation of Mg and Ca ions on HMG-CoA lyase 
activity in freeze-clamped homogenate of rat liver
A concentrated homogenate was prepared in buffer containing 50mM-Tris 
HCl (pH 7.5) , 250mM-Sucrose, 2mM-DTT and diluted (10-fold) into the same 
buffer (#) or buffer containing 50mM-K2HPO^ (pH 7.4) , 15mM-EDTA, 15mM-EGTA, 
250mM-NaCl, 2mM-DTT (A). At the intervals shown, samples of the incubation 
mixtures were assayed spectrophotometrically for HMG-CoA lyase (see Section 
2.7) .
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Although it is evident that a considerable proportion of 
HMG-CoA lyase activity in freeze-clamped liver homogenates was 
suppressed following the chelation of Ca^* (and Mg^^), the residual 
activity was still in approximately 20-fold excess of the activity of 
HMG-CoA reductase in the liver. This level of HMG-CoA lyase activity 
would still interfere severely with any subsequent determinations of 
HMG-CoA reductase activity in these homogenates. Furthermore, it is 
probable that the loss of activity of HMG-CoA lyase following the 
lengthy incubations (at 0-4°C) (Fig. 3*3) was the result of 
proteolytic degradation. Since it is known that HMG-CoA reductase is 
also susceptible to proteolysis (Ness ^  al., 1981) these types of 
incubations may lead to the dissociation of the catalytic domain of 
HMG-CoA reductase ('53K' reductase; see Section 1.2.2) from the 
endoplasmic reticulum and possibly to a change in catalytic activity, 
rate of degradation or ability of the enzyme to be regulated (see 
Section 1.3). Although proteolysis inhibitors can be added to 
homogenates it is not always possible to inhibit all types of 
proteases during such lengthy incubations.
3.2.2 Isolation of Microsomal Membranes
HMG-CoA lyase is a soluble enzyme of the mitochondrial matrix 
(Clinkenbeard ^  al., 1975a) and therefore it should be possible to 
separate microsomes and hence HMG-CoA reductase from the 
lyase-containing supernatant (due to lysis of mitochondria). To test 
this, a microsomal fraction was obtained from the homogenate of 
freeze-clamped liver by standard centrifugation steps (see Methods) 
and the effect of washing the pellet by resuspension and 
centrifugation was investigated.
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Table 3»2 demonstrates that when unwashed microsomes were
assayed for HMG-CoA reductase using ^^C-HMG-CoA as substrate, 80^ of 
14
the C-labelled material that migrated with the same as 
mevalonolactone was the result of NADP-independent reactions and 
concluded to be the product of HMG-CoA lyase. This level of 
NADP-independent radioactivity was reduced to 25% by a further 
washing of the membranes (Table 3-2) but this was still approximately 
5-fold greater than the level (i.e. 5-10%) routinely encountered in 
hand-homogenized tissue and therefore unsuitable for the accurate 
determination of HMG-CoA reductase activity required.
A further disadvantage of using the freeze-clamped technique 
in this way is that the disruption of intracellular membranes as the 
result of freezing (see above) would lead to a more diverse membrane 
population. This in turn could lead to a greater variation in the 
quantitation of HMG-CoA reductase activity with respect to membrane 
protein.
3.2.3 Conclusions
From these results it is evident that the freeze-clamping 
technique is unsuitable for the determination of the activity of 
HMG-CoA reductase m  vivo, because the vast excess of HMG-CoA lyase 
released into the homogenate during the homogenization process can 
never be sufficiently removed. Consequently it was concluded that 
the only way to eliminate the interference of HMG-CoA lyase was to 
remove the intact mitochondria by differential centrifugation.
TABLE 3.2
Partition of NADP-Dependent and NADP-independent Formation of
14 14
C Material with 0.55-0.75 from C-HMG-CoA between the Supernatant
and Membrane Pellet of Unwashed and Washed Microsomal Fractions
Isolated from a Sample of Freeze-Clamped Liver
Various fractions of freeze-clamped liver homogenates were 
assayed for HMG-CoA reductase activity (see Section 2.8). Controls 
from which NADP was omitted were run concurrently.
14
Fraction obtained by centrifugation
Total homogenate
Unwashed microsomal pellet
supernatant
Washed microsomal pellet
supernatant
C-material recovered with
R^ 0.55-0.75 (d.p.m.)
+NADP
13380
32820
4805
4770
-NADP
46140 29940
10771
33960
1206
3960
NADP-
DEPENDENT
16200
2609
3599
810
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3.3 The Cold-clamping Technique
The emergence of the requirement for the retention of 
mitochondrial integrity coupled with the fundamental requirement of a 
rapid sampling technique (see above) led to the development of the 
cold-clamping technique. In this technique, mitochondrial lysis is 
avoided by rapidly cooling (rather than freezing) the liver to 0°C 
followed by the rapid homogenization in a medium designed to preserve 
the phosphorylation status of regulatory enzyme in vivo (see above). 
Using this method, intact mitochondria and hence HMG-CoA lyase could 
be removed from the homogenate by differential centrifugation and 
HMG-CoA reductase assayed relatively free from interference.
3 .3.1 Development of the Cold-clamping Technique
(a) Description of clamps
The clamps designed for this technique consisted of two 
circular stainless-steel blocks (diam. 5 cm) carried at the ends of 
the two arms of tongs which could be freely shut and opened. Each 
block had a raised cutting edge (height 1.5 mm) down one side and 
extending approximately 4/9 of the circumference (Fig. 3.4) and a 
groove of the same, but reciprocal shape (1.5 mm deep) symmetrically 
opposite. The raised edge and the groove on each block were 
confluent at one point, but were separated by a distance equivalent 
to approximately 1/9 of the circumference at the diametrically 
opposite side of the blocks. The blocks were mounted on the arms of 
the tongs in such a manner that the raised edge of the one fitted 
into the groove of the other, with the confluent cutting edges and 
diametrically opposite gaps being positioned perpendicularly to the
(a)
{b)
(c)
Fig. 3.4 Details o f construction of stainlessrsteel blocks used
for obtaining samples o f rat liver by cold-clamping 
(a) Face of one block: 1, cutting edge; 2, gap; 3, 
groove. (6) Transverse (equatorial) section through 
the two blocks with clamps shut, (c) Top view of 
clamps to show mounting of blocks on handles.
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plane of closure of the tongs. In use the tongs were held with the 
gap pointing vertically upwards so that excess liver sample squashed 
between the two blocks could escape through the gap. The effect of 
shutting the tongs was to produce a circular cutting edge throughout 
the lower and lateral parts of the two apposed blocks; the clamping 
action simultaneously cut a sample (approximately 1 g) of the liver 
lobe and smeared it in a thin layer over the cooled surfaces of the 
blocks.
(b) Cold-clamping of liver
A schematic representation of the procedure is given in Fig. 
3.5 and also demonstrated photographically in Fig. 3.6. Animals were 
anaesthetized with pentobarbital (60 mg/kg body wt.) and allowed to 
stabilize for 15-20 min (see Section 2.1). The abdominal 
cavity was opened and the liver was dissected free of surrounding 
tissue by cutting the mesenteries. The left lateral lobe of the 
liver was threaded 2-3 mm from the edge with a Mersilk silk suture 
(4/0 gauge, round bodied 16 mm needle, Ethicon, Edinburgh, Scotland, 
U.K.). This allowed the lobe to be lifted out vertically from the 
abdominal cavity. (The use of a suture rather than a pair of forceps 
to lift the liver lobe was necessitated by the interference of 
forceps with the action of the cutting edges of the clamps ; routinely 
no bleeding of the liver or any other adverse effects of the 
technique were apparent.) The lobe was clamped between ice-cooled 
stainless-steel blocks (see above). The shut clamps containing the 
liver sample were immediately held over the mouth of a plastic funnel 
inserted into the top of the body of a Teflon/glass homogenizer. The
Fig- 3.5 Diagrammatic representation of cold-clamping of 
rat liver samples
(a) Lifting of left lateral lobe of liver and positioning of 
cold-clamps (vertical section); (b) sampling of liver; (c) flushing 
of liver sample into body of homogenizer with extraction medium;
(d) homogenization of tissue with a Teflon/glass homogenizer. The 
liver is drawn as the cross-hatched area. The scale at the bottom 
of the diagram gives the approximate times taken routinely to perform 
the different parts of the procedure.
H
3
Ca)
CJ1
Fig. 3.6 Photographic representation of the cold-clamping 
technique
Left lateral lobe of liver is lifted between the cooled faces 
of the blocks. Arrow denotes cutting edge of blocks.
h
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clamps were opened and the liver sample was washed directly into the 
homogenizer by squirting 25 ml of ice-cold extraction medium over the 
inner surfaces of the metal blocks. The tissue was then homogenized 
for 5s (three passes) with a motor-driven pestle (1000 rev./min).
The entire procedure was completed in less than 10s. The resulting 
homogenate was used as a source of mitochondria, for the studies in 
mitochondrial respiration (see Section 2.10), or microsomes, for the 
assay of HMG-CoA reductase as described in Methods (section 2.8.2).
3 .3.2 Validation of the Cold-clamping Technique
Two criteria were used in order to ascertain whether the 
cold-clamping technique was suitable for the study of changes in the 
phosphorylation state of HMG-CoA reductase vivo. (i) The
efficiency of the technique to preserve the phosphorylation state of 
a cytosolic enzyme which is known to undergo reversible 
phosphorylation-déphosphorylation, pyruvate kinase, was tested by 
direct comparison with the freeze clamping technique (pyruvate kinase 
is free from interferences from other enzymes in crude homogenates). 
(ii) The cold-clamping technique was used to investigate whether 
artefactual changes in the phosphorylation state of HMG-CoA reductase 
occurred, as suspected, when liver samples were obtained in the 
conventional manner (see section 3.1).
(a) Retention of pyruvate kinase kinetics
In these experiments the liver of a rat was sampled in three 
ways; (i) one lobe was freeze-clamped, (ii) a second lobe was 
cold-clamped, and (iii) a third was excised and minced (for practical
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reasons cold-clamping was always performed on the left lobe, but the 
use of the other lobes was randomized so as to eliminate the 
possibility of variations between lobes, although no such variations 
were ever observed). All subsequent treatment of the tissue was 
identical, except that freeze-clamped tissue was homogenized with a 
Polytron tissue disintegrator (see Section 2,8.1). The activity of 
pyruvate kinase of the three samples was measured at several 
suboptimal concentrations of phosphoenolpyruvate (see Table 3*3) and 
at 3 mM-phosphoenolpyruvate, which was ascertained to measure maximal 
activity of the enzyme. In addition, the activity of pyruvate kinase 
in a portion of the freeze-clamped sample homogenate which had been 
incubated with a protein-phosphorylating mixture (see section 2.9*2) 
was also measured at the same phosphoenolpyruvate concentrations to 
obtain information about the kinetics of the fully phosphorylated 
enzyme with respect to phosphoenolpyruvate concentration. The 
results of three such experiments are given in Table 3*3; activities 
of pyruvate kinase at suboptimal phosphoenolpyruvate concentrations 
are expressed as a percentage of the maximal activity. It is evident 
that, whereas the kinetics of pyruvate kinase at suboptimal 
phosphoenolpyruvate concentrations were very similar in homogenates 
of freeze-clamped and cold-clamped samples, those for the minced 
liver samples were very different, and were much more similar to 
those of the fully phosphorylated enzyme. These results demonstrated 
that cold-clamping preserved almost intact (compared with 
freeze-clamping) the activity state of pyruvate kinase iu vivo, and 
therefore appeared to be an equally effective sampling technique in 
minimizing the artefactual apparent increase in phosphorylation of
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pyruvate kinase that occurred in the time taken to mince the tissue. 
If the rapidity of change in phosphorylation status of pyruvate 
kinase during sampling is representative of that of other enzymes 
that are regulated by phosphorylation-déphosphorylation, the above 
results would suggest that cold-clamping is as valid a technique as 
freeze-clamping for the sampling of tissue situ in studies on the 
effects of different physiological conditions on the activity state 
of these enzymes vivo. Both techniques are superior in this 
respect to excision and mincing of the liver followed by 
homogenization.
(b) Preservation of expressed/total activity (E/T) ratio for 
HMG-CoA reductase by cold-clamping
These experiments were performed when the activity of HMG-CoA 
reductase was maximal i.e. at 6h into the dark phase of the diurnal 
rhythm (D-6) (see section 4.2). Rats were anaesthetized 20 min 
before sampling of the liver. The left lateral lobe of the liver was 
sampled by cold-clamping followed by immediate homogenization in 
medium containing EDTA and F . The right lateral lobe was excised 
and minced on an ice-cold Petri dish and homogenized in the same 
medium. All subsequent treatments of the two homogenates and 
microsomal pellets were identical (see Methods; Section 2.8.1). The 
results of four such experiments are given in Table 3*4. It is 
evident that the E/T ratios were always appreciably higher in 
homogenates of cold-clamped liver samples than in minced samples. 
Moreover, this difference was solely due to a lower expressed
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activity in minced samples than in cold-clamped samples (O.96 + 0.18 
and 1.34 + 0.22 nmol/min per mg of microsomal protein at 37^0 
respectively; P < 0.005, paired 't' test). The total HMG-CoA 
reductase activities for microsomes prepared from both types of 
samples were identical (1.84 + 0.20 nmol/min per mg of microsomal 
protein). These experiments illustrated that the longer delay 
between sampling of the liver and homogenization in the F” and 
EDTA-containing medium introduced by mincing of the tissue resulted 
in a markedly reduced expressed activity of HMG-CoA reductase, i.e. 
an increased proportion of the enzyme was phosphorylated. Thus it 
was concluded that when liver was excised and minced the relative 
amounts of the enzyme in phosphorylated and dephosphorylated states 
were modified from their respective values vivo during the time 
that elapsed between liver sampling and homogenization in a F~- and 
EDTA-containing medium. These marked changes did not occur when the 
liver was sampled by cold-clamping.
It is noteworthy that if animals were stunned by a blow to the 
head and then killed by cervical dislocation prior to the excision, 
mincing and homogenization of the liver (the conventional manner of 
sampling) the E/T ratio of HMG-CoA reductase was very much lower than 
the equivalent ratio recorded in the homogenates of minced liver 
obtained from anaethetized animals (Table 3*5.). This very much 
depressed ratio too was the consequence solely of a marked depression 
in the expressed activity ; the total activity remained 
identicial to the total activity observed in the homogenates of both 
minced and cold-clamped samples. The value obtained for the E/T 
ratio of HMG-CoA reductase in experiments in which rats were killed
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by cervical dislocation was very similar to that obtained by Brown 
et al. (1979). Nordstrom et al. (1977) and Dugan et al. (1982).
3 .3.3 Assessment of Mitochondrial Integrity in Cold-clamped Liver 
Since the primary reason for using cold-clamping instead of 
freeze-clamping was to retain mitochondrial integrity an assessment 
was made of the intactness of mitochondria in homogenates of 
cold-clamped liver. This was performed by measuring the latency of 
mitochondrial marker enzymes and by measuring their O^-consumption in 
the presence of ADP (state 3) and after its depletion (state 4) in 
the presence of malate and glutamate as substrates (see Methods, 
section 2.10).
(a) Latency of mitochondrial enzymes 
The activities of glutamate dehydrogenase, a 
mitochondrialmatrix enzyme (Lehninger, 1982) and citrate synthase, an 
inner membrane enzyme (Weitzman & Danson, 1976) were determined in 
the supernatant fractions after intact mitochondria had been 
separated out by centrifugation (see Table 3.6). These two enzymes 
were chosen to provide information about: (i) the lysis of 
mitochondria i.e. release of glutamate dehydrogenase and (ii) the 
degree of disruption of the inner mitochondrial membrane i.e. 
exposure of citrate synthase.
The activities of both enzymes were almost completely latent 
in homogenates of cold-clamped rat liver samples. Routinely, 
approximately 1% of the total activity of citrate synthase and 3$ of 
the total activity of glutamate dehydrogenase were overt in the
TABLE 3.6
Activities of Citrate Synthase and Glutamate Dehydrogenase 
in the Post-Mitochondrial Supernatant of Homogenates of 
Cold-Clamped Liver
Homogenates of cold-clamped liver samples were centrifuged at 
500g for 5 mins (a) and then twice at 7000g (b) and (c). Citrate 
synthase and glutamate dehydrogenase activities were determined in 
the supernatant of the two high speed superntants and expressed as a 
percentage of the activities obtained in the low speed supernatant. 
Enzymes were assayed as described in Methods (sections 2.9.3 and 
2.9.4).
Centrifugation step
(a) 500g (5 mins)
(b) 7000g (10 mins)
(c) 7000g (10 mins)
Enzyme Activity (%)
Citrate Synthase Glutamate dehydrogenase 
TOO 100
6.9 2.9
6.4 2.7
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mitochondrial supernatant (Table 3.6). These values are similar to 
latency obtained with conventional homogenization (Zammit, 1980a). 
Therefore the integrity of the mitochondrial inner membrane was 
largely preserved with respect to accessibility of the respective 
substrates to the two enzymes and of the leakage of glutamate 
dehydrogenase from mitochondrial matrix. It is unclear why citrate 
synthase should have an apparently higher activity within the 
mitochondrial supernatant.
(b) Respiratory control of mitochondria 
In homogenates of cold-clamped liver samples, the rate of 
O^-consumption by the mitochondria was 56.8 + 8.0 nmol O^/min per mg 
mitochondrial protein at 37°C (n=6) and the respiratory control ratio 
(state-3/state-4, see above) averaged 7.5, (12 determinations; range 
4.0-12.5). These values were very similar to values obtained from 
mitochondria preparations obtained from liver sampled in the 
conventional manner (Zammit & Robinson, 1982; Zammit, 1980b).
3.4 Discussion
The cold-clamping technique provides rapid sampling and 
homogenization of liver with an apparent retention of structural and 
functional integrity of the mitochondria. This produces a system in 
which the activity of HMG-CoA reductase can be accurately determined 
without the interference of HMG-CoA lyase.
The use of this technique has enabled, for the first time the 
demonstration that HMG-CoA reductase exists largely in the active, 
dephosphorylated form in vivo at 6h into the dark period (D-6).
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This is in contrast to in the observations of Brown et al. (1979) 
who reported that the majority of the enzyme was invariably 
phosphorylated. It is concluded that this observation is the result 
of the employment of this the rapid sampling technique and its 
efficiency in rapidly stopping the reversible 
phosphorylation-déphosphorylation of HMG-CoA reductase.
The observations made in this study confirm the suggestion 
made in Section 3(i) that the persistently low E/T ratio obtained by 
Brown et (1979) and others (see previously) in liver was 
artefactual. Furthermore, the direct comparison of the cold-clamping 
technique with the conventional method of preparing tissue 
homogenates has identified two possible factors which could account 
for the observations made by these workers:
(i) It is evident from Table 3.4 that the phosphorylation of 
HMG-CoA reductase is increased (i.e. E/T ratio decreased) in tissue 
that had been minced for a period of time before homogenization.
Thus, the relative activities of the kinases and/or the phosphatases 
were modified in some way during this delay possibly through the 
effect of anoxia and emphasize the need of a rapid sampling method of 
tissue which is being actively perfused by blood.
The fact that the amount of HMG-CoA reductase in the 
phosphorylated form increased in the minced samples from 
anaesthetized rats was unexpected since this modulation requires ATP, 
the cellular concentration of which would fall rapidly following 
anoxia. This effect is also opposite to that observed in the case of 
other enzymes modulated by reversible phosphorylation e.g. pyruvate 
dehydrogenase (E. Kilgour, unpublished observations) which becomes
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more dephosphorylated in similar conditions. It is possible that 
this effect is the result of an allosteric activation of reductase 
kinase by the inevitable increase in the intracellular concentrations 
of ADP during anoxia as recently proposed by Harwood et (1984).
(ii) It is evident from Table 3«5 that the added factor of 
killing the animal by cervical dislocation before the preparation of 
the tissue homogenate as in (i) above resulted in an even greater 
decrease in the proportion of HMG-CoA reductase in the 
dephosphorylated form. It is probable, therefore, that the 
phosphorylation system of HMG-CoA reductase is very sensitive to 
adrenergic stimulation such as would occur in rats acutely stressed 
by a stunning blow to the head (see Callingham & Barrand, 1979). The 
comparison of the E/T ratio of HMG-CoA reductase from these animals 
with the equivalent ratio obtained from animals treated as in (i) 
above reveals that this effect is greatly reduced by excising the 
liver from animals that had been anaesthetized 20 minutes earlier. 
Both of these factors are eliminated by the use of the cold-clamping 
technique. Moreover, in the light of the prominent effects of 
stress, further precautions were also taken in subsequent experiments 
and the animals were trained to being handled at least 4 days before 
they were used.
The retention of good respiratory control and full latency of 
inner-membrane and matrix enzymes by mitochondria isolated from 
homogenates of cold-clamped samples extends the possible fields of 
hepatic metabolic studies to which the cold-clamping technique could 
be applied. Thus it should be possible to study metabolic processes
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in isolated mitochondria obtained after rapid cold-clamping and 
differential or gradient centrifugation. For example, this new 
technique could potentially be a method of investigating the 
regulation of the mitochondrial 2-oxoacid dehydrogenase complexes 
e.g. pyruvate, 2-oxoglutarate and branched-chain 2-oxoacid 
dehydrogenases (Randle et al., 1984). These complexes are known to 
be regulated by phosphorylation-déphosphorylation and to be 
controlled to some extent by the levels of free Ca^* within the 
mitochondria. This technique would enable the study of these systems 
in intact mitochondria providing the kinases and phosphatases can be 
rapidly controlled for example by the combined use of Ca^^-ionophores 
(e.g. A23187) and Ca^^-chelators (e.g. EGTA) to remove Ca^ '*’ from the 
mitochondria.
Similarly, the ability to rapidly prepare different cell 
fractions from cold-clamped rat liver samples could enable the 
sampling of liver situ and the measurement of the relative 
amounts of soluble and membrane bound forms of enzymes, the 
regulation of which may be mediated partly by reversible 
interconversion between soluble and membrane bound forms (Wilson, 
1978), e.g. CTP:choline phosphate cytidylyl transferase (Vance & 
Pelech, 1984).
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CHAPTER 4
CHANGES IN THE PHOSPHORYLATION STATE OF HMG-CoA REDUCTASE IN 
DIFFERENT PHYSIOLOGICAL CONDITIONS
4.1 Introduction
The cold-clamping technique (see Chapter 3) overcomes the 
problems met by previous workers in assessing the involvement of 
reversible phosphorylation in the regulation of hepatic HMG-CoA 
reductase activity vivo (Chapter 1). It makes possible the 
quantitation of the fraction (E/T ratio) of the hepatic enzyme in the 
active form vivo, under different physiological conditions. In 
order to demonstrate that this parameter is responsive to normal, 
physiological stimuli, the expressed and total activities of HMG-CoA 
reductase were studied in several different physiological conditions 
which involve acute hormonal and nutritional variations. The three 
physiological conditions studied were: (i) the diurnal rhythm of 
feeding; (ii) the withdrawal of food for various, short and 
medium-term periods and (iii) the pregnant and lactating states.
These conditions were chosen because they represent entirely 
physiological conditions characterized by different levels of food 
intake and hormonal status.
The diurnal pattern of feeding shown in normal rats kept in 
conditions of alternate 12h light:12h dark is thought to provide the 
main stimulus for the diurnal rhythm in the total activity of hepatic 
HMG-CoA reductase (i.e. amount of enzyme protein; see Section 
1.3 .3). In normal-fed rats, the total activity of HMG-CoA reductase
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and the rate of cholesterogenesis rise subsequent to the availability 
of food even during the light period (Dugan et al., 1982; Edwards et 
al., 1972). In addition, the diurnal rises of both HMG-CoA 
reductase activity (Hamprecht et , 1969; Dietschy & Brown, 1974; 
see Rodwell e^ , 1976) and cholesterogenesis (Brown , 1979;
Dietschy & Brown, 1974) have been reported to be markedly suppressed 
by prolonged fasting for 24h although there is also evidence that the 
rhythm of HMG-CoA reductase activity persists in these conditions 
although the diurnal peak of activity is much depressed (Hamprecht
et al., 1969).
This diurnal increase in the rate of cholesterol formation in 
the liver during the period of active feeding in the rat is important 
in enabling the maintenance of the relatively stable compositional 
ratios of cholesterol (free and esterified) and triglycerides in the 
plasma lipoproteins. The cholesterol synthesized allows the 
secretion of endogenously formed triglyceride as VLDL. (Cholesterol 
formed in the intestinal mucosa is incorporated into chylomicrons 
that are secreted into the lymphatic system). Consistent with this 
function of cholesterol formation, the increased dietary intake of 
fat by the animal (Goldfarb & Pitot, 1972) or the increased delivery 
of fatty acids to perfused rat liver (Goh & Heimberg, 1979) generates 
an increased total activity of hepatic HMG-CoA reductase.
The diet-related signals which stimulate changes in the rate 
of HMG-CoA reductase synthesis have not been defined. In Chapter 1 
(Section 1.3.3) the possible roles of insulin, glucagon and 
glucocorticoids were discussed because of the diurnal variations in 
the plasma concentrations shown by these hormones. They may be
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involved not only in the generation of the diurnal rhythm in total 
activity but may also affect a variation in the fraction of the 
enzyme in the active form. Although Edwards et. 1980 presented evidence 
that the specific activity of hepatic HMG-CoA reductase varied during 
the diurnal cycle, this view was not generally i accepted (see e.g.
Dugan e^ al., 1982; Section 3.1). However, in view of the observed 
ability of the phosphorylation state of HMG-CoA reductase to be 
modulated by hormones e.g. insulin and glucagon (see Ingebritsen,
1983; Section 1.5) and cholesterol (mevalonolactone) in isolated 
hepatocytes iai vitro (see Parker et al., 1983; Section 6.1) and by 
pharmacological doses of glucagon and cholesterol in the whole animal 
in vivo (see Beg & Brewer, 1982), it was anticipated that changes in 
the E/T ratio of this enzyme would be observed in response to diurnal 
variations in the condition of the animals.
The diurnal feeding activity of the rat under normal 
conditions incorporates durations (4-8h) of reduced food intake (see 
Fig. 4.4). During these periods the most significant hormonal 
changes that occur are in the plasma concentrations of insulin and 
glucagon which fall and rise respectively in response to the modest 
fall in blood glucose (see White e^ al., 1984). Therefore the use 
of different variations of starvation may provide information about 
the likely period of diurnal fast that are central to the maintenance 
of the diurnal rhythms of total activity and the fraction of the 
enzyme in an active form.
Pregnancy and lactation represent interesting physiological 
conditions not only with respect to important hormonal changes that 
occur in the transition from the normal, unmated animal to the gravid
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and lactating animal (see below) but also because of the hyperphagia 
that accompanies the two conditions with relative hypophagia around 
parturition (Cripps & Williams, 1975; Walker & Hahn, 198I). The 
increased food intake provides the additional nutritional 
requirements imposed on the mother by the growing foetus in pregnancy 
and by milk production in lactation.
In the rat, pregnancy is characterized by the progressive 
establishment of hyperinsulinaemia, lipidemia and an increased 
vulnerability to ketosis after food deprivation (referred to as 
'accelerated starvation'; see Freinkel, 1980). In women, the hyper- 
lipidemia, characterized by marked hypertriglyceridemia rPottei^Neste1, 
1977; Darmady & Potter, 1982) and hypercholesterolaemia (Curiel et 
al., 1982; McMurry et al., 1981; Tolino et aJ., 1980; Skryten et 
al., 1980) has been shown to be due to the increased circulating 
levels of lipoproteins particularly VLDL and LDL (Hillman e^ al.,
1975; Wrath & Knopp, 1977) with minimal increases in HDL (Curiel et 
al., 1982). Similar changes are evident in the rat (Bosch & Canejo,
1967; Ramirez ^  , 1983; Lorenzo et al., 1979). However, it is
noteworthy that rat and human are two of a small number of mammalian 
species in which hypercholesterolaemia accompanies the later phases 
of pregnancy (see Connor & Lin, 1967; Tietz ^  , 1976); most
other species are hypocholesterolaemic in the gravid state.
Triglyceridemia in the pregnant rat has been shown to be the 
result of increased novo synthesis in the liver and, in late 
pregnancy, of the decreased utilization of lipoproteins in the 
periphery (Lorenzo e^ aT., 1981; Hamosh e^ al., 1970). The 
increased synthesis is thought to be a response to the
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hyperinsulinaemia characteristic of this stage of pregnancy (Lorenzo
et al., 1981; Flint et aly, 1979) as well as the increased
circulating levels of progesterone and oestrogen (Kalkoff & Kim,
1979). Similarly, hypercholesterolaemia in the rat during late
pregnancy may result from the increased cholesterol intake that
accompanies hyperphagia (Cripps & Williams, 1975; Walker & Hahn,
1981) in addition to a decreased catabolism of plasma lipoproteins in
the periphery (see above). However, whilst Feingold et al. (1983)
have suggested that the rates of hepatic cholesterogenesis
r ^
(determined by the incoporation of [ Hl-H^O into cholesterol) 
increases towards the end of the gestation period, Leoni et al.
(1984) have suggested that this rate (determined by [ ”'^C]-acetate 
incorporation into digitonin precipitable sterols) remains constant 
throughout late pregnancy at the same value as observed in virgin 
animals and only decreases on the day of parturition.
The lipidaemia of pregnant rats is rapidly relieved at the 
onset of lactation (Scow e^ al., 1964; Hamosh et al., 1970) as the 
result both of a decrease in the rate of entry of triglycerides into 
the circulation (Agius et al., 1981) and a greatly increased 
clearance of triglyceride-rich lipoproteins by the mammary gland 
(Otway & Robinson, 1968). In further contrast to the pregnant 
animal, the lactating animal is mildly hypoinsulinaemic (Flint et 
al., 1979; Robinson ^  al., 1978) and is characterized by a high 
circulating concentration of prolactin (Flint et al., 1979;
Amenomori et al., 1970;). In addition, the plasma concentrations of 
progesterone fall during late pregnancy and recover during early 
lactation (Flint et al., 1979).
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Consequently, this transition period between pregnancy and 
lactation is characterized by marked hormonal (and nutritional) 
changes. It represents an interesting condition in which to study 
the physiological variations in expressed and total activities and in 
particular in the phosphorylation state of the enzyme. Changes in 
these parameters of HMG-CoA reductase activity would be expected 
because of involvement of hepatic cholesterogenesis in the provision 
of VLDL by the liver for utilization by the adipose tissue and 
mammary gland in pregnancy and lactation respectively.
4.2 Diurnal Rhythm
4.2.1 Experimental
Microsomes were isolated from cold-clamped liver homogenates 
obtained at 2h intervals throughout the diurnal light/dark cycle and 
the total and expressed activities of HMG-CoA reductase were 
determined as described in Methods (Section 2.8).
4.2.2 Results
(i) Diurnal variation in total activity
The total activity of HMG-CoA reductase showed a well-defined 
diurnal rhythm in agreement with work from other laboratories (see 
Sections 1.3.3 and 4.1). In the present study, this activity in 
microsomes obtained from rats sampled at the mid-dark time point 
(D-6) was approximately 5.3-fold higher than in microsomes obtained 
from rats sampled in the middle of the light phase (L-6), see Fig. 
4.1. This high activity at D-6 was part of a plateau of activity 
which lasted for 8h in the dark phase, i.e. from D-2 to D-10. The
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Fig. 4.1 Diurnal variation in the expressed (Q) and total (#} activities 
of HMG-CoA reductase in rat liver microsomes
Values are means ± S.E.M. for three to seven determinations performed 
on microsomal preparations obtained from separate rats, except for L-2 and 
L-4 values, which are averages of two separate determinations which gave 
very similar results. L/D and D/L refer to the light/dark and dark/light 
transitions respectively.
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plateau of high total activity consisted of two maxima, i.e. at D-4 
and D-8, separated by a moderate decrease in activity at D-6. This 
observation was consistent with a previous report by Shapiro &
Rodwell (1972) (see also Rodwell ^  , 1973; 1976).
The rise of total HMG-CoA reductase activity to the value 
obtained during the plateau was very rapid and occurred primarily 
during the first 2h of the dark period, i.e. between the light/dark 
transition (L/D) and D-2. A similarly rapid and marked decrease in 
total HMG-CoA reductase activity occurred between D-10 and D/L. As a 
result of these rapid increases and decreases in total HMG-CoA 
reductase activity at the beginning and at the end of the dark period 
respectively, the diurnal peak of total HMG-CoA reductase activity is 
virtually symmetrical around the high activity that occurred between 
D-2 and D-10 (Fig. 4.1).
(ii) Diurnal variation in the fraction of HMG-CoA reductase 
in the phosphorylated form (E/T ratio)
The degree of activation of HMG-CoA reductase by protein 
phosphatase varied markedly depending on the phase of the light:dark 
cycle at which the microsomes were obtained from rats. Thus the 
enzyme in microsomes from animals the livers of which were sampled 4h 
into the light period (L-4) was activated 3.5-fold after phosphatase 
treatment whereas HMG-CoA reductase in microsomes prepared from 
livers of animals at D-4 was activated only 1.2-fold. Consequently 
the E/T ratio varied markedly in a diurnal pattern between 28$ and 
80$ at the nadir and peak respectively of the cycle (Fig. 4.2) and 
demonstrated that the phosphorylation state of HMG-CoA reductase 
varies in response to normal physiological stimuli vive.
90
80
.2 70 
2  
Sr 
1  60 
O  
CO
03
S 50
09
Im n
%
o
cs
40
30
S< 20 
*T3 
09
%
09
10
J J
L-2 L-4 L-6 L-8 L-10 L/D 0-2 0-4 0-6 0-8 0-10 0/L
Time into light (L) or dark (0) period (h)
Fig. 4.2 Diurnal variation in the fraction of HMG-CoA reductase in the 
active form in rat liver microsomes
Microsomes prepared from cold-clamped livers were used to obtain 
! expressed' and 'total' activities of HM3-CoA reductase at 2h intervals 
of the light/dark cycle in which the rats were maintained. Values are 
means ± S.E.M. for three to seven determinations performed on microsomal 
preparations obtained from separate rats, except for L-2 and L-4 values, 
which are averages of two separate determinations which gave very similar 
results.
82
This diurnal variation in the E/T ratio of HMG-CoA reductase 
had several important differences from the diurnal pattern of 
variation observed for total activity: (a) the E/T ratio had a 
pronounced well-defined peak at D-4 in contrast to the much broader 
(8h-long) plateau of the high total acitivity between D-2 and D-10. 
(b) The increase to and decline from this peak in E/T ratio were much 
more gradual than the corresponding phases of the cycle in the total 
activity above. Thus, the E/T ratio increased initially linearly 
with time over the lOh period between L-6 and D-4. The decrease in 
the E/T ratio after the D-4 peak was even more gradual such that the 
fraction of the enzyme in the active form was still over 50$ at the 
D-L transition point. (c) The peak and nadir of the diurnal 
variation in E/T ratio did not coincide with those for the diurnal 
cycle for total activity (D-6 and L-6). The peak for the ratio 
occurred at D-4 and the nadir occurred at the corresponding time 
point in the light cycle 12h later i.e. at L-4. Therefore there was 
an apparent 2-3h phase difference between the two diurnal cycles in 
addition to the other differences described above.
The variation in the fraction of HMG-CoA reductase in the 
active form through the light/dark cycle had several effects on the 
resultant diurnal cycle in expressed activity of the enzyme (Fig.
4.1). Because of the increase in the E/T ratio, concomitantly with 
the increase in total activity of HMG-CoA reductase during the dark 
period the expressed activity of the enzyme increased 15-fold 
compared with only a 5.3-fold increase in total activity. In 
addition the effect of the relatively slow, steady increase in E/T 
ratio between L-6 and D-4 resulted in a more gradual increase and
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decrease in the expressed activity of HMG-CoA reductase than in its 
total activity.
4.2.3 Discussion
This study demonstrated that the fraction of HMG-CoA reductase 
in the phosphorylated form, as determined by the E/T ratio, varies in 
the liver of rats m  vivo in response to normal physiological stimuli 
that occur during the diurnal cycle. These observations contrasted 
with those made by Brown et (1979) and by Dugan et al. (1982) who 
reported that the protein phosphatase treatment of rat liver 
microsomes always resulted in an approximate 7-fold activation of 
HMG-CoA reductase activity irrespective of the phase in the light:dark 
cycle at which the animals were sampled.
The variations in the E/T ratio m  vivo were, in general, 
similar to the diurnal variations shown in the total activity in that 
maxima and minima occurred in the mid-region of the dark and light 
periods respectively. Since the diurnal rhythm in total activity is 
thought to be regulated by factors related to the feeding activity of 
the animals (see Section 4,1) these observations suggest that the E/T 
ratio may be similarly responding to a diumally varying stimulus (or 
group of stimuli) related to feeding.
Two major differences were evident, however, between the two 
rhythms: this may reflect either the different modes of action of a 
common stimulus (or stimuli) or the involvement of different stimuli 
in the maintenance of the two rhythms. Thus there was a phase 
difference of 2-gh between the T and E/T rhythms, the latter reaching 
a peak (and nadir) earlier than the former (see Fig, 4.3). But
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to the calculated value of the inactive, phosphorylated enzyme (E/EP)
(A) .
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perhaps the most significant difference was the more gradual approach 
to and decline from a definite peak at D-4 shown by the E/T ratio 
compared to the very sharp increase and decrease to a broad, bimodal 
peak in total activity. In this respect, it is noteworthy that the 
gradual increase in the E/T ratio observed between L-6 and D-4 more 
closely parallels the gradual increase in food intake of the rats as 
the animals commence feeding in anticipation of the dark period (see 
Fig. 4.4; Peret ^  , 1973; Bruckdorfer et al., 1974; Munday &
Williamson, 1983). Hence when these distinct rhythms are combined 
(i.e. when expressed activity is considered), it is apparent that 
changes in the E/T ratio have an important role in producing a 
diurnal rise in effective HMG-CoA reductase activity vivo which 
may more closely approximate to the feeding behaviour of the animals. 
In addition, it increases the range over which the expressed activity 
varies by nearly 3-fold (see Fig. 4.1).
A similar dampening effect on the diurnal cycle of the 
expressed activity was evident for the latter part of the dark phase 
when HMG-CoA reductase activity was decreasing due to a slower 
decrease in the E/T ratio than in total activity. This different 
behaviour of total activity and the E/T ratio from i.e. D-4 onwards, 
is further suggestive that the two diurnal rhythms are responding to 
different stimuli or responding differently to the same stimulus.
The observations that a progressive decrease in the E/T ratio 
occurs for approximately 4h prior to any decrease in total activity 
suggests that the increased phosphorylation of the enzyme presages 
the degradation of the enzyme protein (see Fig. 4.3). Thus, if 
phosphorylation of the enzyme identifies it as a better substrate
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for intracellular processing (proteolysis), the increase in the 
proportion of the enzyme in the phosphorylated state that occurs 
after D-4 could facilitate the onset of the sharp decline in total 
activity that occurs between D-8 and D-L. Support for such a 
suggestion has emerged from reports that phosphorylated HMG-CoA 
reductase in microsomal membranes isolated from whole liver (Parker 
et al., 1984) or hepatocytes (Parker et al^ ., I985) is more
susceptible to proteolytic attack vitro by Ca^ '*’-dependent, 
leupeptin and calpastatin-sensitive protease calpain-II present in 
rat liver cytosol. Therefore changes in the phosphorylation state 
in vivo present a possible signal for the increased degradation of 
the enzyme during the latter part of the dark period (Fig. 4.3).
Such a mechanism has previously been cited for liver pyruvate kinase 
(Engstrom et , 1982) and yeast fructose-1-6-bisphosphatase 
(Muller & Hozer, I98I). A steady-state model has been proposed which 
recognizes fractional degradative rate constants for the 
phosphorylated and dephosphorylated species (Gibson et , 1984). 
Similarly during the phase of the diurnal cycle in which HMG-CoA 
reductase activities increase (i.e. L-10 to D-4) the increase in the 
E/T ratio for HMG-CoA reductase could diminish the rate of enzyme 
degradation and therefore contribute to the diurnal rise in the 
concentration of enzyme protein in the microsomes.
The precise nature of the stimuli involved in generating the 
diurnal rhythm in the E/T ratio of HMG-CoA reductase is undetermined. 
However, insulin, because of its known effects on the E/T ratio of 
HMG-CoA reductase in isolated rat hepatocytes (see Ingebritsen, 1983) 
and the association of the secretion of this hormone with the diurnal
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pattern of feeding activity (see Section 4.1) may have a major role. 
Indeed, the defined diurnal peak in the E/T ratio parallels closely 
the diurnal rhythm of the concentrations of insulin in the 
circulation (i.e. both peak at D-2 to D-4; Knox et al., 1979; Peret 
et ^ . , 1973; Bruckdorfer et al., 1974; Fig. 4.2). (In preliminary 
experiments it was found that plasma insulin concentrations in the 
animals used in the present study were in fact, higher at D-4 than at 
D-2).
Insulin is also known to influence the synthesis of HMG-CoA 
reductase (i.e. the total activity; see Section 1.3.3). Hulcher et 
al. (1985) have recently demonstrated that the cyclic variations in 
insulin coincide with variations in the total activity of HMG-CoA 
reductase in primates m  vivo. It is possible therefore the 
differences observed between the rhythms of the E/T ratio and the 
total activity are the result of the different mechanisms of action 
of insulin involved in the generation of each parameter: (i) covalent 
protein phosphorylation determining the E/T ratio which would be 
expected to reflect acutely the changing concentrations in the 
appropriate stimuli (e.g. insulin) in the blood, and (ii) a slower 
response required for the induction of enzyme protein synthesis. 
Support for this proposal, at least for the diurnal rise, has been 
obtained from studies in diabetic animals, (discussed in the next 
chapter), in which the administration of insulin produced a rapid 
increase in the E/T ratio followed after a lag period of 
approximately 2-3h by a marked increase in the concentration of 
enzyme protein in the liver (see Section 5.3.1 (iii)).
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Further analysis of the data suggests, however, that other 
factors besides plasma insulin concentrations are probably also 
involved in establishing the rhythms in total activity and the E/T 
ratio. The bimodal peak in total activity is remarkably similar to 
the pattern shown in the feeding activity of the normal rat and 
reflected to a lesser extent by the plasma concentration of insulin 
(see Peret e_t aJ., 1973). The E/T ratio, however, appeared to be 
unaffected by this secondary period of increased feeding activity 
suggesting that this parameter may be responding to a further 
antagonistic factor to insulin. This could be the effect of 
mevalonate as the intracellular concentration of this metabolite 
increases i.e. as the consequence of the increased activity of 
HMG-CoA reductase (see Chapter 6). Alternatively such an effect 
could be mediated by the diurnal rhythm observed in the plasma 
concentrations of glucagon (Murakami et al., 1981).
A further complication inherent in the interpretation of the 
possible role of insulin in the diurnal rhythm of the E/T ratio and 
total activity is that it assumes a direct relationship between the 
concentration of insulin in the peripheral and portal blood. Thus 
Balks & Jungermann (1984) have indicated that whilst portal insulin 
concentrations do increase during the dark period of the diurnal 
cycle, the variations from basal level in the light period are only 
modest; greater changes occur in the portal concentrations of 
glucagon.
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4.3 Food Deprivation
4 .3.1 Experimental
Animals were sampled at D-4 and food was withdrawn from them 
for 3 different periods: 4h, 12h and 24h prior to sampling. The
protocol is illustrated in Fig. 4.4.
4 .3.2 Results
The withdrawal of food from animals 24h prior to the sampling
of the liver by cold-clamping at D-4 resulted in a very marked
reduction (85%) in the total activity of microsomal HMG-CoA reductase 
compared to animals fed ad lib. (Table 4.1; ). This activity
of HMG-CoA reductase after 24h starvation was very similar to that 
observed in the microsomes obtained from livers samples at the nadir 
of the normal cycle (i.e. O.308 + 0.056 v 0.360 + 0.085 nmoles/min 
per mg of microsomal protein respectively; . ). Concomitant
with the fall in total activity was a marked decrease in the E/T ratio
from 79.9 + 4.1% in control animals to 29.9 + 5.0%. The value of
this ratio in animals starved for 24h was also similar to that seen at 
the nadir of the normal cycle (i.e. 30.6 + 3.0%).
The withdrawal of food from animals 12h before sampling (i.e.
at L-4) also resulted in the depression of both the total activity
and the E/T ratio from the values for control animals (Table 4.1;
). However, the effects on these parameters were 
quantitatively less than those obtained after 24h starvation (see 
above). The total activity was depressed by about two-thirds (from 
2.065 + 0.357 to 0.691 + 0.215 nmoles/min per mg of microsomal
protein) and the E/T ratio was depressed to 49.5 + 5.1%.
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Fig. 4.4 Experimental protocol used for t±ie assessment of the effect 
of various durations of food withdrawal on, the activity of 
HMG-CoA reductase and the fraction of enzyme in the active form.
Food was withdrawn from normal rats at three different time points in 
the diurnal rhythm of food intake, namely L/D (A) , L4 (B) , and D4 (C) , 
preceding a standard sampling time, i.e. D-4 to generate different 
durations of food deprivation, i.e. 4h (A) , 12h (B) , and 24h (C) .
HMG-CoA activity was determined in microsomes prepared from the liver at 
D-4. (Data for the food intake of rats was redrawn from Peret et al., 
1973).
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When food was withdrawn 4h prior to sampling i.e. at the 
beginning of the dark period (which normally coincides with the onset 
of the most active period of feeding, see Fig. 4.4), the only effect 
observed was on the E/T ratio which achieved values similar to those 
observed after a 12h period of starvation. There was only a minimal 
effect on total activity (Table 4.1). Thus, whereas the E/T ratio 
was depressed to 50.0 + 5.2% (i.e the same value as after the 
starvation), the total activity was maintained at a level not 
significantly different from that of control animals.
It was evident therefore that the E/T ratio, and not the total 
activity, was capable of responding acutely to short-term (4h) 
starvation. Thus, it can be calculated that of the marked 
suppression (halving) in the resulting expressed activity (from 1.661 
+ 0 .334, in control animals, to 0.785 + 0.133 nmoles/min per mg 
microsomal protein in starved animals) observed after 4h of 
starvation the increase in phosphorylation of the enzyme contributed 
the major part (73%). As the duration of starvation was prolonged, 
however, the contribution of the decline in total activity became 
more important such that the relative contribution of changes in the 
E/T ratio and total activity became approximately equal (47% and 53% 
respectively) after the 12h starvation. After 24h starvation the 
fall in total activity accounted for approximately 61% of the 
observed decrease in expressed activity. It is suggested that the 
latter observation resulted not from a decreased importance of the 
phosphorylation status of the enzyme but rather from the attainment 
of the maximal degree of phosphorylation obtainable in vivo (i.e.
E/T ratio approximately 25% at the nadir of the diurnal rhythm. 
Section 4.2) such that its contribution could not be further 
increased.
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4.3-3 Discussion
The effect of withdrawing food from an animal for 24h on the 
diurnal rise in total activity has been reported previously (see 
Rodwell e^ , 1976; see Section 4.1). In this study, a similar, 
apparently complete, suppression of the rhythm in total activity was 
observed such that the level of total activity attained in the 
microsomes of liver sampled at D-4 was virtually identical to that 
normally seen at the nadir of the light:dark cycle. It was evident 
that the effect was progressive (Fig. 4.6) and did not merely reflect 
the non-resumption of active food intake during the L/D transition. 
Thus the withdrawal of food for 12h prior to D-4 did not suppress the 
total activity as much as when the food was withdrawn 24h prior to 
sampling. These observations suggest: (i) that the feeding activity 
between D-4 and D-12 of one diurnal cycle results in the generation 
of additional stimuli for the synthesis of HMG-CoA reductase (rise in 
total activity) of the subsequent cycle, and (ii) the diurnal rise in 
total activity in the dark period requires a continuous signal 
produced as the result of the gradually increasing intake of food 
from L-4 to D-4 (see below).
By contrast, the diurnal rise in the E/T ratio was 
disproportionately affected by the different periods of food 
withdrawal. The withdrawal of food from the animal at L/D resulted 
in an abrupt cessation of the diurnal rise in E/T and, indeed, 
partially reversed the rise observed during the normal diurnal rhythm 
such that the E/T ratio at D-4 was lower than the value of the ratio 
of control animals at L/D No additional effect on the
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E/T ratio was produced by the withdrawal of food for a further period 
of 8h prior to sampling at D-4 (Fig . 4.6). Because of this
distinct behaviour of the E/T ratio and the total activity in 
response to 4 and 12h starvation, their relative contributions 
towards the combined effects on the effective (expressed) HMG-CoA 
reductase in the liver vivo was very dependent on the duration in 
starvation; changes in the E/T ratio were quantitatively more 
important in the adaptation of the expressed activity over short-term 
starvation (4h) whereas the converse was evident in conditions of 
long term starvation (24h) (see Fig. 4.6; cf. Beg & Brewer, 1981). 
These data are interpreted as suggesting that for livers sampled at 
D-4 induction of the synthesis of HMG-CoA reductase protein (i.e. 
total activity) is reponsive to stimuli that occur prior to L/D, the 
value of the E/T ratio at D-4 is primarily determined by stimuli that 
occur between L/D and D-4.
The factors responsible for these effects can only be 
surmized. However, it is noteworthy that the maxima observed in the 
diurnal rhythms of the circulating concentrations of glucocorticoids 
and insulin occur at L-10 and D-2 respectively (Knox et al., 1979; 
Bruckdorfer et ^ . , 1974). Therefore if the above suggestion is 
valid, the generation of the separate rhythms in these hormones could 
provide the appropriate stimuli before and after the L/D transition 
point. The primary effects of glucocorticoids on cellular metabolism 
involve the control of gene expression through the modulation of the 
concentration of mRNA either through transcriptional or 
post-transcriptional control (see Rousseau, 1984). These 
observations are consistent with a primary involvement of circulating
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glucocorticoid concentrations in the generation of HMG-CoA reductase 
mRNA (see Clarke al., 1984) and ultimately enzyme protein, i.e. 
total activity. By contrast, insulin is known to influence the 
synthesis and covalent phosphorylation of enzyme proteins (for a 
review, see Goldfine, I98I) and in particular HMG-CoA reductase 
(Krone & Greten, 1984; Spence et al., 1985; see Section 1.3*3 & 1.5) 
Thus, as proposed in the previous study in this chapter, insulin may 
be the primary stimulus regulating the increased dephosphorylation of 
HMG-CoA reductase (increased E/T ratio) between L/D and D-4 but it 
may also provide the continuous signal apparently required for the 
maintenance of protein synthesis (see above). By analogy with its 
effects on another hepatic enzyme, tyrosine aminotransferase (TAT) 
(Krahl, 1974; Pilkis & Park, 1974; Fain, 1974), insulin could 
regulate the translation of HMG-CoA reductase mRNA (Krone & Greten, 
1984) thus complementing the proposed transcriptional control of 
glucocorticoids (see Goldfine, 198I). It is suggested, therefore, 
that both insulin and glucocorticoids are jointly required for the 
establishment of the diurnal rhythms in total activity, whereas, of 
the two, insulin is the major determinant of the E/T ratio. Such a 
synergism between insulin and glucocorticoids has been previously 
reported for the maintenance of normal hepatic lipogenesis (Amatruda
et al., 1983).
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4.4 Pregnancy and Lactation
4.4.1 Experimental
Expressed and total activities of HMG-CoA reductase were 
measured in microsomes obtained from cold-clamped liver homogenates 
prepared at D-4 from female animals that were either unmated or at 
different stages of pregnancy and lactation. Animals were matched 
for age.
4.4.2 Results
The total activity and E/T ratio of HMG-CoA reductase observed 
in samples of liver taken from animals on day-12 of pregnancy were 
very similar to those observed in samples taken from the virgin 
animal, i.e. 1.4-1.5 nmoles/min per mg of microsomal protein and 
approximately 65/6 respectively (Fig. 4.7 & Fig. 4.8). This value for 
the E/T ratio in virgin animals at D-4 was slightly lower than the 
equivalent value in male animals (i.e. 65% vs 82%, approximate 
values, see Section 4.2.2).
Throughout the second half of pregnancy there was a gradual 
decrease in total HMG-CoA reductase activity (expressed on a unit 
microsomal protein basis; Fig. 4.7). However, this never reached 
less than 80% of the value observed for unmated animals. By 
contrast, there was a marked and rapid decrease in the E/T ratio 
during the last 2 days of pregnancy (i.e. from 60% to 25%, 
approximate values, Fig. 4.8).
After parturition both parameters increased in value (Fig. 4.7 
& 4.8). However, the E/T ratio started to increase on the
first day post—partum reaching the same level (approximately 55%) as
^  2.5
Z
£
tt 2.0
a
E
i "
z
CQ
09
CO
CO
s
CO
Z
1.0
0.5
f-
I L_
.£ -10 
09
6 -2 P 2 6
Days relative to parturition
10 12
CD
09
Fig. 4.7 Total activity of HMG-CoA reductase in isolated liver microsomes 
in virgin rats, rats at various stages of pregnancy and lactation 
and 24h-weaned rats
Total HMG-CoA reductase activity was determined (see Section 2.8) in 
microsomal membranes isolated from cold-clamped liver samples obtained 4h 
into the dark period. Values are means ± S.E.M. for three to six 
determinations obtained from separate rats.
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Fig. 4.8 Expressed/total activity ratio (E/T) of hepatic BMG-CcA reductase 
in virgin rats, rats at various stages of pregnancy and lactation 
and 24h weaned rats
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dark period. Values for the E/T ratio (percent) are means ± S.E.M, for thre 
to six determinations obtained from separate rats.
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on day-14 of pregnancy after only 4-days (Fig. 4.8). The total 
activity, which was constant over the period of parturition, 
increased (doubled) only after the second day post-partum (Fig.
4.7).
By day-12 of lactation, the E/T ratio tended to decrease 
to a value lower than those achieved after If days post-partum and, 
indeed, of that found in virgin animals (i.e. 40^ vs 65/5 approximate 
values,Fig. 4.8). Similarly, there was a gradual decline in total 
activity between days-4 and -12 of lactation although its value at 
day-12 was still higher than those observed in virgin animals in the 
mid-stage of pregnancy (Fig. 4.7).
Largely as a result of the marked changes in the E/T ratio 
during the last 5 days of pregnancy, the expressed activity of 
HMG-CoA reductase showed a rapid and marked decrease during the same 
period to a value approximating to 50^ 5 of that observed in unmated 
animals (Fig. 4.9). As the E/T ratio recovered during the first 2 
days post-partum there was little change in total activity and 
consequently no significant increase in expressed activity. However, 
after the second day of lactation, both the E/T ratio and total 
activity increased simultaneously to the values observed on day-4 of 
lactation. Consequently the expressed activity increased 
approximately 3.3-fold over the same period such that at day-4, it 
was approximately 1.3-fold that observed during the mid-stage of 
pregnancy or in the unmated animals (Fig. 4.9).
During peak lactation (day-12), concomitant decreases in the 
E/T ratio and the total activity resulted in a depression of the 
expressed activity to a value slightly lower than those observed in 
unmated animals (Fig. 4.9).
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The removal of pups from Isolating dams 24h before sampling on 
day-12 of lactation induced opposing changes in total activity and in 
the E/T ratio of HMG-CoA reductase. The total activity decreased 
(from 1.939 + 0.226 to 1.504 + 0.108 nmoles/min per mg of microsomal 
protein; P < 0.005 paired 't' test; Fig. 4.7) whereas the E/T ratio 
tended to increase (39.3 + 8.1% to 46.9 + 9.6%; difference not 
statistically significant; Fig. 4.8). Because of these opposite 
responses the expressed activity was unchanged 24h after weaning
(Fig. 4.9).
4 .4.3 Discussion
Hepatic cholesterogenesis is required during pregnancy and 
lactation to maintain VLDL synthesis that accompanies the increased 
endogenous formation of triglycerides in these states (see Section
4.1). VLDL is required by the adipose tissue (pregnancy) and the 
mammary gland (lactation) as a source of fatty acids (Hamosh et al., 
I97O; Zinder et al•, 1976) but is also possibly used by the mammary 
gland as a source of cholesterol for milk secretion (Zinder et al., 
1976; Gibbons et al., I983). Thus the observations from the present 
study that the expressed activity of HMG-CoA reductase was modestly 
increased compared with unmated animals during mid-pregnancy and 
lactation were consistent with these requirements. They also 
correlated well with previous determinations of the rate of hepatic 
cholesterogenesis in these conditions (when expressed as activity per 
wet wt. of tissue; Leoni et ai., 1984; Gibbons et al_., 1983)» Taken 
in combination with the much increased liver weight during these 
states (Feingold et al., 1983; Campbell & Fell, 1976) the sustained
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total activity and value of E/T ratio of HMG-CoA reductase would 
account for the increased rate of cholesterogenesis when expressed as 
activity per whole organ in pregnancy (Feingold et al., 1983) and 
lactation (Feingold & Moser, 1985).
The present study also demonstrated that the expressed 
activity of HMG-CoA reductase decreased markedly during the last days 
of pregnancy before recovering 2-4 days post-partum. Significantly, 
this decrease resulted almost exclusively from a marked decrease in 
the E/T ratio; there was no equivalent decrease in the total 
activity. (Thus the decrease in the E/T ratio accounted for about 
80% of the decrease in expressed activity when late-pregnant animals 
are compared to virgin animals). Whilst this decrease in the 
expressed activity correlated closely with the decrease in the rate 
of cholesterogenesis and expressed activity of HMG-CoA reductase 
during the last days of the gestation period as shoi>m by Leoni et 
al. (1984), the marked decrease in the E/T ratio that accompanied
this decrease was not observed by these workers. This discrepancy, 
as discussed in Chapter 3, is likely to be the direct result of the 
conventional method of liver sampling used by these workers which 
must have resulted in artefactual data.
The different responses of the E/T ratio and total activity to 
the physiological changes occurring in the metabolism of the rat 
during late pregnancy demonstrates: (i) the physiological importance
of changes in the E/T ratio in determining the value of the expressed 
activity while the animal maintains a relatively high concentration 
of enzyme protein. It also suggests (ii) that the mechanisms 
determining the values of total activity and the E/T ratio are
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regulated independently. The decrease in expressed activity of 
HMG-CoA reductase coincided with a marked decrease in circulating 
insulin concentrations (Flint et , 1979; Lorenzo et , 198I; 
Benito et al., 1982) food intake (Walker & Hahn, I98I; Cripps & 
Williams, 1975) and hepatic lipogenesis (Lorenzo et , 1983;
Benito et a2., 1982) as shown in Fig. 4.10. These concomitant 
changes suggest that the modulation of the phosphorylation state of 
HMG-CoA reductase enables the co-ordination of the rate of hepatic 
cholesterogenesis with the rate of lipogenesis such that the 
reduction in the amount of triglyceride formed is accompanied by 
decreased rates of cholesterol synthesized for VLDL formation and 
secretion. The physiological significance of the maintenance of this 
high level of enzyme protein may be to enable a very rapid response 
(increase) in the rate of hepatic cholesterogenesis on the resumption 
of feeding after parturition through an activation of the existing 
enzyme (increase in E/T ratio; see Fig. 4.10).
The suggestion that the values of the E/T ratio and total 
activity are determined by independently regulated mechanisms was 
supported by two further observations during lactation: (a) the two
parameters show opposing responses (i.e. a decrease and a modest 
increase for total activity and the E/T ratio respectively) in the 
liver of mid-term lactating dams following the removal of pups 24h 
earlier and (b), the E/T ratio commenced a recovery two days prior 
to any increase in total activity at the onset of lactation.
In view of the proposed primary involvement of insulin in the 
generation of the diurnal rhythm of the E/T ratio of HMG—CoA 
reductase (see Sections 4.2, 4.3) it is plausible that
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the decrease in this parameter during the last days of pregnancy is 
the direct consequence of the accompanying fall in the plasma 
concentration of insulin (Fig. 4.10). However, the involvement of 
other hormones cannot be excluded. Thus, there is a concomitant fall 
on plasma progesterone concentrations (Flint et al., 1979; Benito et 
ni., 1982; Lorenzo et ^ . , I983) although there is no indication 
that this hormone modulates protein phosphorylation. The involvement 
of hormones other than insulin in affecting the E/T ratio is more 
obvious during lactation. The E/T ratio increased 2-fold during the 
first 4 days of lactation at a time when there is no increase in the 
plasma concentration of insulin (Fig. 4.10). Similarly, the large, 
transient increase in plasma insulin after weaning (Igius et , 
1979; Burnol et ai., I983) was accompanied by only a modest rise in 
the E/T ratio. The plasma concentration of a number of hormones is 
increased during lactation. They include progesterone corticosterone 
and prolactin (Flint e^ al., 1979; Flint et , 1984; Menomori et 
al., 1970). Although the acute effects of prolactin on liver 
metabolism has not been determined the marked increase in its 
concentration in the circulation during parturition may coincide with 
the commencement of the increase in the E/T ratio. Furthermore, the 
rapid decline in the levels of this hormone on weaning may be a 
mechanism by which the expected effect of insulin on the E/T ratio in 
these animals is counteracted. The phosphorylation state of HMG-CoA 
reductase during pregnancy and lactation may also be affected by the, 
as yet uninvestigated, variations in the rate of cholesterol uptake 
by the liver, animals (see below).
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Source of references include Walker & Hahn (1981), Cripps & Williams (1975) 
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Agius et al. (1979), Lorenzo et al. (1981) (lipogenesis).
99
The total activity of HMG-CoA reductase would also be 
determined by the result of the individual hormonal and/or 
nutritional changes on the turnover of the enzyme. The fact that
the total activity was maintained at a high level during late
pregnancy suggests that the decrease expected in this parameter due 
to the fall on plasma insulin concentrations (see above) was 
effectively counteracted by other factors. A likely candidate for 
this antagonism is the reduced delivery of cholesterol from 
chylomicron remnants to the liver during the relative hypophagia that 
occurs around parturition. The factors responsible for the increase 
observed in total activity during early lactation is unknown, 
although in view of possible involvement of glucocorticoids in the 
regulation of HMG-CoA reductase protein synthesis (see Section 4.3.3) 
it is noteworthy that lactation is a hypercorticoid condition. The 
increasing concentration of prolactin in the circulation during this
phase of lactation may also be involved.
As indicated in the foregoing discussion, the increase 
observed in the expressed activity of HMG-CoA reductase during 
lactation is paradoxical, not only because of the low circulating 
concentration of insulin but also because of the gross hyperphagia of 
the lactating rat. Under these conditions both the total activity 
and E/T ratio of this enzyme would be expected to be reduced due to 
the increased delivery of dietary cholesterol to the liver via 
chylomicron remnants (see Section 1.3.1(i) and Chapter 6). Although 
hyperphagia, albeit less severe, is evident in rats during 
mid-pregnancy, its anticipated effects on the parameters of HMG-CoA 
reductase activity are possibly counteracted by the accompanying
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hyperinsulinaemia of this state. During lactation, two possible 
mechanisms could be responsible for the apparent lack of feedback 
regulation of the activities of HMG-CoA reductase by the increased 
level of dietary intake of cholesterol:
(1) The rate of chylomicron remnant-mediated delivery of 
cholesterol to the liver may be restricted. This could be achieved 
by an increased depletion of the cholesterol content of these 
particles at the periphery. Evidence exists that during lipoprotein 
lipase action on chylomicrons (and VLDL) in the capillaries of 
mammary tissue, cholesterol (and cholesterol ester) is taken up by 
the mammary secretory cells (Zinder ^  al., 1976). Since the rates 
of cholesterogenesis within the mammary gland are relatively low an 
appreciable proportion of the cholesterol (approx. I6mg/day on Day-15 
of lactation; Clarenburg & Chaikoff, 1966) secreted into the milk is 
obtained from the circulation (Connor & Lin, 1967; Gibbons et al., 
1983).
(2) The delivery of cholesterol to the liver could be 
decreased by the attenuation of chylomicron remnant and LDL binding 
and internalization either by through a decrease in the number of 
surface receptors in the liver or by decreasing the affinity of these 
receptors for their ligands. Such an adaptation is known to occur 
under pathological conditions in which the normal response of hepatic 
HMG-CoA reductase to dietary cholesterol intake is lost or stunted 
(Barnard et al., 1984). It may be related to the altered 
composition (especially of apoproteins) of the lipoproteins (Levy et 
al., 1985). In lactation these effects could ensure a longer
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residence time of chylomicron remnants and LDL in the circulation and 
consequently a more complete depletion of their cholesterol content 
by the mammary gland.
The mechanisms involved in the maintenance of a high expressed 
activity of HMG-CoA reductase in spite of hyperphagia provides scope 
for further study of the relationship between peripheral and hepatic 
lipoprotein metabolism. Feingold and Moser (1985) have recently 
reported that the feedback mechanism of dietary cholesterol on 
hepatic cholesterogenesis is intact during lactation. However, the 
increased requirement for bile and synthesis specifically induced 
during lactation and anticipated increased bile flow in response to the 
hyperphagia of this condition would be expected to produce major effects 
in the specific activity of HMG-CoA reductase. Similar effects may also 
occur during the diurnal cycle of feeding.
4.5 General Conclusions
The use of the cold-clamping technique has enabled the 
quantitation of the phosphorylation state of HMG-CoA reductase in 
vivo. The data presented in this chapter have demonstrated that 
this parameter varies considerably in different physiological 
conditions in response to acute hormonal and nutritional changes.
These observations demonstrate that reversible phosphorylation has an 
important physiological role to play in the regulation of hepatic 
HMG-CoA reductase activity and cholesterogenesis ijn vivo and 
provides a mechanism by which this pathway can be regulated in 
concert with hepatic fatty acid synthesis and estérification (see 
Section 5.1; Fig. 5.1). Indeed, in the three conditions studied a 
change in the phosphorylation status of HMG-CoA reductase appeared to
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be the primary mechanism through which the effective (expressed) 
activity of HMG-CoA reductase became rapidly adapted to the immediate 
needs of the animal. Thus in short- and medium-term starvation (up 
to 12h; i.e. the duration of starvation that is most physiologically 
relevant to the rat, see Section 4.3) the decrease in the E/T ratio 
accounted for approximately 50-75/6 of the changes observed in 
expressed activity. Moreover, these changes in the phosphorylation 
state of HMG-CoA reductase serve to co-ordinate more closely the 
expressed activity (i.e. cholesterol formation) with the feeding 
activity of the animal and the requirement for VLDL secretion by the 
liver (see Section 4.1 and 4.2). In these conditions, changes in the 
phosphorylation state amplify the effects of variations in HMG-CoA 
reductase activity produced by rapid changes in the rates of 
synthesis (and possibly degradation) of the enzyme. Similarly during 
late pregnancy, changes in the E/T ratio of HMG-CoA reductase appear 
to be the sole mechanism involved in mediating the decrease in the 
rate of hepatic cholesterogenesis during this period.
10^
CHAPTER 5
EFFECTS OF HORMONAL TREATMENT OR DEFICIENCY ON HMG-COA REDUCTASE
IN RAT. LIVER IN VIVO
5.1 Introduction
In Chapter 4, it was demonstrated that the fraction of HMG-CoA 
reductase in the phosphorylated form varied markedly in a number of 
physiological conditions vitro. Changes both in the 
phosphorylation status and in the concentration of the enzyme (due to 
the very short half-life) can occur in response to acute changes in 
the hormonal and nutritional status e.g. as demonstrated by the 
distinctive diurnal rhythms of the two parameters. Although changes 
in the phosphorylation state of the enzyme occur more rapidly than 
changes in enzyme concentration, nevertheless they may also persist 
in response to long-term changes in hormonal conditions (e.g. those 
induced by starvation or diabetes) due to chronic changes in the 
relative activities of protein kinases and phosphatases. Although 
the response to some hormones of the bicyclic cascade mechanism 
described for the regulation of HMG-CoA reductase has been described 
in isolated hepatocytes (see e.g. Ingebritsen, 1983) little work has 
been done to determine the types of hormones that could be involved 
in the regulation of this system in vivo.
In the present study the effect of acute hormonal treatment 
in vivo on the phosphorylation state of HMG-CoA reductase has been 
investigated. In particular, the effects of two types of hormone 
were studied: (a) the pancreatic hormones insulin and glucagon
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because of the important role played by these hormones in the control 
of hepatic metabolism in relation to dietary intake and (b) the 
catecholamines, because of the apparently profound effects of stress 
on the phosphorylation state of this enzyme (see Chapter 3).
Insulin and glucagon are considered to be the main homeostatic 
hormones with respect to the synthesis and supply of substrates by 
the liver to extrahepatic tissues. Insulin stimulates glycogen and 
lipid synthesis whereas glucagon promotes fatty-acid oxidation, 
glycogen breakdown and gluconeogenesis. These antagonistic effects 
result in the homeostatic regulation of blood glucose as well as in 
changes in production and secretion of ketone bodies and lipoproteins 
by the liver under different physiological conditions. Their effects 
are known to be mediated through reversible phosphorylation of key 
enzymes in the pathways of carbohydrate and lipid metabolism. In 
conditions characterized by low glucagon, and high insulin 
concentrations, key enzymes (e.g. glycogen synthase, pyruvate 
kinase, pyruvate dehydrogenase, acetyl-CoA carboxylase) involved in 
anabolic processes are largely dephosphorylated and active (Fig. 5.1 
for a review see Geelen et ^ . , 1980). Under the inverse conditions 
(i.e. low insulin/glucagon ratio) these enzymes are phosphorylated 
and inactive whereas 'catabolic' enzymes (e.g. glycogen phosphorylase 
Fig. 5.1) are activated through phosphorylation. Because of this 
reciprocal relationship between the degree of phosphorylation and 
activity in the two sets of enzymes, conditions that favour the 
activity of protein kinases result in a catabolic state of the liver 
whereas those that favour protein phosphatase activity result in 
anabolic activity. Moreover, the same set of protein kinases and
Glucose
1(+)
Glycogen
2(-)
3(-)
Fructose-6-Phosphate 4(+)
Fructose-2,6- 
Bisphosphate
Phosphatidyl
Choline Triglyceride
12(+)
Choline Diglyceride
Phosphatidate
Glycerol Phosphate
7C+)Acetyl-CoA Malonyl-CoA #  Fatty Acyl-CoA
lolesterol
Esters
8(+)HMG-CoA Mevalonate Cholesterol
9(-)
Bile Acids
Fig. 5.1 Interconvertible enzymes of carbohydrate and lipid metabolism
Enzymes regulated by reversible phosphorylation are numbered and presented 
in the dephosphorylated form i.e. in conditions characterized by low glucagon, 
high insulin. (Increased (+) and decreased (-) enzyme activity.)
(1) glycogen synthase; (2) glycogen phosphorylase; (3) phosphorylase 
kinase; (4) 6-phosphofrueto-2-kinase/fruetose-2,6-bisphosphatase; (5) pyruvate 
kinase; (6) pyruvate dehydrogenase; (7) acetyl-CoA carboxylase; (8) HMG-CoA 
reductase; (9) HMG-CoA reductase kinase; (10) acyl-CoA cholesterol acyltrans- 
ferase; (11) diglyceride acyltransferase ; (12) cytidylyl transferase;
(13) cholesterol 7oc-hydroxylase
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phosphatases can potentially mediate both reciprocal processes and 
some cases of this are well established (e.g. glycogen metabolism; 
see Cohen, 1982).
In view of the early demonstrations that the phosphorylation 
state of HMG-CoA reductase can be modulated in isolated hepatocytes 
(by insulin and glucagon) and in intact animals by pharmacological 
doses of glucagon (see below) there are indications that these 
hormones may be primary factors involved in the modulation of the E/T 
ratio. For example, in the diurnal cycle (see Chapter 4) it is 
possible that the phosphorylation state of HMG-CoA reductase is 
regulated co-ordinately with that of other enzymes of hepatic 
lipogenesis.
■ Although, as indicated above, the effect of an intraperitoneal 
injection of glucagon to whole animals has been reported (see Beg et 
al., 1981; Section 1.5) these experiments were performed using 
classical liver sampling and fractionation techniques for the 
preparation of microsomes and therefore were susceptible to the same 
problems and artefacts outlined in Chapter 3- Indeed it can be 
calculated that the 'active' enzyme in the studies of Beg et al., 
represented only approximately 13% of the total activity of the 
enzyme. This low level of activation is possibly unphysiological 
because, as the results reported in the previous chapters indicate 
the E/T ratio never appears to fall below about 25% when measured iM 
vivo. Consequently, a reappraisal of the effects of glucagon and an 
initial investigation of those of insulin on E/T ratios in vivo was 
desirable.
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Modes of Action of Hormones
(i) Pancreatic hormones
The mode of action involved in the pleiotropic effects of
insulin on cellular metabolism is not clearly understood in spite of
numerous theories (for a review, see Fain, 1984). Insulin can induce
both the phosphorylation and dephosphorylation of cellular proteins
in vivo. The current emphasis, however, is on membrane protein
kinases and phosphatases due to the recent discovery that the insulin
receptor displays tyrosine kinase activity (Kasuga et al., 1982;
Avruch et ai., 1982). However, other than its autophosphorylation
activity no other protein substrates in the cell have been identified
2+for this kinase. Numerous second messengers including Ca (Czech, 
1977); peptides (see Larner et al., 1979; 1982), inositol 
trisphosphate (see Farese, 1984) and polyamines (see Cohen, 1985) 
have also been proposed to mediate insulin action.
In contrast, the cellular effects of glucagon are thought to 
be mediated solely by its increasing the intracellular concentration 
of cyclic AMP as the consequence of activating plasma membrane bound 
adenylate cyclase (Heyworth & Houslay, 1983). The increased cAMP 
concentration activates cyclic AMP-dependent protein kinase (type-A 
protein kinase) which is known to phosphorylate numerous 
intracellular proteins (see above; see Cohen, 1985) on serine or 
threonine residues (Krebs & Beavo, 1979).
(ii) Catecholamines
Epinephrine and nor-epinephrine regulate physiological 
processes via their interactions with a variety of plasma membrane 
receptors. These receptors are classified into 2 types, ^ and ^  that
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are further subdivided into and 6^ , 6 . This classification
is based on the cellular effect elicited by the two hormones and by 
the relative potencies of their agonists (Table 5.1). The 
catecholamine a^-adrenergic receptor system (for a review see Exton, 
1985) exerts its action on target tissues via the increase in 
cytosolic Ca^^ concentration. Its effects are perhaps best 
characterized in smooth muscle (e.g. of blood vessels or intestine) 
in which occupancy of their receptor induces contraction or 
relaxation respectively. In the liver o^-mediated effects include 
the activation of glycogenolysis through the increased activity of 
phosphorylase a (Charest e^ ^ . , 1983; 1985) and increased 
gluconeogenic activity through effects at several sites including the 
phosphorylation and inactivation of pyruvate kinase (Garrison at 
al., 1979). a 2"(Bylund & U'Prichard, I983) and 3- (see Stiles et 
al., 1984) adrenergic receptors exert inhibitory or stimulatory 
effects on adenylate cyclase activity via the influence of GTPbinding 
proteins Ni and Ns, respectively. Thus the binding of agonist to 
Ug-receptors decreases, whereas that at 3-receptors increases 
intracellular cyclic AMP concentrations (cf. for glucagon, see 
above). The liver possesses primarily 32~a-drenergic receptors 
(Minneman & Molinoff, I98O; Lacombe et al., 1976) which have a very . 
much greater affinity for epinephrine than norepinephrine (Table
5 .1). The 3^ -adrenergic receptors which have an approximately equal 
affinity for epinephrine and norepinephrine are found primarily in 
the heart, adipose tissue and brain (Minneman & Molinoff, 1980; Table
5.1). Juvenile male rats possess a very active 3-adrenergic system 
capable of mediating glycogen mobilization from the liver but ageing
TABLE 5.1
Adrenergic Receptor Subtypes, their Target Tissues 
and Mechanism of Action
Receptor Agonists 
(order of potency)
EPI > Ne > ISO
Major 
Target Tissues
Smooth muscle 
*Liver 
Heart
Adipose tissue 
Kidney 
Sweat +
Salivary glands 
Brain
Mechanism of 
Action
Alter
cellular Ca 
fluxes
2 +
EPI > NE > ISO Adrenergic 
nerve endings 
Liver 
Platelets 
Adipose tissue 
Endocrine 
pancreas 
Vascular smooth 
muscle 
Kidney 
Brain
Inhibit
adenylate
cyclase
ISO > NE EPI
ISO > EPI »  NE
Heart 
Adipose tissue
Liver 
Skeletal muscle 
Smooth muscle 
Endocrine 
pancreas 
Salivary glands
Stimulate
adenylate
cyclase
Stimulate
adenylate
cyclase
EPI
NE
ISO
*
epinephrine
norepinephrine
isoproterenol
only important in certain species e.g. rat; in humans 
3-adrenergic response predominates (Exton, 1985)
(Taken from Lefkowitz et al. (1983) and Exton (1985)
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causes a progressive decline in this response such that in mature
rats, glycogen mobilization is mediated primarily by the effects of
-adrenergic receptors (Morgan ^  al., 1983; Katz et , 1985).
Thus rats at the age used in the present study (i.e. weeks, l60-200g)
A
would be approaching the mid-point of this transition period (see 
Blair et al., 1979a,b; Morgan et al., 1983) and would have been 
expected to respond both to ^  and ^ effects of catecholamines.
5.2 Experimental
In each of the following studies, the expressed (E) and total 
(T) activities of HMG-CoA reductase and hence the E/T ratio were 
determined in the microsomal fraction isolated from liver samples 
obtained by the cold-clamping technique (see Chapter 3) as described 
in Methods (Section 2.8). .
5.3 Results
5.3.1 Acute Alterations in Plasma Insulin Concentrations
The effects of acutely and chronically modifying the 
circulating insulin concentrations in rats on the total activity and 
E/T ratio of HMG-CoA reductase were studied. Several different 
approaches were adopted to achieve these alterations:
(i) Intraperitoneal administration of glucose into normal 
rats. This method was used in order to increase plasma insulin 
concentrations within a physiological range without inducing 
hypoglycaemia (see Stans hi e et al., 1976b). (ii) Intravenous 
infusion of anti-insulin serum (raised in guinea-pigs) which was used
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to acutely diminish the plasma insulin concentrations (Martin & 
Baldwin, 1971; Stansbie et , 1975b). (iii) Streptozotocin 
treatment. This 3-cell cytotoxic drug was used to produce chronic 
reduction in circulating insulin concentrations in rats on a 
longer-term basis, (iv) These animals were further used to 
investigate the effects of replenishment of circulating insulin 
concentrations by intravenous infusion and intraperitoneal injection 
respectively.
(i) Intraperitoneal injection of glucose into normal rats
Rats (160-200 g) were injected either with glucose (200 mg) or 
with an equivalent volume of saline (0.8 ml) 4h into the light period 
(L-4). This point in the normal diurnal cycle coincides with basal 
circulating concentrations of insulin (see e.g. Knox et ^ . , 1979) 
and the nadir of the E/T ratio for HMG-CoA reductase (section 4.2). 
The treatment raised blood glucose by 150% after 10 min and 
normoglycaemia was restored after 50 min (Fig. 5.2). Although no 
direct measurements of plasma insulin concentrations were made, it is 
known from previous studies that a similar dose of glucose to rats 
results in moderately elevated circulating levels of this hormone 
(Burnol et ^ . , 1983).
As shown in Fig. 5.2 the administration of glucose to animals 
produced a significant increase in the E/T ratio of HMG-CoA reductase 
after 30 min when compared to saline-injected animals (52.1 + 2.4 v 
33.9 + 3.1; n = 3) and only appeared to last as long as the 
hyperglycaemia persisted. The rise in the E/T ratio was due to a 
marked increase in the expressed activity without any significant
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Fig - 5.2 Effect of int-raperitoneal injectxcm of gltiicose on Ça) blood
glucose concentration and (b| the E/T ratio of hepatic HMG-CoA 
reductase at L-4
(a) Glucose (200mg) was injected into rats at L-4 (arrow) Blood glucose 
concentration ( ) was determined in Wiole blood samples obtained from the
tail of anaesthetized rats (see Section 2.11.1) . |b) Tbe e/T ratio for
HMG-CoA reductase was determined in cold clamped liwr samples simultaneous 
to, and at 15 and 30 min. subsequent to the injection (arrow) of gluco.se 
or saline (Q) • Values are means ± S.E.M. ercept for 30 min. values which 
were averages of two separate determinations which gave very similar results.
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variation in the total activity (results not shown). A much more 
gradual and modest increase in the E/T ratio was observed in control 
animals, this may have resulted from the normal increase in expressed 
activity that occurs after L-4 during the diurnal cycle (Section
4.2).
(ii) Intravenous infusion of anti-insulin serum (A.I.S.)
The effects of acutely diminishing the circulating insulin 
concentration on the E/T ratio of HMG-CoA reductase in the liver was 
investigated by intravenous infusion of an aliquot of guinea-pig 
serum containing an antibody raised against insulin (see Methods; 
section 2.13). In order to maximize the putative response of changes 
in E/T, this treatment was performed at D-3.5, a point in the diurnal 
cycle at which the circulating insulin levels are high and the E/T 
ratio is near-maximal (see Chapter 4). Futhermore, the total 
activity of HMG-CoA reductase at this time in the diurnal rhythm is 
relatively stable.
That the antibody in the serum was effective in decreasing
insulin concentrations in the treated rats was ascertained by
determining the concentration of glucose in the blood obtained from
the tail subsequent to the intravenous infusion of 1 ml of A.I.S.
Treatment of rats with A.I.S. resulted in a maximal increase in blood
15-
glucose of 2-fold after^BO min (Fig. 5.3) but the degree of 
effectiveness varied markedly between animals; the range of 
hyperglycaemia generated is demonstrated in Fig. 5.4. However, in 
each case, the return to normoglycaemia was as rapid as the initial 
rise in the blood glucose observed after the administration of
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Fig. 5.3 Effect of intravenous infusion of anti-insulin serum (A.I.S.) on 
blood glucose concentration
A.I.S. (1ml) (#) or control serum (A) were infused into anaesthetized
rats at D-3.5 to D-4 and blood glucose concentration determined in whole 
blood samples obtained from tail at 10 min. intervals.
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Fig. 5.4 Effects of different degrees of insulin deficiency on the E/T 
ratio of microsomal HMG-CoA reductase in amimals treated with 
A.I.S.
Rats were intravenously infused with control serum (1ml; 15 and 30 min#) 
or A. I.S. (1ml; 15 min ■  ; 30 min A ) - The straight line was obtained by 
performing linear regression analysis; the correlation coefficient was -0.61.
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A.I.s. This was presumably due to an increased secretion of insulin 
from the pancreas in response to the increased blood glucose 
concentration with consequent titration of the limited amount of 
antibody infused.
Coincidental with the peak of glucose concentrations 15-30 min 
after the infusion of A.I.S. there was a significant decrease in 
expressed activity of the enzyme (1.035 + 0.104 to 0.760 + 0.169 
nmoles/min per mg of microsomal protein) without any discernable loss 
of total activity (1.571 + 0.176 v 1.621 + 0.107 nmoles/min per mg 
of microsomal protein) (Table 5.2). Consequently the E/T ratio was 
markedly depressed from 63.0 + 2.5 to 49.8 + 6.9%. A similar fall 
in the E/T ratio was observed in animals that had been treated with 
A.I.S. for 15 mins (Table 5.2).
In control animals (to which serum from non-immunized 
guinea-pigs was administered) the total activity of HMG-CoA reductase 
and E/T ratio were not significantly different from those observed in 
other animals treated similarly but with saline at the same time of 
the diurnal cycle (e.g. E/T = 63.0 + 2.5%, serum cf. 68.0+1.1%, 
saline after 15 or 30 min).
There was an inverse correlation between the E/T ratio and the 
degree of hyperglycaemia induced by A.I.S. in individual animals.
This suggests that the E/T ratio was directly affected by the 
concentration of insulin in the circulation.
(iii) Streptozotocin treatment
Long-term insulin deficiency was induced in rats in order to 
investigate (a) the effects of chronic insulin deficiency and (b)
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the acute and medium-term effects of insulin replacement on the E/T 
ratio of HMG-CoA reductase. In the case of (a) the livers of animals 
were sampled at D-2 whereas in (b) insulin replacement was commenced 
at D-2 and continued over the subsequent 4h period. This time period 
was chosen in order to demonstrate the effects of either deficiency 
or replacement of insulin at a time of day when the circulating 
concentration of the hormone is high in normal, untreated animals.
Streptozotocin (150mg/kg body wt.) was administered to rats by 
intraperitoneal injection. The animals were used 7-8 days later when 
the effect of insulin deficiency on HMG-CoA reductase activity was 
maximal (see Lakshmanan et al., 1973). This dose of streptozotocin 
was the highest routinely tolerated by the animals. However, it was 
effective to variable extents in inducing insulin deficiency in rats 
as indicated by the wide range of hyperglycaemia resulting in 
individual animals i.e. 10-38mM. In Fig. 5.5 and 5.5 the E/T ratio 
and total activity of HMG-CoA reductase in the livers of diabetic 
rats are plotted as a function of the respective concentrations of 
blood glucose achieved in the individual animals. It is evident that 
moderate insulin deficiency resulting in glycaemia equivalent to 20mM 
blood glucose or less had no significant effect on the E/T ratio 
(Fig. 5.5). Thus the ratio remained close to 80% as exhibited in the 
livers of normal animals at D-2. However, for animals that developed 
a glycaemia in excess of 20mM glucose, there was a distinct inverse 
relationship between the level of blood glucose and the value of the 
E/T ratio for HMG-CoA reductase. Therefore, if the degree of 
hyperglycaemia can be considered to be an inverse index of the degree 
of insulin deficiency, it is evident that the phosphorylation state
of HMG-CoA reductase was only affected when the concentration of the 
hormone was decreased below a threshold value represented by a 
glycaemia of 20mM.
100 r
o
ô
co
o-t-'
•o
CDœœ
2.
1
80
g
2
1
CD
CD
S 60
O
3
%
40
20
0
#
eu 10 20 30
Blood glucose concn. (mM)
40
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coefficient was -0.82.
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The reason for the marked discrepancy between the 
effects of hyperglycaemia on the E/T ratio of HMG-CoA reductase 
produced by streptozotocin and A.I.S. treatment is unknown 
but may be a result of ^ he different experimental conditions.
The total activity of HMG-CoA reductase also was affected only 
by more severe hypoinsulinaemia the effect being evident at a 
glycaemia level greater than 20mM (Fig. 5.6). Although this 
correlation was very similar to that observed for the E/T ratio it 
was less strong, at least on an empirical linear basis. This was 
reflected in a lower correlation coefficient (r = - 0.38) and 
resulted partly from the variability in the absolute values of 
HMG-CoA reductase routinely encountered on assay of the enzyme as 
discussed previously. The E/T ratio being independent of the 
absolute specific activity of the enzyme was subject to a much lesser 
degree of variability between individual animals.
The consequence of the similar sensitivities of the two 
parameters of HMG-CoA reductase activity was that both the total 
activity and E/T ratio determined in liver extracts of severely 
insulin deficient animals (hyperglycaemia > 35mM) were very similar 
to'those obtained at the nadir of the normal diurnal cycle (cf. 
Section 4.2).
(iv) Insulin administration to diabetic rats
For these experiments only diabetic rats that had blood 
glucose concentrations in excess of 30iiM were used. Two experiments 
were performed: (1) insulin was (6(J) admxnistered acutely by 
intravenous infusion via the femoral vein into anaesthetized rats 4h 
into the dark period (D-4) and the liver was sampled. 15—20 min later;
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and (2) insulin (24l4) was injected intraperitoneally into conscious 
rats every 60 mins for 4h, commencing 2h into the dark period; these 
rats were then anaesthetized 20 min before the sampling time during 
the period D2-D6. This latter procedure was adopted to produce a 
more gradual increase in circulating insulin concentrations such as 
would be expected to occur in vivo.
In the acute (intravenous infusion) experiments , the blood 
glucose concentration was decreased from 31.8 + 2.1 to 22.2 + 1.5mM 
(means + S.E.M., n = 5) after 15-20 min. This treatment did not 
affect total activities of HMG-CoA reductase in liver microsomal 
fractions, but it increased the E/T ratio from 48.1 +2.5/5 (n = 11) 
to 98.0 + 4.5% (n = 5), i.e. it resulted in the total 
dephosphorylation and activation of HMG-CoA reductase in the liver of 
the intact animals. In control animals infused with 0.9% NaCI, there 
was no change in the fraction of HMG-CoA reductase in the active 
form.
In the medium-term experiments (intraperitoneal injection of 
insulin) a very gradual decrease in blood glucose concentration was 
achieved, resulting in near-normoglycaemia after 3-4h (Fig. 5.7) of 
insulin treatment. Both the E/T ratio and total HMG-CoA reductase 
activity were increased by this treatment, such that for both 
parameters the values increased from those characteristic of diabetic 
animals to those observed at 2-6h into the dark period in normal 
animals. In these experiments the increase in E/T ratio was not as 
rapid or as extensive as that observed with intravenous infusion of 
insulin, but it was evident within the first 20 min after 
intraperitoneal injection of insulin and was maximal by 60 min, at
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injected hourly intraperitoneally with insulin
Values are means (± S.E.M.) for three to five determinations.
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which time 80% of the enzyme was in the active state (Fig. 5.8a). 
Control diabetic animals injected with 0.9% NaCI showed a continuous 
small increase in the E/T ratio over this 4h period. This is 
presumed to have been due to residual insulin secretion in these 
animals, and suggests that even in relatively severe diabetes 
(30-40mM glucose in whole blood), diurnal changes in the fraction of 
HMG-CoA reductase in the active form may occur; however, the peak of 
this rhythm may be considerably later in diabetic animals than in 
normal rats. The effect was not studied further.
After intraperitoneal injection of insulin, the stimulatory 
effect of insulin on total HMG-CoA reductase activity occurred 2-3h 
later than that observed for the fraction of the enzyme in the active 
form (Fig. 5.8b). Thus, even after 2h of the commencement of insulin 
treatment there was no detectable increase in total HMG-CoA reductase 
activity, whereas at 3h the maximal effect had occurred (Fig. 5.8b). 
At its height, this effect resulted in total reductase activities 
similar to those observed in normal animals 6h into the dark period.
5 .3.2 Intravenous Infusion of Glucagon
The livers of animals used for this experiment were sampled at 
D-3.5 for the reasons mentioned in Section 5.3.2(ii). Glucagon 
(1.25mg/kg body wt., in acidified saline) was infused intravenously 
(total volume of dose, 250ul) into animals via the femoral vein and 
the liver sampled 5 or 10 min later.
A marked inotropic effect of glucagon on the heart of the 
experimental animals was taken as indicative of the effectivenss of 
the infusion procedure. In addition, in order to ascertain that
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glucagon was affecting hepatic metabolism specifically, the 
concentration of glucose in the blood and that of cyclic AMP in the 
liver were measured. Glucagon infusion (10 min) resulted in a 
1.4-fold increase in blood glucose concentrations as would be 
expected from the well-documented effect of glucagon in increasing 
hepatic glycogenolysis (Whitton, 1981) and gluconeogenesis (Hue et 
al « f 1981). As shown in Fig. 5.9 glucagon infusion induced a 
transient 10-fold increase in the concentration of cyclic AMP in the 
liver after 5 min which had returned to normal levels by 18 min.
The infusion of glucagon (5 or 10 min) produced a modest, but 
not statistically significant, decrease in the total activity of 
HMG-CoA reductase (i.e. 1.857 + 0.329 to 1.359 + 0.480 or 1.441 + 
0.218 for 5 and 10 min infusion respectively; Table 5.3). This 
effect could possibly have been due to an increased proteolytic 
degradation in response to the expected increased phosphorylation of 
the enzyme following glucagon treatment. However, the short period 
between hormone administration and sampling may suggest that the 
apparent decreases in total activity were the consequence of the 
natural variation encountered in the determination of this activity 
(see above).
The same treatment produced no significant effect on the E/T 
ratio (Table 5.3). This result was unexpected since Beg et 
(1979) had previously presented evidence to suggest that the 
subcutaneous administration of glucagon could effect an increased 
phosphorylation of HMG-CoA reductase concomitant with a decrease in 
activity (see Section 1.5). In addition, Ingebritsen et al. (1979) 
had reported similar changes in the E/T ratio of HMG-CoA reductase in
03
$
03
"5
E
o
Coo
<
u
<3-
03
03
CJ
CD
I  Control
 I____0 L IX
Time (min)
Fig. 5.9 Effect of glucagon on the concentration of cyclic AMP in liver
Glucagon was infused intravenously into anaesthetized rats and samples 
of liver taken by freeze-clamping at the intervals indicated and analyzed 
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isolated hépatocytes incubated with glucagon. Consequently it was 
necessary to investigate any possible reasons for these apparent 
discrepancies.
The present results suggested that the bicyclic 
phosphorylation system of HMG-CoA reductase was either insensitive to 
the glucagon-mediated increase in cyclic AMP concentrations vivo 
or, alternatively, the effectiveness of cyclic AMP was counteracted 
in the liver by an antagonistic mechanism e.g. the activatory effect 
of insulin. The latter effect would tend to be exacerbated by 
increased insulin secretion in response to the hyperglycaemia caused 
by the increased circulating concentrations of glucagon.
To test this latter hypothesis the effect of glucagon on the 
E/T ratio of HMG-CoA reductase vivo was investigated in three 
conditions designed to reduce the possible counter regulatory effect 
of insulin:
(i) Simultaneous infusion of somatostatin 
In the first approach, cyclic somatostatin was infused 
intravenously at a constant rate (100-200yg/kg body wt. per h) for 10 
min previous to and also during the 10 min period between the 
infusion of glucagon and cold-clamping. Somatostatin is a hormone 
that blocks the secretion of both insulin and glucagon from the islet 
cells of the pancreas (Guillemin & Gerich, 1976; Taborsky & Smith, 
1980; Bone e^ al., 1984) and hence will negate the increased 
secretion of insulin in response to the increased plasma 
concentration of glucagon.
The infusion of somatostatin alone (15-20 min) produced no 
significant change in the E/T ratio of HMG-CoA reductase when
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compared to animals infused with saline (Table 5.4 cf. Table 5.3). 
However, when glucagon was infused simultaneously with somatostatin a 
marked, although not statistically significant decrease was observed 
in this ratio (Table 5.4). The concomitant and much larger increase 
in blood glucose (compared to controls. Table 5.4) suggested that 
this effect of glucagon on the E/T ratio was evident in the presence 
of somatostatin because of the inhibition of the compensatory surge 
of insulin secretion. Thus when the response of insulin to transient 
hyperglycaemia was prevented an effect of glucagon on the E/T ratio 
could be demonstrated. The fact that this effect was only modest may 
be the consequence of the substantial residual amount of insulin 
still remaining in the circulation after 10-20 min infusion of 
somatostatin (Chideckel ^  al., 1974).
(ii) Liver sampling at D-9.5
A second approach used to test for the possible counter 
regulatory effect of insulin on glucagon action was to sample the 
liver in animals during the declining phase of the diurnal cycle in 
plasma insulin concentrations (i.e. at D-9.5). At this point of the 
diurnal cycle both the total activity and the E/T ratio of HMG-CoA 
reductase are still relatively stable before the rapid decline 
observed over the D/L transition (see Section 4.2). By doing the 
experiments at this phase of the light-dark cycle it was anticipated 
that the basal level of insulin in the circulation would be 
sufficiently low to allow an effect of glucagon to become apparent 
(see e.g. Knox et al., 1979). At the same time the activities of 
HMG-CoA reductase would still be sufficiently high to allow accurate 
quantitative measurements to be made (see Section 4.2; Fig. 4.1).
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Again in contrast to the experiments in normal animals at 
D-3.5 the intravenous infusion of glucagon at D-9.5 caused a
depression in the E/T ratio (70.1 + 10.7% to 57.1 + 5.5%) although
this effect was not statistically significant. This effect was 
observed without any appreciable effect on total activity (Table 5.3) 
indicating that they were not artefacts arising from inadequate 
enzyme assays.
(iii) Use of diabetic animals
In a third series of experiments glucagon (1.25ng/kg body wt.) 
was intravenously infused into anaesthetized rats made severely 
hypoinsulinaemic by treatment with streptozotocin 7-8 days 
previously. Glucagon infusion produced a marked decrease in the E/T
ratio (49.6 + 5.0% to 30.3 + 6.6%; Table 5.3) when compared
to diabetic animals infused with saline and was due to a very marked 
(30%) fractional decrease in the expressed activity (0.372 + 0.066 to
0.269 + 0 .096) in the absence of any change in total activity. These 
results again demonstrate that when the insulin response to 
hyperglycaemia was suppressed, the effect of glucagon on HMG-CoA 
reductase activity became apparent. These effects of glucagon were 
not accompanied by a further increase in the level of glycaemia as 
previously observed (Table 5.3) because of the depletion of liver 
glycogen which occurs in the first few days following streptozotocin 
treatment.
5 .3.3 Adrenergic Agonists and Antagonists
Liver samples used for the determination of HMG-CoA reductase 
activities in this study were obtained from rats at D-3.5 to D-4.
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All agents were administered intravenously via the femoral vein 
(see Methods, Section 2.4 & 2.5).
(i) Epinephrine
Epinephrine, whether administered in a single dose 
(0.63-1.50yg/kg body wt. in lOOyM ascorbic acid; 250yl infused; 2.5 
min) or by a constant infusion (1.60yg/kg body wt. per min; 5 min) 
produced no discernable effect on the E/T ratio or total activity of 
HMG-CoA reductase (Table 5.5). (Because no difference was observed 
between the methods of administration or the concentrations of 
hormone used the data were pooled and compared with animals infused 
with a similar volume of saline). The bolus infusion of epinephrine 
had to be executed with extreme care, especially at high 
concentrations to avoid fatal tachycardia.
The time course of the effect of epinephrine on liver cyclic 
AMP concentrations was monitored in freeze-clamped tissue as 
previously described for glucagon (Section 5.3*2). It showed a very 
rapid and transient 3-fold increase in the cyclic AMP concentration 
in liver which peaked after 1 min; it returned to basal levels after 
only 3 min. Fig. 5.10. In comparison to an equivalent treatment of 
glucagon, these effects were both more transient and less potent 
(Fig. 5.10 cf. Fig. 5.9). However, Foulkes & Cohen (1979) have 
shown that the intravenous infusion of epinephrine (although in very 
much greater quantity) will modulate the phosphorylation state of 
protein inhibitor-1 in rabbit skeletal muscle within a similar time 
scale.
TABLE 5.5
Effects of Epinephrine Infusion on Hepatic Microsomal HMG-CoA 
Reductase Activity and the Fraction of Enzyme in the Active Form
Microsomal HMG-CoA reductase (expressed and total) were 
determined in cold-clamped samples of liver from animals 
intravenously infused with epinephrine (0.63-1.SOyg/kg body wt., see 
text) or saline, at D-3.5. HMG-CoA reductase activity is expressed 
as nmole/min per mg of microsomal protein at 37°C. Values are means 
(+ S.E.M.) for the numbers of separate determinations shown in 
parenthesis.
Treatment 
Saline (4)
Epinephrine (12)
HMG-CoA Reductase Activity 
Expressed (E) Total (T) E/T (%)
1.349 + 0.179 1.987 + 0.269 68.0 + 1.7
1.105 + 0.96 1.701 + 0.100 64.7 + 3.4
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Fig. 5.10 Time course of the effect of epinephrine on the concentration 
of cyclic AMP in liver
Determinations were made as described in legend to Fig. 5.9. Bar 
indicates range of liver cyclic AMP concentrations recorded in normal, 
unstimulated rats (Data for control range taken from Steiner et , 
1972) .
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(ii) 3-adrenergic antagonist
A general 3-adrenergic antagonist (propranolol; 12^/kg 
body wt. ) was infused intravenously 1h prior to the sampling of the 
liver by cold-clamping. It was evident that this treatment had no 
discernable effect on the E/T ratio or total activity of HMG-CoA 
reductase when compared to untreated animals at the same time of the 
diurnal cycle (see Table 5.6).
(iii) g -^adrenergic antagonist
A specific a^-adrenergic antagonist (prazosin; 5^g/kg body 
wt. in 0.8mM lactic acid) was infused intravenously into normal rats 
1h prior to the sampling of the liver by cold-clamping at D-3.5.
This treatment produced a modest increase in the E/T ratio compared 
to control animals infused with carrier only (81.1 + 2.7% to 91.1 + 
5.2%; Table 5.6) without any significant change in the total activity 
(1.715 + 0.483 vs 1.815 + 0.675 nmoles/min per mg of microsomal 
protein).
5.4 Discussion
The most striking observation from the present study was that 
insulin appeared to be pre-eminent in the control of the 
phosphorylation state of HMG-CoA reductase in the intact animal in 
vivo. It is evident that in normal animals under physiological 
conditions only treatments in which the circulating insulin 
concentrations were increased (administration of glucose) or acutely 
decreased (anti-insulin serum) could respective increases or 
decreases in the E/T ratio be observed. By contrast, when glucagon
TABLE 5.6
Effects of 3- and a -^Adrenergic Antagonist Infusions on 
Hepatic Microsomal HMG-CoA Reductase Activities and the Fraction of
Enzymes in the Active Form
Prazosin ( -antagonist; 5^g/kg body wt. in 0.08m  lactic 
acid) or propranolol (general 6-antagonist; 125pg/kg body wt.) in 
physiological saline were administered intravenously into rats under 
ether anaesthetia. After 1h, a sample of the liver was obtained by 
cold-clamping and used for the determination of expressed and total 
activities of HMG-CoA reductase. Animals were sampled at D-4. 
HMG-CoA reductase is expressed as nmoles/min per mg of microsomal 
protein at 37^C. Values are means (+ S.E.M.) for the numbers of 
separate determinations shown in parenthesis.
Treatment 
Control (3)
Propranolol (5)
Control
Prazosin
(3)
(4)
HMG-CoA Reductase Activities 
Expressed (E) Total (T)
1.713 + 0.329 
1.879 + 0.296
1.507 + 0.608 
1.532 + 0.395
2.216 + 0.275 
2.372 + 0.358
1.815 + 0.675 
1.715 + 0.483
E/T (%) 
76.8 + 6.9 
78.7 + 3.0
81 .1 + 2 . 7  
91. 1 + 8 . 2
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or epinephrine (agents that are known to produce antagonistic effects 
to those of insulin in the liver e.g. on glycogen metabolism, see 
Whitton, 1981) were administered to whole animals between D-3 and D-4 
of the diurnal cycle the E/T ratio was not reduced. During this 
phase of the light-dark cycle the circulating insulin concentrations 
are high- This observation was unexpected because previous studies 
of the effects of glucagon on rat hepatocytes m  vitro (Ingebritsen 
Gt al., 1979; Henneberg & Rodwell, 1981; 1985) or glucagon 
administration to animals vivo (Beg et ^ . , 1979) had indicated 
that they result in increased phosphorylation of HMG-CoA reductase 
(see Section 1.5). However, the physiological significance of this 
effect of glucagon vivo is doubted because of the artefactual 
increase in the phosphorylation state that would occur in the method 
of sampling used in this study (see Chapter 3;). In the present study, 
glucagon tended ^ o produce an inhibitory effect on the expressed 
activity of HMG-CoA reductase only under conditions in which insulin 
secretion was suppressed either in the course of the normal diurnal 
cycle (by using animals at D-9.5 in the diurnal cycle; see Section 
5.3.2(ii)) or pharmacologically (by using chronically 
insulin-deficient animals or the simultaneous infusion of 
somatostatin, see Section 5.3.2.(i)). These observations suggest that 
when the concentrations of insulin were high they were sufficient to 
antagonize any effects these agents had in decreasing the E/T ratio 
of HMG-CoA reductase in the liver of these animals. Such insulin 
concentrations appeared to prevail physiologically at D-4 but not at 
D-9.5 and also in response to hyperglycaemia induced by hormones that 
mobilize liver glycogen. These observations are therefore consistent
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with the reported effects of glucagon on the E/T ratio in hepatocytes 
which were studied in the absence of any antagonizing effect of 
insulin.
The apparent dominance of insulin in the control of the 
phosphorylation state of HMG-CoA reductase suggests that insulin may 
play the major role in establishing the diurnal rhythm observed in 
the E/T ratio of hepatic HMG-CoA reductase (see Section 4.2; Fig. 
4.2). This conclusion is drawn from a number of observations made 
in the present study which confirm the observations made in the 
previous chapter.
( 1 ) The E/T ratio was markedly depressed in the microsomes 
obtained from the liver of insulin-deficient animals at a time in the 
diurnal cycle that coincides with the peak of the diurnal rhythm of 
the ratio in normal animals (Fig. 5.8a cf. Fig. 4.2). This suggests 
that the diurnal peak in the E/T ratio is depressed in these animals. 
That this was the direct result of insulin deficiency was supported 
by the observation that the réintroduction of insulin in such a way 
as to gradually restore normoglycaemia (i.e. intraperitoneal 
injection of insulin) restored (within 40 min) the E/T ratio to 
values observed in normal animals at a similar time of day (Fig. 
5.8a).
Furthermore, if a high circulating concentration of insulin 
was maintained on these animals by the repeated intraperitoneal 
administration of insulin, the E/T ratio continued to increase 
gradually over D-4 to D-6 when, in normal animals this ratio would 
have normally started the decline from a peak at D-4 (Fig. 5.8a cf. 
Fig. 4.2). This observation, in combination with the observed fall
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and rapid activation of HMG-CoA reductase effected by intravenous 
infusion of insulin (Section 5.3.1.(iv)) demonstrates that the 
hyperinsulinaemia induced in these conditions overcomes any 
counter-regulatory effect that may be provoked by the accompanying 
hyperglycaemia.
(2) Acute removal of insulin from the circulation by the 
infusion of anti-insulin serum at a time approximating the 
attainment of the normal diurnal peak in the E/T ratio produced a 
marked decrease in this ratio. Since under these experimental 
conditions the pancreatic response would be to increase insulin 
secretion in response to the increased blood glucose concentration 
the observed decrease in the E/T ratio could not have been due to the 
secretion of a counter-regulatory hormone.
(3) The E/T ratio was increased by the administration of 
glucose at a time in the light:dark cycle when both the E/T ratio and 
plasma insulin concentrations were at their lowest. The close 
correlation observed between the plasma glucose concentration and the 
E/T ratio suggests that it is primarily caused by the concomitant 
increase in plasma insulin concentrations (see Stansbie et al., 
1976b). It seems, therefore, that the value of the E/T ratio is 
largely determined by the circulating concentrations of insulin and, 
in support of this, a strong correlation was observed between the 
relative hyperglycaemia of a series of diabetic rats and the 
resulting E/T ratio of HMG-CoA reductase on the liver (Fig. 5.5).
The present study investigating the effect of insulin 
administration to diabetic animals also demonstrated that insulin is 
required for the full expression of the total activity of HMG-CoA
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reductase (i.e. synthesis of enzyme protein). This response of 
HMG-CoA reductase is well documented (e.g. Lakshmanan et al., 1973; 
Huber et al., 1973; Uchida et , 1979; Young et al., 1982; 
see Section 1.3*3) but it is of interest that this effect lagged 2-3h 
behind the rapid effect observed in the E/T ratio (see above; Fig. 
5.8a&b). Not only is the magnitude of this lag period consistent with 
the expected requirement for the induction of protein synthesis but 
it is also similar to the phase separation observed between the 
respective diurnal rhythms of the E/T ratio of HMG-CoA reductase and 
the total activity in vivo (see Section 4.2.2). It was also evident 
that both parameters sensitive to the same range of insulin 
concentrations (Fig. 5.5 & 5.6.). In both instances moderate 
hypoinsulinaemia (blood glucose < 20mM) had little discernable effect 
both on the E/T ratio and total activity. In more severely diabetic 
animals (blood glucose 20-38mM) there was a negative correlation 
between the severity of hyperglycaemia and both total activity of 
HMG-CoA reductase and the E/T ratio. These observations are 
consistent with the important role of insulin in the generation of 
the diurnal rhythm for both total activity (although probably not the 
sole determinant, see Section 4.3-3) and the E/T ratio. Furthermore, 
they may contribute to the apparent variable effect of 
streptozotocin-induced insulin deficiency on the rate of hepatic 
cholesterogenesis (Feingold e^ 3^., 1982; Nakayama & Nakagawa, 1977)
and the fraction of HMG-CoA reductase in the active form (see Goodman
et ^ . ,  1982; Young et , 1982) reported in the literature. Only
animals in which the extent of hypoinsulinaemia induced
experimentally is sufficiently severe to increase blood glucose above
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20mM would exhibit any significant depression of expressed HMG-CoA 
reductase and cholesterogenesis ^  vivo.
The mode of action of insulin in promoting the 
dephosphorylation of HMG-CoA reductase is, as yet, unknown. This is, 
in part, due to the lack of understanding of the mechanism of insulin 
action (see introduction to this chapter). The mechanism could 
involve the inhibition of kinases and/or the activation of the 
phosphatases constituting the bicyclic system operation on HMG-CoA 
reductase (see Section 1.4.2). The mechanisms by which the 
activities of reductase kinase and reductase kinase kinase are 
regulated have not been identified (except for the activation of 
reductase kinase by ADP; see Sections 1.4.3*1 and 3-4). However, by 
analogy with the effects of insulin on protein phosphatase activities 
involved in glycogen metabolism (see Cohen et al., 1985; Cohen,
1985) it is possible that the effects of insulin HMG-CoA reductase 
are mediated primarily through similar mechanisms.
HMG-CoA reductase and reductase kinase are substrates for 
three of the four protein phosphatase activities characterized in the 
control of carbohydrate and fat metabolism, namely protein 
phosphatase-1, -2A and -2C (by the terminology of Ingebritsen &
Cohen, I983). In spite of the very high specific activity of protein
phosphatase-2C towards HMG-CoA reductase there is no evidence that
this phosphatase activity is regulated within the cell. However,
evidence is emerging that insulin may influence the activities of 
protein phosphatases-1 and -2A. For example, the observation that 
spermine (a polyamine) increases the specific activities of protein 
phosphatase-1 and in particularly phosphatase-2A towards a number of
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cellular substrates in rabbit skeletal muscle (Tung et al., 1985) 
has been linked with the proposed second messenger activity of 
polyamines for insulin (see Cohen, 1985). Although protein 
phosphatase may have an important role to play in the regulation of 
cytosolic reductase kinase, protein phosphatase-1 is likely to have 
the major HMG-CoA reductase phosphatase activity by virtue of its 
partial association with the microsomal membrane of cell homogenates 
(Ingebritsen ^  , 1983b; Section. 1.4.3 .2). In chronic insulin
deficiency the effects on protein phosphatase activities may include 
not only effects on the specific activity of protein phosphatase-1 
but also on the concentration of this enzyme. Thus the activity of 
protein phosphatase-1 is decreased by 40-50% in chronically 
insulin-deficient animals (Foulkes & Jefferson, 1984; 
Dragland-Meserve et al^., 1985). Moreover, the activation of HMG-CoA 
reductase (i.e. the increase in the E/T ratio) induced by insulin 
administration (intravenous or intraperitoneal injection) to diabetic 
animals could be mediated by the concomitant, rapid (5 min) 
activation of protein phosphatase-1 by this hormone as demonstrated 
by Shahed et al. (1980) and Dragland-Meserve et al. (1985).
In Chapter 1, two mechanisms were described by which protein 
phosphatase-1 activity could be regulated, namely via the putative 
effects of protein inhibitors-1 and -2. Although Cohen (1980) has 
proposed inhibitor-2 as a target for insulin action its involvement 
in the regulation of HMG-CoA reductase would seem unlikely on two 
accounts: (1) the phosphorylation of inhibitor-2, through which
dissociation and activation of protein phosphatase-1 are produced 
(see Section 1.4.3 .2) is achieved by a cyclic AMP-independent protein
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kinase activity on a serine-threonine residue (Ballou et al., 1983; 
Hammings e^ al., 1982). The kinase activity associated with the 
event of insulin binding, however, is specific for tvrosine residues 
(Fain, 1984). (2) The protein phosphatase species with which
inhibitor-2 interacts is found exclusively in the cytosol (Cohen, 
1985). As such, this activity will not readily effect the 
phosphorylation of microsomal bound HMG-CoA reductase although it is 
possible that its limited activity may contribute to the 
dephosphorylation and activation of cytosolic reductase kinase.
The phosphorylation state and hence activity of inhibitor-1 
has been shown to be modulated by insulin in both skeletal muscle 
(Foulkes et al., 1980; 1982) and adipose tissue (Nemenoff et al., 
1983) iji vivo and as such has been proposed as a primary mechanism . 
underlying the effects of insulin on cellular metabolism in these 
tissues. A protein of similar properties, has been found in the rat 
liver (Khandelwal et al., 1977; Goris, 1978). Significantly the 
specific acitivity of this protein inhibitor is found to be greater 
in the liver of diabetic animals and therefore, may account for the 
apparent depressed activity of protein phosphatase-1 in these animals 
(Khandelwal et ^ . , 1977). The action of insulin on protein 
inhibition-1 could therefore facilitate the rapid increase in E/T 
ratio of HMG-CoA reductase observed after the injection of insulin to 
diabetic animals (see above; Section 5.3.1.(iv); Fig. 5.8a). It is 
not known, however, how insulin mediates its effects on inhibitor-1.
The mechanism of acute glucagon-mediated inhibition (at low 
insulin concentrations iji vivo) of HMG-CoA reductase could be 
achieved indirectly through the increased phosphorylation of
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inhibitor—1 (the activities of both reductase kinase and reductase 
kinase kinase are cyclic AMP-independent see Section 1.4.3.1), 
However, the fact that the activation state of HMG-CoA reductase is 
unaffected by glucagon under conditions of high, but physiological, 
insulin concentrations in spite of a large increase in the 
intracellular concentration of cyclic AMP (Fig. 5.9) suggests that 
even if insulin does not mediate its effects via the suppression of 
the levels of the metabolite it can antagonize its effects on the 
activity of HMG-CoA reductase. One mechanism by which insulin could 
achieve this was described by Larner et al. (1979; 1982) who 
demonstrated that insulin could directly inhibit cyclic AMP-dependent 
protein kinase activity (Fig. 5.11). Alternatively, insulin could 
act directly on protein phosphatase-1 activity in such a way as to 
ovecome any increased effect of inhibitor-1 on protein phosphatase-1 
under conditions of increased levels of cyclic AMP (Fig. 5.11).
It is significant that even under conditions in which insulin 
secretion was suppressed (i.e. either by using normal animals at 
D-9.5 or by infusing somatostatin) the administration of large, 
pharmacological doses of glucagon produced only modest decreases in 
the E/T ratio of HMG-CoA reductase (Tables 5.3 & 5.4). By contrast 
when severely hypoinsulinaemic (diabetic) animals were used glucagon 
produced a much more marked decrease in the fraction of HMG-CoA 
reductase in the active form. It is noteworthy that the exposure of 
rat hepatocytes to glucagon (10 ^M) does not completely antagonize 
the effects of insulin (10 ^^-10 ^M) on the E/T ratio of HMG-CoA 
reductase (Parker e^ al^ ., 1981). These observations raise the 
question as to whether it is the insulin concentration to which
Glucagon Insulin
P.MA C .
cA M P ATP
cAM P-dep  
protein kinase
lnh-1 lnh-1
HMG-CoA R P'ase
(EX
I
H M G -C oA  R HMG-CoA R
Inactive Active
Fig. 5.11 Hypothetical mechanism for the dominant effect of insulin
on the phosphorylation state of HMG-CoA reductase (HMG-CoA R)
via HMG-CoA reductase phosphatase (HMG-CoA R Phase)
Insulin (via an unknown intermediate; ?) could activate directly
HMG-CoA reductase phosphatase and simultaneously inhibit the action of
glucagon on the same enzyme (via inhibitor-1, Inh-1) through an 
inhibition of cyclic AMP-dependent (cAMP-dep) protein kinase. (A.C., 
adenylate cyclase; P.M., plasma membrane).
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hepatocytes are exposed ^  vivo or the insulin:glucagon ratio that 
is important in the regulation of the E/T ratio of HMG-CoA reductase. 
On the present evidence it would appear that the absolute 
concentration of insulin is more important at high insulin 
concentrations but that the insulin:glucagon ratio becomes important 
at very low insulin concentrations. Cherrington & Steiner (1982) 
reached a similar conclusion in a study investigating the effects of 
these hormones on hepatic glycogen metabolism. They found that under 
conditions in which the absolute concentrations of insulin and 
glucagon were both increased the effects of insulin (i.e. decreased 
glucose production) clearly dominated. Relatively low concentrations 
of insulin could antagonize the effects of glucagon on the rates of 
glycogenolysis and gluconeogenesis.
From the foregoing discussion, the effects of epinephrine 
through the interaction with 3-adrenergic receptors (through 
increased concentrations of cyclic AMP) would not be expected to be 
detectable at least in the presence of normal insulin concentrations. 
Epinephrine produced a more transient, less potent (3-fold; Fig.
5.10) increase in the concentration of cyclic AMP in comparison with 
equivalent measurements made following the administration of glucagon 
(i.e. 10-fold; Fig. 5.9). This difference may be a reflection on 
the concomitant interaction of epinephrine with the ot^-receptor which 
acts to lower the concentration of cyclic AMP (see Section 5.1) or 
alternatively due to the limited amount of hormone that could be 
administered in vivo without precipitating fatal tachycardia (see
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Section 5*3*3(i))* Nevertheless, epinephrine will also interact with
a^-adrenergic receptors (see Table 5.1) and thus increase the cytosolic 
2+
Ca concentration. In view of the recent demonstration that two 
Ca. " -dependent kinases i.e. Ca^^-phospholipid-dependent protein 
kinase-C and Ca -calmodulin-dependent protein kinase phosphorylate 
HMG-CoA reductase in vitro (Beg et al., ig85a&b; see Section 
1.4.3.1) the modulation of cytosolic Ca^ '*’ concentrations of the liver 
in vivo would be expected to induce a decrease in the E/T ratio. 
Therefore it is suggested that physiological concentrations of 
insulin also antagonize the effects of a^-receptor occupancy. Such 
an antagonism between insulin and a -receptor-mediated effects on 
enzirmes of glycogen metabolism in rat hepatocytes has been reported 
previously (Massague & Guinovart, 1978; Blackmore et ^ . , 1979;
Thomas e;t al., 1985).
In contrast to the insensitivity of the E/T ratio of hepatic 
HMG-CoA reductase to general 3-adrenergic receptor blockade (which 
is consistent with the proposed insignificance of changes in 
intracellular levels of cyclic AMP on the enzyme in the presence of 
high concentrations of insulin), the specific blockade of 
a^-adrenergic receptors in vivo did produce an increase in the E/T 
ratio (Table 5.6). This observation suggests that under normal 
physiological conditions, the occupancy of a .^-adrenergic receptors 
antagonizes the effects of insulin such that when these effects are 
blocked, insulin is able to produce a greater increase in the E/T 
ratio than is seen at a similar time in the diurnal cycle in normal 
animals. Since the circulating levels of catecholamines increase 
during the activity of feeding (Barrand & Callingham, 1983) it is
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possible that such an antagonism between a.j-adrenergic receptor 
occupancy and insulin binding on the E/T ratio of HMG-CoA reductase 
on the liver could account for the less than total (i.e. 80-85%) 
dephosphorylation of the enzyme at the peak of the diurnal cycle (see 
Section 4.2).
It is evident therefore that the intravenous infusion of 
epinephrine under the present conditions in vivo will not mimic the 
profound decrease observed in this parameter as the result of severe 
stress i.e. as encountered in the conventional method of killing an 
animal by a stunning blow to the head and cervical dislocation (see 
Chapter 3) • However it has been noted previously that the 
intracellular cyclic AMP concentrations were only modestly increased 
following the administration of epinephrine. It may therefore be 
that the increase in plasma catecholamine concentration achieved by 
the intravenous infusion was much lower than that achieved 
physiologically in animals as the result of stress (see Kvetnansky 
et , 1978; 1980) and therefore not able to produce the same effect
i.e. in opposition to the high insulin concentrations. In support of 
this mechanism, Foulkes ^  (1982) demonstrated that
isoproterenol, a potent 3-adrenergic agonist could only antagonize 
the effects of insulin on the phosphorylation state of protein 
inhibitor-1 in perfused skeletal muscle when its concentration was 
increased to values equivalent to those expected for catecholamines 
in the circulation as the result of severe stress. Futherraore, it 
has been demonstrated that epinephrine at suitably high 
concentrations can block the insulin induced-rise in the E/T ratio in 
isolated rat hepatocyte preparations (Henneberg & Rodwell, 1981). In
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view of the apparent relative importance of o^-adrenergic-mediated 
effects in the regulation of the phosphorylation state of HMG-CoA 
reductase, it is possible that the acute effects of stress are 
controlled primarily via the sympathetic innervation such that the 
effective concentration of norepinephrine, which will act on the 
liver only through a.^ - and a^-adrenergic receptors, is very high in the 
vicinity of the cell. However, it has to be appreciated that when 
rats are killed by cervical fracture other factors, such as transient 
anoxia, can affect liver metabolism (and the phosphorylation state of 
HMG-CoA reductase) in the period between killing the animal and 
sampling of the liver (see Chapter 3). Under conditions of severe 
stress, it is possible that the combined effects of the increased 
intracellular concentrations of cyclic AMP and C a ^  produce a greater 
change in the phosphorylation state of HMG-CoA reductase than can be 
achieved by either alone. It has recently been shown that the 
a .^-adrenergic responses of rat liver glycogen metabolism are 
potentiated by a cyclic AMP-dependent mechanism (Morgan et al., 1984; 
see also Jakobs et al., 1985).
In conclusion, the present data have demonstrated that the 
effects of insulin dominate in the regulation of the phosphorylation 
state of hepatic HMG-CoA reductase vivo. These observations 
highlight the difficulties encountered in studying the effects of 
specific hormones in vivo as well as the problems inherent in the 
interpretation of the results obtained vitro by exposure of 
hepatocytes to individual hormones.
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ACUTE REGULATION OF THE ACTIVITY OF HMG-CoA REDUCTASE 
BY DIETARY CONSTITUENTS
CHAPTER 6
6.1 Introduction
In previous chapters it was demonstrated that the expressed 
activity of HMG-CoA reductase is closely related to the food intake 
of the animal (see e.g. Section 4.2 & 4.3). It is possible that, in 
addition, the phosphorylation state of HMG-CoA reductase could be 
acutely modulated through the direct effects of individual dietary 
constituents. In this respect, previous work has indicated that 
cholesterol or cholesterol precursors (e.g. mevalonate) can lower 
the fraction of enzyme in the active form when administered to whole 
animals in vivo (Beg et ^ . , 1981; 1982; 1984b; Arebalo et ,
1981; Erickson ^  al., 1980) or, to isolated hepatocytes ^  vitro 
(Parker et si., 1983). These effects, which have been shown to
involve the increased incorporation of [^^Pl-phosphate from 
[^^P]-ATP:Mg^* into HMG-CoA reductase protein (Beg & Brown, 1981; 
1982) and reversed by the addition of protein phosphatase (see e.g. 
Erickson et &!., 1980; Arebalo et ^L., 1980; 1981), appear to occur 
before any changes occur in the concentration of enzyme in the cell. 
Although this latter effect is generally thought to be the 
consequence of an increased rate of enzyme degradation (Hardgrave et 
1979; Arebalo et , 1981) there is evidence that this could 
be the result of irreversible inactivation of existing enzyme 
(Arebalo et al., 1982).
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The ability of dietary constituents (e.g. cholesterol) to 
modulate the activity of the existing enzyme by covalent 
phosphorylation vivo is, however, not universally accepted (see 
Kleinsek et al., 1980; Jenke et ^ . , 198I; Dugan et , 1982).
Using immunotitration techniques, these workers concluded that the 
changes in the enzyme activity of HMG-CoA reductase observed after 
short-term cholesterol-feeding were the consequence of changes in the 
quantity of enzyme rather than to the modulation of catalytic 
activity. Therefore it was necessary to use the cold-clamping 
technique to resolve the controversy as to whether the administration 
of such factors could acutely alter the E/T ratio of HMG-CoA 
reductase ^  vivo.
A number of other dietary components are known to modulate 
hepatic HMG-CoA reductase and cholesterogenesis vivo. For 
example, in rats, the feeding of unsaturated fats induces an increase 
in the activity of HMG-CoA reductase (Goldfarb & Pitot, 1972; Goh & 
Heimberg, 1979). Recently, in studies in man, emphasis has been 
placed on the correlation between dietary components and the control 
of serum cholesterol levels mainly in response to the suggestion of 
the strong correlation between serum cholesterol levels and 
atherosclerotic diseases (see Grundy, 1978; Brown & Goldstein, 1978). 
One component of the diet in particular, milk, has received 
appreciable attention following the observation that East African 
(Masai) tribesman have low serum cholesterol concentrations in spite 
of the consumption of large quantities (4-5 litres/day) of fermented 
whole milk (Mann & Spoerry, 1974). This observation was paradoxical 
because the high saturated fat content of milk and especially the
^although the significance of these effects is controversial.
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large proportion of cholesterol (0.22-0.41 wt. percent of total 
lipids in bovine milk; 3mg/g milk fat; Christie, 1978, Renner, 1903) 
would have been expected to produce hypercholesterolaemia. Therefore 
it was suggested that milk contained a hypocholesterolaemic factor 
(Mann & Spoerry, 1974). Subsequent observations indicated that 
sufficient amounts of yoghurt and unfermented milk (whole, low-fat, 
skim) also exhibited a hypocholesterolaemic effect both in man and 
animals (Mann, 1977a,b; Howard & Marks, 1977; Nair & Mann, 1977; 
Kritchevsky e^ , 1979; Richardson, 1978). Several substances 
have been suggested as candidates for this 'milk factor' and include 
HMG-acid (Mann, 1977b), lactose (Helms, 1977) Ca^+ (Howard, 1977), 
orotic acid (bovine milk; Ahmed et ^ . , 1979; Bernstein et al.,
1976; 1977; Dull et al., 1983), uric acid (human milk; Ward et al., 
1982) and factors contained in the milk fat globule, particularly the 
fat globule membrane (Antila £t al., 1980; National Dairy Council, 
Digest, 1982). Other reports have suggested that fermented milk had 
a greater ability to produce a hypocholesterolaemic effect than 
non-fermented milk (Rao ^  ^ . , 1981; Hussi ^  , 1981). The
presence of this factor in milk is, however, controversial since 
several investigators have failed to observe hypocholesterolaemic 
effect of milk (e.g. Hepner et al., 1979; Massey, 1901; Roberts et 
al., 1982). Further work indicated that the lack of control of 
dietary intake during the experimental period when the milk was used 
to supplement the diet contributes to the inconsistency of the 
results (Roberts et ^ . , 1902; see Howard & Marks, 1902).
Consequently it was suggested that the hypocholesterolaemic effect 
observed in the above experiments may be, in part, due to the 
variability in the dietary lipid intake.
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Nevertheless, a number of these proposed factors e.g. orotic 
acid have been shown directly to modulate the total activity of 
HMG-CoA reductase vivo (see Richardson, 1978; Marlett et ^ . , 
1981). It is possible that the same factors, or others present in 
the milk could have a more acute effect on the rates of liver 
cholesterogenesis. Therefore, various fractions of milk were tested 
for their ability, when administered orally, to affect acutely the 
E/T ratio of hepatic HMG-CoA reductase. These effects could be 
directly compared with the effects of mevalonolactone elicited in the 
same series of experiments.
6.2 Experimental
Rats were lightly anaesthetized and intubated with 
mevalonolactone (750-780mg/kg body wt.; total volume, 0. 3ml ), various 
spray-dried milk fractions (whole milk, skim milk, buttermilk or whey 
proteins; 1.8g/kg body wt.; total volume, 0.8ml) or distilled water 
(control) as described in Methods (Section 2.3)* After 20 min 
(mevalonolactone) or 30 min (milk factions) a sample of the liver was 
taken using the cold-clamping technique and used to determine 
expressed and total microsomal HMG-CoA reductase activities as 
described in Methods (Section 2.8). Cold-clamped samples of liver 
were obtained 4h into the dark period (i.e. at D-4).
Compositional analysis of the milk fractions for total solids, 
fat, crude proteins (see Section 6.3*3) was performed by the methods 
described in Section 2.14.2.
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6.3 Results
6.3.1 Administration of Mevalonolactone
The oral administration of mevalonolactone produced a marked 
decrease in the E/T ratio from 78-9 + 2.9% to 50.5 + 5.0% after 20 
min (Table 6.1). This decrease was accompanied by a modest decrease 
(approximately 21%) in the total activity (Table 6.1) but this was 
not statistically significant and may have resulted from natural 
variation routinely encountered in the determination of total 
activity (see Sections 6.3.2 & 5.3). The combined effects of these 
individual changes in the E/T ratio and total activity resulted in a 
decrease (approximately 53%) in the expressed (i.e. from 1.543 +
0.227 to 0.725 ± 0.124 nmoles/min per mg of microsomal protein at 
37°C; Table 6.1). This effect was primarily accounted for (i.e. 
about 78%) by the changes in the E/T ratio. The administration of 
distilled water (as a control) into normal animals by stomach 
intubation produced very little effects on these parameters of the 
enzyme activity which were very similar to values determined in 
untreated rats at the same time in the diurnal cycle (cf. Section 
4.2).
6 .3.2 Administration of Milk Fractions
When compared to the administration of distilled water 
(control) only buttermilk of the four milk fractions administered 
showed anv detectable effects on the E/T ratio of HMG—CoA reductase 
(Table 6.2). Administration of this fraction provoked a statistically 
significant (P < 0.05) increase in this parameter (from 72.1 + 3*1%
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to 88.9 ± 4.4%; Table 6.2). By contrast, the E/T ratio determined 
in liver samples obtained from rats treated with other fractions i.e. 
whole milk and skim milk were very similar to those observed in 
animals treated with distilled water only (i.e. range 72.1% to 74.8%; 
Table 6.2) although the administration of whey protein fraction 
induced a modest and statistically insignificant increase in this 
parameter (i.e. from 72.1 +3.1 to 79.2 + 5.4%, Table 6.2).
The total activities for HMG-CoA reductase determined in these 
experiments showed considerable variation. This was assumed to be 
due to the variation routinely encountered in the determination of 
this parameter (see also Section 5.3).
6.4 Discussion
The marked decrease observed in the E/T ratio of hepatic 
HMG-CoA reductase in rats ^  vivo as the result of the 
administration of a large dose of mevalonolactone by intragastric 
intubation was consistent with previous studies, both vitro and 
in vivo (see Section 6.1). It was confirmed that the initial 
changes observed in the expressed activity of the enzyme are due to 
rapid phosphorylation and inactivation of existing enzyme (see Beg & 
Brewer, 1981).
The employment of the cold-clamping technique has further 
enabled the quantitation of the mevalonolactone-induced 
phosphorylation of HMG-CoA reductase (i.e. the variation from 
normal ). Thus after 20 min the E/T ratio was decreased by 
approximately 40% (i.e. from 78.9 ± 2.5% of normal animals to 50.5 +
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5.0% of treated animals). This effect was therefore very similar to 
the previously determined effects of acute (i.e. A.I.S., or chronic 
insulin-deficiency (see chapter 5). It was also similar to, although 
less extensive than, the effects of the incubation of rat hepatocytes 
with mevalonolactone (see Parker e^ ai., 1983). This suggests that 
mevalonolactone may be rapidly absorbed from the gut and elicits 
acute effects on liver metabolism.
The mechanism by which mevalonolactone mediates its effect on 
the phosphorylation state of HMG-CoA reductase is unknown although 
there is evidence to suggest that both reductase kinase(s) and 
phosphatase(s) may be involved (mevalonate addition to microsomes 
will not directly modulate the activity of HMG-CoA reductase;
Erickson e_t ai., 1980). Gibson et ai. (1981) and Parker et ai.
(1983) who used isolated hepatocytes vitro and Erickson et ai. 
(1980) and Beg et ai., (1984b) who worked on rats ^  vivo. have 
demonstrated that mevalonolactone treatment produces a rapid and 
marked (40-70%) inhibition of reductase phosphatase activity. These 
effects were not the consequence of a direct action of mevalonate (or 
mevalonolactone) on the phosphatases but rather were suggested to be 
mediated by the action of derivatives formed in the subsequent 
metabolism of mevalonate in the cell. Among these, inorganic 
pyrophosphate (released during squalene synthesis), mevalonate 
pyrophosphate and isopentenyl pyrophosphate inhibit reductase 
phosphatase activity vitro (Parker ^  > 1983, see Fig. 6.1).
Beg et al. (1984b) have presented evidence that the treatment 
of whole animals with mevalonolactone results in the stimulation 
vivo of both reductase kinase (2- to 3-fold) and reductase kinase
Acecyl-CoA
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HMG-CoA
Reductase
Kinase
HMG-CoA
Reductase
Reductase
phosphatase
Mevalonate
ATP
ADP
Phosphomevalonate
ATP
ADP t ADP
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Fig. 6.1 Possible effects of Mevalonate Metabolism on the effective 
activities of HMG-CoA reductase kinase and phosphatase.
The increased mevalonate concentration in the hepatocyte due to 
mevalonolactone-feeding could produce both an activation of reductase 
kinase activity and a reduction in reductase phosphatase activity as 
shown.
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kinase (4-5-fold). These effects could be elicted by the formation 
of derivative of mevalonate (see Beg et sa., 1984b; see above).
However, it is possible that these activations were induced by the 
previously characterized stimulatory effect (at least on reductase 
kinase) of an increased intracellular concentration of ADP (see 
Harwood et , 1984) which may occur as a consequence of the
increased metabolism of mevalonate in the hepatocyte vivo.
Mevalonate is the substrate for mevalonate kinase and this, together 
with the subsequent two enzymes in the cholesterogenic pathway, 
involves the hydrolysis of ATP and consequent generation of ADP (Fig.
6.1). Thus, under conditions of excessive loading of the liver (or 
isolated hepatocytes) with pharmacological doses of mevalonolactone, 
partial depletion of cellular ATP concentrations could occur with a 
consequent rise in intracellular ADP. Such an effect is known to be 
produced by fructose loading of the liver (Phillips & Davies, 1985). 
Therefore, it would be of interest in future experiments to determine 
the effects of the administration of mevalonolactone ^  vivo on the 
intracellular concentration of ADP (and ATP).
The increased metabolism of mevalonate in hepatocytes would 
also be expected to result in an increased concentration of cholesterol 
and non-sterol metabolites of mevalonate in the liver ce11^ These may 
contribute to the modulation of the phosphorylation state of HMG-CoA redu< 
3j,thx2Uglineither have been shown to influence the activity of reductase 
kinases or phosphatase(s). Nevertheless, it has been reported to 
facilitate the phosphorylation of HMG-CoA reductase by increasing the 
rigidity of the endoplasmic reticulum and making the enzyme a better 
substrate for the action of the reductase kinases (see Gibson &
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Parker, 1985). Consequently, the rapid decrease observed in the 
phosphorylation state of HMG-CoA reductase may be the result of the 
combined effects of mevalonate (or a derivative thereof) and 
cholesterol.
The fact that mevalonolactone produces this marked decrease in 
the E/T ratio 4h into the dark period (i.e. D-4) was very significant 
because it represented a factor that could reverse the apparently 
dominant effects of the high plasma insulin concentrations 
characterizing this time of the light/dark cycle (i.e. D-4; see 
Chapters 4 & 5). It will be recalled that the administration of 
glucagon at a similar time was unable to decrease the E/T ratio 
except when insulin secretion was simultaneously suppressed (see 
Section 5*3)• This may suggest that mevalonate mediates its effects 
on the E/T ratio of HMG-CoA reductase via a mechanism completely 
distinct from the modulation of reductase kinase and phosphatase 
activities, and may therefore involve changes in membrane fluidity 
(see above). However the more marked decrease in the E/T ratio 
produced by mevalonolactone treatment in comparison to the effects of 
glucagon may merely reflect the fact that the effect of this 
metabolite was not counteracted by a compensatory increased secretion 
of insulin. It is possible, therefore, that if physiological changes 
occur in the liver concentration of mevalonate or a metabolite 
thereof (e.g. oxysterols), this would represent a major mechanism 
for the counter-regulation of the effects of insulin. If this 
suggestion is valid it would favour the direct involvement of 
mevalonate (or its metabolites) in the regulation of HMG-CoA 
reductase phosphorylation independently of any effect on reductase
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phosphatase activities. This is because, as described elsewhere (see 
Chapter 5), such effects appear to be effectively dominated by 
insulin. This is particularly interesting in the case of the diurnal 
rhythm in the E/T ratio observed in normal rats since an increased 
intracellular concentration of mevalonate may result from the diurnal 
peak in flux through the HMG-CoA reductase reaction at D4 and thus 
may signal the decline from the peak between D-4 and L-2 (see Section
4.2).
The significance of the decrease in the total activity 
observed 20 min after the oral administration of mevalonolactone is 
difficult to assess (Table 6.1) because of the large variation 
routinely observed in the determination of this parameter (see 
Section 5.3). Nevertheless, it is possible that this decrease 
corresponded to previously observed decreases in the total activity 
following the exposure of hepatocytes to mevalonolactone vitro 
(Parker et al., 1983) as well as mevalonolactone treatment vivo 
(Arebalo ^  al. ? 1980; 1982). Although further studies are 
required, the present observations lend support to the recent 
proposition that the increased phosphorylation of HMG-CoA reductase 
(i.e. decreased E/T ratio) results in the increased degradation of 
the enzyme (see Orci ^  al.,1984; Gibson & Parker, 1985).
Of the various milk fractions administered to rats only 
buttermilk had any appreciable effect on the E/T ratio of hepatic 
HMG-CoA reductase. Buttermilk consists of the aqueous phase 
remaining after the removal of butter-fat from cream by churning and 
contains most of the milk fat globule membrane. Consequently, the 
observation that this fraction induced an increase in the E/T ratio
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of* HMG—CoA reductase was unexpected because (i) of* the enriched 
membrane composition and hence large cholesterol content of this 
fraction, and (ii) the possibility that a hypocholesterolaemic factor 
resides in this membrane (see Section 6.1). In human milk, 
cholesterol accounts for 0.6-0.7% of total lipids in the fat globule 
membrane compared to 0.2-0.3% of total lipids in the intact milk fat 
globule (Jensen et al., 1980; Renner, 1983). As indicated above, the 
increased dietary intake of cholesterol-enriched food would have been 
expected to induce a decrease in the E/T ratio. It is appreciated 
that the present short-term study may not be directly comparable with 
the long-term manipulations used to identify the initial effects of a 
hypocholesterolaemic factor and also that, besides, the presence of 
such a factor is controversial.-
The milk fat globule membrane is also a rich source of 
phospholipids. They account for approximately 60% of total milk 
phospholipids (Jensen et al., 1980). The phospholipid content of 
buttermilk represents an enrichment of approximately 30 to 35-fold in 
comparison to the total lipid content of intact milk fat globules. 
Consequently, the cholesterol/phospholipid ratio is markedly 
decreased in the fat globule membrane and, therefore, in the 
buttermilk fraction. It is possible, therefore, that the increased 
dietary intake of phospholipids directly or in relation to 
cholesterol induced the increase in the E/T ratio of HMG-CoA 
reductase observed following the administration of buttermilk to rats 
(Table 6.2) in spite of the concomitant cholesterol intake.
Alternatively, this fraction may have produced the observed 
increase in the E/T ratio via an increased stimulation secretion of
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insulin (i.e. to a greater extent) than other fractions. This 
however, is improbable since the factor most likely to produce such 
an effect, i.e. lactose and casein are present in other sub-fractions 
of milk (Table 6.3) but eachh induced no similar increase in the E/T 
ratio (Table 6.2).
In conclusion, the marked decrease observed in the E/T ratio 
of hepatic HMG-CoA reductase following the administration of 
mevalonolactone together with the effect of buttermilk, demonstrates 
that the phosphorylation state of the enzyme can be modulated acutely 
by dietary manipulation. In the case of mevalonolactone it is 
suggested that this is the effect of the direct effect of the dietary 
factor on the hepatocyte 3^ vivo and therefore may play an important 
role in the diurnal rhythm of the phosphorylation state of HMG-CoA 
reductase that occurs in response to feeding. The reasons for the 
changes in the E/T ratio induced by buttermilk are less clear 
although it will be of interest to determine the effects of e.g. the 
oral administration of phospholipids, particularly
phosphatidylcholine, phosphatidylethanolamine or sphingomyelin which 
are the most prominent phospholipids of bovine milk.
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